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Abstract 
 
Cyanobacteria (blue-green algae) are a group of ancient prokaryotic organisms 
which have become synonymous with water quality deterioration. An array of 
compounds is produced by aquatic cyanobacteria, the largest group being the 
oligopeptides. A major class of cyanobacterial oligopeptides are the microcystins; 
cyclic heptapeptides which contain the unique amino acid Adda (3-amino-9-
methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid). Due to their ability to 
inhibit protein phosphatases 1 and 2A and as they are concentrated in the liver, 
microcystins can be highly toxic to animals. 
 
Anabaenopeptins are cyclic hexapeptides which contain a carbonyl-linked 
sidechain amino acid and a ring which is cyclised through the sidechain amine of 
the position two D-lysine. Matrix-assisted laser desorption/ionisation-time of 
flight mass spectrometry (MALDI-TOF MS) analysis of a cyanobacterial bloom 
sample from Lake Wiritoa (Manawatu, New Zealand) led to the identification of a 
new anabaenopeptin. The putative structure for anabaenopeptin 906 was 
constructed using tandem MS (MS/MS) data, in conjunction with the sequences of 
the known anabaenopeptins. 
 
A Microcystis species (CYN06) isolated from Lake Hakanoa (Huntly, New 
Zealand) was investigated as it produced a large number of microcystin congeners. 
Liquid chromatography-MS/MS analysis was used to identify seventeen known 
microcystin congeners and to characterise ten new variants. Two of the new 
microcystins, MC-FA and MC-WA, were structurally characterised using amino 
acid analysis and nuclear magnetic resonance (NMR) spectroscopy. The other 
new congeners included MC-FAba, MC-WAba, MC-FL, MC-WL as well as 
[Asp
3
] analogues of MC-FA, MC-WA, and [Asp
3
] analogues of two known 
congeners; MC-RA and MC-RAba. A review of the number of microcystin 
congeners produced by reported cyanobacterial strains placed CYN06 in the upper 
ten percentile. However, CYN06 differed from the other strains as it showed 
relaxed substrate specificity at position two and four and simultaneously produced 
microcystin congeners which contained no arginine residues, one arginine residue 
and two arginine residues. 
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Microcystis CYN06 also contained an unidentified microcystin with a mass of 
1014.5 Da. Structural characterisation by NMR spectroscopy indicated that it was 
an analogue of MC-WA which contained N-formylkynurenine at position two. As 
N-formylkynurenine is a known oxidation product of tryptophan it was proposed 
that further unidentified microcystins from CYN06 contained two other oxidation 
products of tryptophan; kynurenine and oxindolyalanine. This is the first report of 
the presence of oxidised tryptophan residues in microcystins. 
 
Analysis of a cyanobacterial hydroterrestrial mat sample collected from Miers 
Valley in Eastern Antarctica indicated the presence of fourteen new oligopeptides. 
A combination of MS/MS and amino acid analysis was used to characterise eight 
new microcystins which each contained a position one glycine. A recently-
developed thiol derivatisation technique indicated that the position seven amino 
acid in each of the microcystins was very likely dehydrobutyrine. Different 
combinations of variable modifications at positions two, four and five resulted in 
eight unique structures. These included four microcystins with Adda moieties 
which possessed an O-acetyl group (ADMAdda) instead of the conventional C9 
methoxy. As well as being the first report of microcystins containing a position 
one glycine, this is the first report of ADMAdda-containing microcystins in the 
southern hemisphere. The putative structures of six new Antarctic linear peptides 
were determined through a combination of mass spectrometric techniques. The 
compounds contained an N-terminus with the molecular formula C9H14NO2 
linked to isoleucine, two aromatic amino acids and an ester-linked 
hydroxyphenyllactic acid. The hydroxyphenyllactic acid C-terminus and the 
unidentified N-terminus suggest that these new compounds are a novel class of 
cyanobacterial oligopeptide. 
 
Seven different sample preparation techniques for the quantitative analysis of 
microcystins by MALDI-TOF MS were assessed for signal reproducibility and 
sensitivity using a cost-effective internal standard (angiotensin I). The sensitivity 
of six of the preparations was acceptable, as was the reproducibility for two 
thin-layer preparations performed on a polished steel target. Both thin-layer 
preparations could be used with a MALDI-TOF mass spectrometer which 
automatically acquires data. The thin-layer-spot preparation could also be used in 
an automated sample preparation work-flow. Further investigation using this 
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preparation demonstrated that linear quantification of three different microcystin 
congeners ([Dha
7
] MC-LR, MC-RR and MC-YR) was possible. Use of this 
MALDI sample preparation will allow large numbers of microcystin-containing 
samples to be analysed rapidly and at low cost. 
 
A batch culture experiment using Microcystis CYN06 exhibited a decreased 
abundance of arginine-containing microcystins as nitrate concentrations decreased. 
Linear regression of the relationship between log10 microcystin content and nitrate 
concentration revealed slopes which were dependent upon the number of arginine 
residues present in the compound. During this experiment the abundance of 
congeners with a single arginine residue at position two did not change (p > 0.05), 
whilst the abundance of the congeners with a position four arginine decreased 
significantly (p ≤ 0.001). This suggests that there could be an element of 
selectivity in regards to which arginine in the microcystin structure is modulated 
and could explain why congener modulation in response to nitrogen concentration 
has not been observed previously. Whilst it was not proven that nitrogen supply 
was the causative factor for the congener modulation, the results from this 
experiment warrant further study in this area. 
 
This research has significantly expanded our knowledge of oligopeptide diversity, 
improved an existing method of quantifying microcystins and shed new light on 
the regulation of the abundance of microcystin congeners. The identification of 
eighteen new microcystins is a 16% increase upon the 111 presently characterised. 
Also reported was the identification of nine oxidised analogues of tryptophan-
containing microcystins from Microcystis CYN06. The presence of oxidised Trp 
residues in microcystins has not been reported previously and will allow 
researchers working with samples of Trp-containing microcystins to now assign 
the oxidised analogues. Seven new cyanobacterial oligopeptides were 
characterised during this study, six of which may belong to a novel class of linear 
peptides. A sample preparation designed for the quantification of microcystins by 
MALDI-TOF MS gave comparative performance to the previously reported 
method but was compatible with automated high-throughput sample preparation 
and data acquisition. For the first time, a culturing experiment showed a 
relationship between the abundance of arginine-containing microcystins and 
nitrogen supply. 
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CHAPTER 1 
 
Introduction 
 
 
1.1 CYANOBACTERIA 
The phylum Cyanobacteria are a group of ancient prokaryotic organisms 
originating between three and four billion years ago.
1
 They consist of oxygenic 
photosynthetic prokaryotes which harness energy from the sun using 
chlorophyll-a with water as the reductant.
2
 Cyanobacteria primarily use carbon 
dioxide as a carbon source, making their need for nutrients minimal and 
consequently have been reported in a wide range of environments, including 
extreme habitats such as geothermal springs, desert soils and the Polar regions.
3
 
 
The five orders of cyanobacteria; Chroococcales, Pleurocapsales, Stigonematales, 
Nostocales and Oscillatoriales, are distinguished by the physical characteristics 
shared by the members of each order. Chroococcales and Pleurocapsales are 
unicellular cyanobacteria which may form colonies (aggregates of cells held 
together by an exopolysaccharide secretion), but never form true filaments.
2,4
 
Whilst Chroococcales reproduce by binary fission, reproduction in Pleurocapsales 
occurs by multiple internal fissions.
2
 Stigonematales are filaments with a sheath 
and truely branched trichomes which may produce heterocysts (pale cells 
specialised in nitrogen fixation which usually have a well differentiated cell wall) 
under certain conditions.
2,3
 Cyanobacteria from the order Nostocales form 
filaments with a sheath and heterocysts, but without truely branched trichomes.
2
 
Oscillatoriales are arranged in the form of filaments without true-branching, 
heterocysts or akinetes (dormant cells with a thickened wall).
2,5
 
 
Since the anthropogenic euthrophication of lakes, ponds and oceans, 
cyanobacteria have become synonymous with water quality issues.
4
 
Cyanobacterial blooms can cause foul tastes and odours,
6
 but some species can 
also produce toxic secondary metabolites (cyanotoxins) which can be harmful to 
humans and animals (Table 1.1). 
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Table 1.1: Cyanotoxins produced by freshwater cyanobacteria. 
Cyanotoxin Primary Target in Mammals Structural Characteristics Reference 
Anatoxin-a 
Nerve synapse; Agonists of 
nicotinic acetylcholine 
receptors 
Bicyclic secondary amine 7 
Anatoxin-a(s)  
Nerve synapse; 
Acetylcholinesterase 
inhibitors 
Organophosphate alkaloid 7 
Aplysiatoxins Skin irritant; Carcinogen Phenolic bislactone 8 
Cylindrospermopsins 
Liver; Protein synthesis 
inhibitors 
Tricyclic alkaloid with 
attached uracil 
9 
Lipopolysaccharides Irritant of all exposed tissue Lipopolysaccharide 10 
Microcystins 
Liver; Protein phosphatase 
inhibitors 
Cyclic heptapeptide 11 
Nodularins 
Liver; Protein phosphatase 
inhibitors 
Cyclic pentapeptide 11 
Saxitoxins 
Nerve axon; Blockage of 
voltage-gated sodium 
channels 
Tricyclic alkaloid 7 
Adapted from Table 3.1 of Reference 12. 
 
Aside from toxic compounds, a multitude of secondary metabolites have been 
reported from cyanobacteria which possess a diverse range of bioactivities.
13
 The 
bioactivities of these metabolites have made them of interest to researchers as 
potential drug candidates and for other beneficial purposes. A high proportion of 
cyanobacterial compounds are wholly peptidic or possess peptidic substructures.
14
 
Cyanobacterial oligopeptides, in particular the microcystins (MCs), will be the 
focus of the remainder of this thesis. 
 
 
1.2 FRESHWATER CYANOBACTERIAL OLIGOPEPTIDES 
Freshwater cyanobacterial oligopeptides are structurally diverse with linear chains, 
rings, multiply cyclised rings, polyketide moieties and a plethora of structural 
modifications reported.
14
 These oligopeptides have been shown, or are assumed, 
to be produced by large multi-enzyme complexes called non-ribosomal peptide 
synthetases (NRPS) or hybrid NRPS/polyketide synthases (PKS).
14
 The eight 
major classes of freshwater cyanobacterial oligopeptides are reviewed in this 
section. 
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1.2.1 Aeruginosins 
Aeruginosins are linear peptides containing four amino acids. As observed in 
aeruginosin 103-A (1),
15
 they contain a hydroxyphenyllactic acid (Hpla) 
N-terminus, 2-carboxy-6-hydroxyoctahydroindole (Choi) in position three and an 
arginine derivative as the C-terminus. The position two amino acid varies, but is 
often in the D-configuration and, at times, can be glycosylated.
16
 The position one 
Hpla can be acetylated,
17
 brominated,
18
 chlorinated
19
 or sulphonated.
16,20
 
Chlorinated
16
 and sulphonated
19
 variants of Choi have also been observed. The 
C-terminus is always an arginine derivative which can take on a variety of 
structures.
15-20
 Members of this class of cyanobacterial peptides are also referred 
to as microcins and spumigins.
14
 
 
 
 
1.2.2 Anabaenopeptins 
Anabaenopeptins are cyclic peptides containing six amino acids. As in 
anabaenopeptin A (2),
21
 the ring is comprised of five amino acids and a D-lysine is 
always present in position two. The sidechain amine of the lysine forms a 
secondary peptide bond with the position five carboxyl group which encloses the 
ring. The lysine also has a ureido bond to a carbonyl-linked sidechain amino acid 
in position one. This carbonyl-linked sidechain and the ring amino acids vary, 
however, an aromatic amino acid has been consistently observed in position four 
and the position five amino acid is always N-methylated.
14
 Members of this class 
of oligopeptides are also referred to as ferintoic acids, lyngbyaureidamides, 
oscillamides, nodulapeptins and schizpeptins.
14,22
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1.2.3 Cyanopeptolins 
Cyanopeptolins are cyclic peptides with six ring amino acids and a sidechain of 
variable length. As observed in cyanopeptolin A (3),
23
 the ring is cyclised by an 
ester bond between the sidechain hydroxyl of the position one threonine and the 
carboxyl group of the position six amino acid. Position three of the 
cyanopeptolins is always occupied by 3-amino-6-hydroxy-2-piperidone and an 
N-methylated aromatic amino acid is always present in position five. The position 
two amino acid is highly variable and a selection of structurally different amino 
acids have been incorporated.
14
 The sidechain of the cyanopeptolins can contain 
Hpla, glyceric acid or an aliphatic fatty acid as the N-terminus. The N-terminus 
can be attached to either a single amino acid, a dipeptide chain, or directly to the 
position one amino acid. All of the amino acids in the cyanopeptolins are present 
in the L-configuration. The cyanopeptolins are referred to by many different 
synonyms including aeruginopeptin, microcystilide micropeptin, nostocyclin, 
oscillapeptin.
14
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1.2.4 Cyclamides 
The cyclamides are cyclic hexapeptides containing thiazole and oxazole moieties. 
As observed in aerucyclamide B (4),
24
 each heterocycle unit (positions one, three 
and five) typically alternates with an amino acid (positions two, four and six). The 
thiazole and oxazole moieties are thought to be formed by dehydration and 
reduction of serine, threonine and cysteine residues.
14
 This class of oligopeptides 
are also referred to as aerucyclamides, dendroamides, microcyclamides, 
nostocyclamides, raocyclamides, ulongamides, tenuecyclamides and 
westiellamides.
14
 
 
 
 
1.2.5 Microginins 
Microginins are linear peptides containing four to six amino acids. As observed in 
microginin FR1 (5),
25
 they contain a 3-amino-2-hydroxy-decanoic acid (Ahda) 
N-terminus, whilst the rest of the chain is comprised of more conventional amino 
acids. The Ahda in position one can be chlorinated
26
 or N-methylated.
27
 The 
position two amino acid is highly variable, whilst the positions four to six amino 
acids are often tyrosine related residues.
14
 N-methylation of the positions three 
and four amino acids is commonly observed
14
 and, at times, an additional tyrosine 
residue has been incorporated as a sixth amino acid.
26,27
 The members of this class 
of cyanobacterial peptides have also been referred to as cyanostatins, oscillaginins 
and nostoginins.
14
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1.2.6 Microviridins 
The microviridins are tricyclic peptides comprised of fourteen proteinogenic 
L-amino acids. As observed in microviridin A (6),
28
  the primary sidechain 
consists of the positions one to three amino acids with an acetic acid N-terminus. 
The first ring is cyclised by an ester bond between the sidechain hydroxyl group 
of the position four threonine and the sidechain carboxylic acid of the position ten 
aspartic acid. The second ring is formed through another ester bond between the 
sidechains of the position nine serine and position twelve glutamic acid. The final 
ring is formed with a secondary peptide bond between the sidechain amine of the 
position six lysine and the sidechain carboxylic acid of the amino acid at position 
thirteen. The secondary sidechain consists of the position fourteen aromatic amino 
acid. Most of the structural variability in the microviridins is observed in the 
primary sidechain, where a variety of amino acids have been utilised.
14
 Evidence 
suggests that microviridins are produced ribosomally as a pro-peptide and then 
processed by tailoring enzymes to form the tricyclic structure.
29,30
 To date, no 
members of this class of cyanobacterial oligopeptide have been named under 
synonyms.
14
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1.2.7 Microcystins 
The microcystins are cyclic heptapeptides which can be toxic to terrestrial and 
aquatic animals. As observed in MC-LR (7),
31
 position five of the microcystins is 
occupied by the β-amino acid, Adda (3-amino-9-methoxy-2,6,8-trimethyl-10-
phenyldeca-4,6-dienoic acid). Microcystins generally contain two conventional 
D-amino acids in positions one and six, as well as D-erythro-β-methylaspartic acid 
(Masp) in position three. The positions two and four amino acids are occupied by 
variable L-amino acids, whilst position seven is often N-methyldehydroalanine 
(Mdha). The microcystins were originally called cyanoginosins,
31,32
 however 
since the 1980s, no other synonyms have been used. 
 
 
 
To date, there have been at least 111 different microcystin congeners 
characterised (7-118; Table 1.2 and Appendix A), mostly due to substitutions of 
the variable L-amino acids in positions two and four, although modifications have 
been reported for all of the amino acids.
33
 Each microcystin congener is named 
according to the single letter code of the amino acids incorporated at positions two 
and four; for example, MC-LR contains leucine (L) in position two and 
arginine (R) in position four. Modifications of the other amino acids are included 
in brackets prior to the congener name; for example, the desmethyl-Mdha variant 
of MC-LR is named [Dha
7
] MC-LR. 
 
 
 
 
Chapter 1 
8 
 
Table 1.2: Structures of the known microcystins.
 
 
Compound X Z A B R1 R2 R3 R4 Reference 
7 Leu Arg Ala Dha CH3 H CH3 CH3 31 
8 Leu Ala Ala Dha CH3 H CH3 H 34 
9 Leu Ala Ala Dha CH3 H CH3 CH3 32 
10 Leu Aba Ala Dha CH3 CH3 CH3 H 35 
11 Leu Aba Ala Dha CH3 H CH3 CH3 36 
12 Leu Val Ala Dha CH3 H CH3 CH3 37 
13 Leu Leu Ala Dha CH3 H CH3 H 34 
14 Leu Leu Ala Dha CH3 H CH3 CH3 37 
15 Ala Arg Ala Dha CH3 H CH3 CH3 38 
16 Arg Ala Ala Dha CH3 H CH3 CH3 39 
17 Tyr Ala Ala Dha CH3 H CH3 CH3 31 
18 Ala Har Ala Dha CH3 H CH3 CH3 40 
19 Arg Aba Ala Dha CH3 H CH3 CH3 41 
20 Leu Arg Ala Dha H H CH3 H 42 
21 Glu Glu(OMe) Ala Dha H H CH3 H 43 
22 Leu Met Ala Dha CH3 H CH3 CH3 37 
23 Leu Phe Ala Dha CH3 H CH3 H 44 
24 Val Phe Ala Dha CH3 H CH3 CH3 45 
25 Leu Tyr Ala Dha H H CH3 H 41 
26 Tyr Aba Ala Dha CH3 H CH3 CH3 41 
27 Val Arg Ala Dha CH3 H CH3 CH3 46 
28 Arg Val Ala Dha CH3 H CH3 CH3 41 
29 Arg Apa Ala Dha CH3 H CH3 CH3 41 
30 Leu Arg Ala Dha CH3 H CH3 H 47 
31 Leu Arg Ala Dhb H H CH3 H 48 
32 Leu Arg Ala Dha CH3 H H CH3 38 
33 Leu Arg Ala Dha H H CH3 CH3 42 
34 Ala Trp Ala Dha CH3 H CH3 CH3 49 
35 Glu Glu(OMe) Ala Dha H H CH3 CH3 43 
36 Glu(OMe) Glu(OMe) Ala Dha H H CH3 H 43 
37 Leu Phe Ala Dha CH3 H CH3 CH3 37 
38 Leu Tyr Ala Dha CH3 H CH3 H 41 
39 Hil Arg Ala Dhb H H CH3 H 50 
40 Leu Arg Ala Dha CH3 CH3 CH3 H 51 
NH
O
Z
H
N
H
N X
HN
N
B NH
HN
AO
O
O
O O
O
O
HO O
R3
R1
OO
R4
R2
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Compound X Z A B R1 R2 R3 R4 Reference 
41 Arg Leu Ala Dha CH3 H CH3 CH3 41 
42 Leu Arg Ala Dha CH3 H CH3 CH3 52 
43 Glu(OMe) Glu(OMe) Ala Dha H H CH3 CH3 43 
44 Leu Arg Ala Ser H H CH3 CH3 53 
45 Hil Tyr Ala Dha CH3 H CH3 H 41 
46 Glu(OMe) Glu(OMe) Ala Ser H H CH3 H 43 
47 Glu Glu(OMe) Ala Ser H H CH3 CH3 43 
48 Leu Tyr Ala Dha CH3 H CH3 CH3 45 
49 Tyr Leu Ala Dha CH3 H CH3 CH3 35 
50 Leu Tyr Ala Ser CH3 H CH3 H 41 
51 Leu Arg Ala Dhb H H COCH3 H 54 
52 Leu Arg Ala Dha CH3 H COCH3 H 55 
53 Leu Arg Ala Dha CH3 CH3 CH3 CH3 51 
54 Leu Arg Ala Dhb CH3 H CH3 CH3 56 
55 Hil Arg Ala Dha CH3 H CH3 CH3 57 
56 Arg Arg Ala Dha H H CH3 H 47 
57 Leu Trp Ala Dha CH3 H CH3 H 44 
58 Leu Arg Ala Ser CH3 H CH3 CH3 38 
59 Phe Arg Ala Dha CH3 H CH3 H 58 
60 Phe Arg Ala Dha H H CH3 CH3 59 
61 Arg Phe Ala Dha CH3 H CH3 H 41 
62 Glu(OMe) Glu(OMe) Ala Ser H H CH3 CH3 43 
63 Arg Tyr Ala Dha H H CH3 H 41 
64 Tyr Met Ala Dha CH3 H CH3 CH3 35 
65 Leu Har Ala Dha CH3 H COCH3 H 56 
66 Leu Arg Ala Dha CH3 H COCH3 CH3 55 
67 Arg Arg Ala Dha CH3 H CH3 H 60 
68 Arg Arg Ala Dhb H H CH3 H 61 
69 Arg Arg Ala Dha H H CH3 CH3 62 
70 Leu Trp Ala Dha CH3 H CH3 CH3 45 
71 Met(O) Arg Ala Dha CH3 H CH3 CH3 38 
72 Phe Arg Ala Dha CH3 H CH3 CH3 38 
73 Arg Phe Ala Dha CH3 H CH3 CH3 41 
74 Hph Arg Ala Dha H H CH3 CH3 63 
75 Tyr Arg Ala Dha CH3 H CH3 H 64 
76 Tyr Arg Ala Dha H H CH3 CH3 65 
77 Hty Arg Ala Dha H H CH3 H 63 
78 Arg Tyr Ala Dha CH3 H CH3 H 66 
79 Arg Tyr Ala Dha H H CH3 CH3 41 
80 Leu Tyr(OMe) Ala Dha CH3 H CH3 CH3 41 
81 Tyr Met(O) Ala Dha CH3 H CH3 CH3 67 
82 Leu Arg Leu Dha CH3 H CH3 CH3 68 
83 Hil Arg Ala Dha CH3 H COCH3 CH3 69 
84 Leu Har Ala Dha CH3 H COCH3 CH3 55 
85 Arg Arg Ala Dha CH3 H CH3 CH3 70 
86 Tyr Tyr Ala Dha CH3 H CH3 H 41 
87 Arg Arg Ala Dha CH3 CH3 CH3 H 71 
88 Arg Arg Ala Dha CH3 H CH3 CH3 52 
89 Leu Arg Ser Dha CH3 H COCH3 CH3 72 
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Compound X Z A B R1 R2 R3 R4 Reference 
90 Leu Arg Ala Ser CH3 H COCH3 CH3 72 
91 Arg Arg Ala Ser CH3 H CH3 H 73 
92 Arg Arg Ala Ser H H CH3 CH3 53 
93 Hty Arg Ala Dhb H H CH3 H 48 
94 Hty Arg Ala Dha H H CH3 CH3 63 
95 Hty Arg Ala Dha CH3 H CH3 H 74 
96 Tyr Arg Ala Dha CH3 H CH3 CH3 31 
97 Arg Tyr Ala Dha CH3 H CH3 CH3 66 
98 Arg Tyr Ala Ser CH3 H CH3 H 41 
99 Tyr Arg Ala Ser H H CH3 CH3 75 
100 (H4)Tyr Arg Ala Dha CH3 H CH3 CH3 57 
101 Hty Tyr Ala Dhb H H CH3 H 76 
102 Arg Arg Ala Dhb H H COCH3 H 54 
103 Leu Arg Ala Dha CH3 C3H6OH CH3 CH3 38 
104 Trp Arg Ala Dha CH3 H CH3 H 58 
105 Hty Arg Ala Dha CH3 H CH3 CH3 74 
106 Hty Arg Ala Ser H H CH3 CH3 63 
107 Tyr Arg Ala Ser CH3 H CH3 CH3 77 
108 Arg Tyr Ala Ser CH3 H CH3 CH3 41 
109 Har Har Ala Dha CH3 H CH3 CH3 78 
110 Hty Hty Ala Dhb H H CH3 H 76 
111 Arg Arg Ala Dha CH3 H COCH3 CH3 79 
112 Trp Arg Ala Dha CH3 H CH3 CH3 38 
113 Hty Arg Ala Dha CH3 H COCH3 H 80 
114 Hty Arg Ala Dhb H H COCH3 H 54 
115 Arg Tyr(OMe) Ala Dha CH3 H CH3 CH3 41 
116 (H4)Tyr Arg Ala Dha CH3 H COCH3 CH3 69 
117 Leu Arg Ala Lan CH3 H CH3 CH3 57 
 
 
Whilst at least 111 microcystins have been reported, the level of structural 
characterisation which has been performed on each congener varies. Many of the 
microcystins listed in Table 1.2 have been characterised solely by tandem mass 
spectrometry (MS/MS) which provides no information on the stereochemistry of 
the amino acids present. Furthermore, the configuration of the unique amino acid; 
Adda (2S,3S,8S,9S; as observed in 7), has only been elucidated on a single 
occasion.
81
 To the best of my knowledge, in all subsequent reports, the 
stereochemistry of Adda has been assumed to be the same due to similar coupling 
constants being observed by nuclear magnetic resonance (NMR) spectroscopy. 
This was also the case for microcystins that contained the O-acetyl-modification 
of Adda (ADMAdda).
55
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The different microcystin congeners range in toxicity from non-toxic to highly 
toxic ([(6Z)-Adda
5
] MC-LR, LD50 > 1,200 µg/kg; MC-LR, LD50 = 50 µg/kg),
33
 
according to their ability to inhibit the important eukaryotic regulatory enzymes; 
serine/threonine protein phosphatases 1 and 2A.
82
 Microcystins predominantly 
affect the liver cells of mammals as they are not able to translocate the membranes 
of most tissues but are actively transported into the hepatocytes.
83
 Inhibition of the 
protein phosphatases in these cells then results in excessive signalling due to a 
lack of regulation via the phosphatases. This may lead to cellular disruption due to 
actin filaments of the cytoskeleton becoming hyperphosphorylated,
84
 or cell 
proliferation and tumour promotion.
85
 
 
1.2.8 Nodularins 
The nodularins are cyclic peptides that are very similar to the microcystins, but 
contain only five amino acids. As in nodularin-R (118), the β-amino acid Adda 
observed in the microcystins is present, as well as Masp and D-glutamic acid. The 
position two amino acid is a variable L-amino acid and the position five 
N-methyldehydrobutyrine moiety is similar to the Mdha found in microcystins. 
Like the microcystins, nodularins can also be potent protein phosphatase 1 and 2A 
inhibitors,
82
 promote tumours of the liver
86
 and be lethal to mammals.
87
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1.3 MICROCYSTIN PRODUCTION 
1.3.1 Biosynthesis of Microcystins 
The ability to synthesise microcystins is dependent on the presence of specific 
NRPS and PKS genes. To date, microcystins have been reported to be produced 
by many cyanobacterial genera including; Anabaena,
74
 Anabaenopsis,
88
 
Aphanizomenon,
89
 Aphanocapsa,
90
 Arthrospira,
91
 Cylindrospermopsis,
92
 
Fisherella,
93
 Hapalosiphon,
94
 Microcystis,
31
 Nostoc,
72
 Oscillatoria,
48
 
Phormidium,
95
 Planktothrix,
71
 Radiocystis,
96
 Synechocystis
97
 and Woronichinia.
98
 
 
In Microcystis, the genes required for synthesis of microcystins (mcyA-J) are 
located in two operons (mcyA-C and mcyD-J) orientated in opposite directions 
and separated by a 750 base pair promoter region.
99-101
 These genes produce a 
multi-enzyme complex consisting of both peptide synthetase and polyketide 
synthase modules which sequentially add onto phenylacetate to produce a peptide 
chain, which is then condensed to form a cyclic ring.
99-101
 In other microcystin-
producing genera, the arrangement of the open reading frames within the gene 
cluster differs slightly.
102,103
 
 
The biosynthesis mechanism of MC-LR was elucidated through a series of 
feeding experiments, genetic mutational studies and sequence comparison with 
known NRPS and PKS.
99-106
 The biosynthesis begins with the addition of 
phenylacetate onto the thiolation domain of McyG (Figure 1.1A) and the 
consecutive addition of four acetates from malonyl-CoA (Figure 1.1B-E).
99
 The 
surplus carbonyl oxygens are reduced to hydroxyl groups and dehydrated, 
forming the C4 and C6 alkenes. The methylations at C17-19 are facilitated by 
C-methyltransferases (CM) and S-adenosyl-L-methionine (SAM).
99,105
 The C20 
methoxyl group is added by an O-methyltransferase (OM; McyJ) after reduction 
of the C9 carbonyl (Figure 1.1B). Finally, an aminotransferase (AMT) adds an 
amino group onto the C3, from what is likely to be a glutamate (Figure 1.1E).
99
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Figure 1.1: Proposed biosynthetic mechanism for the Adda portion of 
MC-LR. Each rectangle, circle, triangle and diamond represents 
an enzymatic domain. Aminoacyl adenylation domain (A); Acyl 
carrier protein (ACP); Aminotransferase (AMT); Acyltransferase 
(AT); Condensation domain (C); C-methyltransferase (CM); 
Dehydratase (DH); Ketoacyl reductase (KR); β-ketoacyl synthase 
(KS); O-methyltransferase (OM). Adapted from Reference 99. 
 
The remainder of the peptide chain is built up from the position six glutamic acid 
by consecutive condensation, adenylation and thiolation domains. Each amino 
acid is recognised by the adenylation domain and loaded onto the thiolation 
domain, while the condensation domain forms the peptide bond with the previous 
amino acid (Figure 1.2).
99
 The Mdha in position seven is incorporated as a serine, 
N-methylated by a N-methyltransferase (NM), then dehydrated by McyI 
(Figure 1.2A-B).
99
 The position one D-alanine is synthesised from the L-amino 
acid by an epimerisation domain (EP) located within McyA2. The leucine and 
arginine incorporated into positions two and four remain in the L-configuration 
(Figure 1.2C & E). The D-Masp incorporated into position three is produced by 
the racemase McyF (RC).
107
 Feeding studies using labelled precursors suggest 
that the Masp incorporated into microcystins is synthesised from acetyl-CoA and 
pyruvic acid,
105
 as opposed to the rearrangement of glutamic acid observed in 
other bacteria.
108
 The racemase responsible for the isomerisation of the D-glutamic 
acid incorporated into position six has been suggested to be located outside of the 
mcy cluster.
107
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Figure 1.2: Proposed biosynthetic mechanism for the peptidic portion of 
MC-LR. Each rectangle and triangle represents an enzymatic 
domain. Aminoacyl adenylation domain (A); Condensation 
domain (C); Dehydratase (DH); Epimerisation (EP); 
N-methyltransferase (NM); Racemase (RC); Thioesterase (TE). 
Adapted from Reference 99. 
 
The mcyH gene included in the mcy cluster is not directly involved in the 
synthesis of microcystins and resembles an ABC-A1 transporter protein.
99
 
Deletion of this gene has been shown to disrupt microcystin production.
109
 A 
phosphopantetheine transferase gene, not located within the mcy cluster, is also 
required to transfer the essential cofactor 4-phosphopantetheine onto the acyl 
carrier proteins of the complex.
99
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1.3.2 Structural Diversity of Microcystins 
There have been at least 111 microcystin congeners characterised to date 
(Table 1.2 and Appendix A) and modifications have been reported at each amino 
acid present in the cyclic peptide. This is due to differences in the coding of the 
microcystin synthase genes of different cyanobacterial strains. 
 
The amino acids incorporated into microcystins are dependent upon the substrate 
specificity of the adenylation domain responsible for loading the amino acid onto 
the microcystin synthase module.
110
 The substrate specificity of the position two  
and four adenylation domains (McyB1 and McyC) is varied, as fifteen different 
amino acids have been incorporated at position two and thirteen at position four 
(Table 1.2 and Appendix A). 
 
Whilst substrate variability is common at McyB1 and McyC, it is less common in 
the other adenylation domains. The position one alanine is more highly conserved, 
with only substitutions for serine and leucine having been reported.
68,72,111
 The 
position three amino acid is also highly conserved, as only Masp and aspartic acid 
have been shown to be present. Glutamic acid has been incorporated into position 
six of every microcystin characterised, although esterified variants have also been 
observed.
35,43,57,71
 Whether these modifications occurred prior to incorporation of 
the glutamic acid residue, were due to an additional transferase domain or were an 
artefact of the purification, remains to be elucidated. 
 
Mdha or dehydroalanine (Dha) are commonly observed at position seven of 
microcystins (Table 1.2 and Appendix A). The Dha variant has been observed 
alongside Mdha-containing microcystins,
112
 which indicates that the McyA 
N-methyltransferase was not working at full efficiency in these instances. 
Dha-containing microcystins have also been observed in the absence of position 
seven N-methylated variants,
42,43,63
 which could suggest that the McyA 
N-methyltransferase was not present. However, sequencing of the mcy gene 
cluster of one of these cyanobacterial strains (Microcystis aeruginosa K-139) 
showed that the N-methyltransferase domain of McyA was still present,
42,100
 
suggesting that the enzyme was not functional. 
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Mdha and Dha are produced by dehydration of N-methylated and non-methylated 
serine residues, respectively.
99
 In some cases, dehydrobutyrine (Dhb) has been 
observed at position seven, which is proposed to be the result of threonine being 
incorporated instead of serine.
48,61
 N-methylated and non-methylated serine 
residues have been observed at position seven, but in each case their Mdha or Dha 
counterpart was also present.
38,43,57,63,72,73,77
 This suggests that the serine analogues 
were the biosynthetic precursors of the Mdha- and Dha-containing microcystins 
and that the McyI dehydrogenase was not functioning at full efficiency. 
 
The occurrence of seco[Asp
3
] MC-RR (119),
71
 a linear microcystin with a 
pyruvate present in position seven, was attributed to hydrolytic cleavage of Mdha. 
The researchers eliminated the possibility of this modification being an artefact of 
the isolation protocol,
71
 but whether the cleavage was enzyme-catalysed or due to 
the conditions inside the cell was not determined. 
 
 
 
Structural diversity of the Adda moiety has been limited to changes in the 
configuration of the C4 and C6 alkenes, and the group present on the C9 oxygen. 
Isomerisation of the C4 and C6 double bonds is thought to be due to 
ultraviolet (UV) irradiation rather than a product of the biosynthesis.
113
 Generally, 
a methoxyl group is present at C9, however, substitution for an acetyl group 
(ADMAdda) and the desmethyl variant (DMAdda) have been observed (Table 1.2 
and Appendix A). The ADMAdda modification indicates that, in some instances, 
the O-methyltransferase McyJ could have relaxed substrate specificity and utilise 
acetyl groups instead of methyl groups. The single report of a DMAdda 
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microcystin congener,
38
 may indicate that McyJ does not always function at full 
efficiency. However, the presence of this microcystin should be regarded carefully, 
as it has been observed that the O-acetyl group in ADMAdda was readily 
hydrolysed,
54
 which produces the respective DMAdda microcystin.  
 
A single strain of cyanobacteria can often produce more than one microcystin 
congener, which could suggest the presence of multiple microcystin synthases. 
However, knockout of a single mcy gene has been shown to render a 
cyanobacterium usually capable of producing multiple microcystin congeners, 
incapable of producing any microcystins.
99-101,104
 This demonstrates that a single 
microcystin synthase was responsible for the production of all of the congeners. 
Multiple microcystin congeners being produced by a single cyanobacterial strain 
are generally due to an adenylation domain possessing relaxed substrate 
specificity, due to the amino acid sequence in the binding pocket.
110,114
 This 
results in a single adenylation domain being able to act upon different amino acids, 
giving rise to multiple microcystin congeners from a single microcystin synthase. 
As discussed, in regards to the position seven amino acid, an inefficient 
transferase or dehydrogenase could also result in multiple microcystin congeners 
being produced by a single cyanobacterial strain. 
 
As mentioned previously, the structural variations observed in microcystins can 
have a marked effect on the toxicity of the compound (Appendix A). The most 
harmful microcystin reported to date is MC-LR (LD50 = 50 µg/kg)
115
 and since 
many of the structural analogues of MC-LR have toxicity data available, 
inferences can be made on the effect of different structural modifications. One 
caveat is that much of the published toxicity data comes from different studies, 
performed using a range of methodologies and undertaken in different laboratories. 
 
The most dramatic change in toxicity results from isomerisation of the diene 
system present in Adda. Generally, both of the double bonds are in the 
E-configuration (MC-LR, LD50 = 50 µg/kg).
115
 When the C6 double bond is 
isomerised to the Z-configuration, the microcystin becomes non-toxic 
([(6Z)Adda
5
] MC-LR, LD50 > 1,200 µg/kg).
52
 A similar decrease in toxicity can 
be produced by modifying the carboxylic acid group of the position six glutamic 
acid, (for example [Glu(OMe)
6
] MC-LR, LD50 > 1,000 µg/kg).
33
 Changes to the 
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C9 methoxyl group of Adda do not cause large differences in microcystin toxicity 
as [ADMAdda
5
] MC-LR has an LD50 of ca. 60 µg/kg
56
 and the desmethyl 
variation of MC-LR, [DMAdda
5
] MC-LR, has half the potency (LD50 = 
90-100 µg/kg).
38
 
 
When Dhb or N-methylserine are present at position seven, the toxicity is still 
relatively high ([Asp
3
, Dhb
7
] MC-LR, LD50 = 70 µg/kg;
48,61
 [MeSer
7
] MC-LR, 
LD50 = 150 µg/kg).
57
 During the binding of MC-LR to protein phosphatases, a 
covalent bond is formed between the terminal alkene of Mdha and a 
cysteine residue of the protein.
116,117
 This bond stabilises the binding of the toxin, 
therefore, the high toxicity of [MeSer
7
] MC-LR and [Asp
3
, Dhb
7
] MC-LR 
suggests that a similar interaction may occur with a position seven serine or Dhb. 
However, the incorporation of lanthionine (a large amino acid composed of two 
alanine residues crosslinked through the β-carbon atoms by a thioether linkage)118 
at position seven causes a large decrease in toxicity ([MeLan
7
] MC-LR, LD50 = 
1,000 µg/kg).
57
 
 
The presence of a position two arginine residue in MC-RR lowers the toxicity of 
the microcystin by approximately one order of magnitude (LD50 = 
500-600 µg/kg).
119,120
 As with MC-LR, isomerisation of the Adda C6 alkene also 
renders the MC-RR congener non-toxic ([(6Z)Adda
5
] MC-RR, LD50 > 
1,200 µg/kg).
52,121
 Incorporation of other large amino acids at position two also 
lowers the toxicity relative to MC-LR, although not as dramatically as observed 
with MC-RR (for example, MC-WR, LD50 = 150-200 µg/kg
38
 and MC-FR, 
LD50 = 250 µg/kg)
38
 However, the tyrosine-containing microcystin; MC-YR, has 
a very similar toxicity to MC-LR (LD50 = 68 µg/kg).
120
 Incorporation of the 
slightly larger amino acid; homoisoleucine, has a small effect on toxicity 
(MC-HilR, LD50 = 100 µg/kg)
57
 and interestingly, incorporation of the smaller 
amino acid alanine at position two causes a fivefold reduction in potency (MC-AR, 
LD50 = 250 µg/kg).
38
 This observation suggests that when microcystin binds to 
protein phosphatases, the position two amino acid has a hydrophobic interaction 
which enhances binding. The crystal structure of MC-LR bound to protein 
phosphatase 2A supports this, as van der Waals interactions are present between 
the position two leucine of MC-LR and the cysteine-266 and arginine-268 of the 
enzyme.
116
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Toxicity data for a microcystin lacking a position four arginine has only been 
reported once. This microcystin; MC-YM(O),  had a potency very similar to that 
of MC-LR (LD50 = 56 µg/kg).
67
 However, little can be inferred from such limited 
information. 
 
In general, the toxicity of microcystins is most dramatically affected by 
isomerisation of the diene system of Adda and esterification of the carboxylic acid 
group of the position six glutamic acid. Incorporation of a large amino acid at 
position seven also interferes with protein phosphatase binding. The incorporation 
of an amino acid at position two which is smaller than leucine causes a slight 
decrease in toxicity. In general, the incorporation of larger amino acids at position 
two adversely affects protein phosphatase binding and lowers the toxicity of the 
compound. The influence of the commonly observed position four arginine 
(Table 1.2 and Appendix A) on microcystin toxicity, is difficult to assess given 
the limited data available. 
 
1.3.3 Environmental Factors Affecting Microcystin Production 
Although the biosynthetic pathway for microcystins has been deduced, there is 
still uncertainty surrounding the transcriptional and post-translational regulation 
of the microcystin synthase. Microcystins were initially thought to be feeding 
deterrents for predators, and studies showing increased microcystin content in 
cyanobacteria exposed to predators supported this theory.
122,123
 However, the 
genes responsible for microcystin synthesis predate the eukaryotic lineage.
124
 
Furthermore, cyanobacteria often produce other non-toxic oligopeptides and 
regulate their production in response to the stimuli which cause increased 
microcystin production.
125-127
 It has been suggested that strains which are not 
capable of producing microcystins may mimic their effect using other 
oligopeptides.
125
 
 
Cyanobacteria have been shown to respond to varying environmental parameters 
in both laboratory and field situations, by altering their production of 
microcystins.
128
 In order to determine the regulatory mechanisms controlling 
microcystin production, many experiments manipulating cyanobacterial cultures 
have been performed (Appendix B). 
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In general, the laboratory studies presented in Appendix B, indicate that factors 
which influence cell growth also affect microcystin production.
129
 Microcystin 
concentrations are maximal around 20-25 C and decreases at higher and lower 
temperatures.
130-136
 A similar parabolic response was observed in studies 
investigating the response to light intensity.
130-132,134,136-138
 Increased phosphorus 
and nitrogen concentrations in general caused higher microcystin 
levels,
131,134,136,137,139
 although several experiments showed contradictory 
results.
131,135
 Zinc was shown to be essential for microcystin production,
140
 whilst 
investigations into the response to iron levels yielded conflicting results.
135,139-141
 
 
Although microcystins are not essential for photosynthesis, a Microcystis 
aeruginosa mutant lacking mcyB showed altered levels of photosynthetic 
pigments,
142
 suggesting some involvement in the photosystem. This corresponds 
well with other studies showing that microcystin production is correlated with 
chlorophyll-a production
143,144
 and that microcystins are embedded in the 
thylakoid membrane.
145
 
 
Several culturing experiments have resulted in a change in the proportion of the 
microcystin congeners present. An investigation of how microcystin production 
alters during different stages of the cell cycle found that the relative abundance of 
the microcystin congeners shifted significantly.
146
 The strain of Microcystis viridis 
studied produced three microcystin congeners; MC-LR, MC-YR and MC-RR, 
which are present at a ratio of ca. 23:67:10 during the stationary phase.
147
 This 
microcystin composition was consistent during the pre-mitotic phase,
146
 however, 
cells in the DNA synthetic phase had increased levels of MC-LR/MC-YR and 
reduced levels of MC-RR. Cells in the mitotic phase showed a rectification of the 
microcystin composition, with an increase in MC-RR and a decrease in 
MC-LR/MC-YR. The researchers did not allude to what might be causing the 
significant shift in microcystin congeners over the different phases of the cell 
cycle. 
 
Increased photon irradiation has been shown to increase microcystin production, 
up to a point.
130-132,134,136-138
 A strain of Planktothrix agardhii which produced 
[Asp
3
] congeners of both MC-LR and MC-RR has been shown to exhibit 
increased levels of MC-LR with increased irradiation.
148
 The implication of this 
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finding is that MC-LR is an order of magnitude more toxic than MC-RR 
(Appendix A), so the resulting phenotype from increased light intensity was more 
toxic. Another study using batch culture and a natural population of Microcystis 
aeruginosa found that at a moderate temperature (20 C) the microcystin content 
would switch from being predominantly MC-LR to a less toxic phenotype that 
was predominantly MC-RR.
135
  At a higher temperature (28 C), this did not 
occur and the levels of MC-LR and MC-RR remained constant. A similar 
observation was noted in another study using Microcystis viridis, where higher 
proportions of MC-RR were reported at lower temperatures  (15-20 C).149 
 
The microcystin MC-RR contains two of the nitrogen-rich amino acid, arginine, 
whereas MC-LR contains only one. An assessment of whether the levels of free 
leucine and arginine in the culture medium would alter the levels of the 
microcystin congeners showed this to be apparent.
150
 When leucine was supplied 
to a strain of Planktothrix agardhii, the ratio of MC-LR/MC-RR increased. When 
arginine was supplied, the opposite effect was observed, however, the response 
was not as pronounced. The researchers further experimented with the level of 
nitrogen in the culture medium,
150
 hypothesising that a shift from high nitrogen to 
low nitrogen would cause an increase in the MC-LR/MC-RR ratio. This was not 
the case during the time course of their study, as the microcystin proportion did 
not shift over 25 days. The researchers theorised that this could be due to the 
phycocyanin pigments, which are utilised in times of nitrogen shortage, not being 
fully depleted over the period of the experiment. Another study using Microcystis 
viridis had similar findings; that the level of nitrogen in the medium did not have 
a significant effect on the abundance of microcystin congeners during the study.
146
 
 
An experiment which assessed whether different nitrogen/carbon ratios (N/C) 
affected the relative abundance of microcystin congeners had similar results.
151
 
The levels of three microcystin congeners (MC-LR, MC-YR and MC-RR) in a 
Microcystis aeruginosa strain were analysed in respect of the N/C ratio supplied, 
and also under light limitation in the presence of excess N/C. Whilst manipulating 
the N/C ratio did not substantially alter the abundance of the different microcystin 
congeners, supplying excess N/C and limiting light caused an increase in MC-RR 
and MC-YR with no significant change to MC-LR levels. Whether this was due to 
the level of nitrogen, the level of carbon or the light limitation is unknown, 
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however, low light intensities have been previously shown to sustain higher levels 
of MC-RR.
148
 
 
 
1.4 METHODS OF MICROCYSTIN ANALYSIS 
Due to the health risk posed by microcystins, the World Health Organisation has 
recommended a ‘safe level’ for drinking waters of 1 µg/L of MC-LR.152 In the 
past, the brine shrimp (Artemia salina) bioassay and mouse bioassay were used to 
detect the presence of toxic compounds in cyanobacterial blooms.
153
 However, 
apart from the symptoms exhibited in the mouse bioassay, these methods gave no 
indication of which toxic compound/s were present.
154
 Nowadays, microcystin 
levels in environmental samples are generally determined by protein phosphatase 
inhibition assay (PPIA), enzyme-linked immunosorbent assay (ELISA), high 
performance liquid chromatography with UV detection (HPLC-UV) or HPLC 
coupled to mass spectrometry detection (LC-MS).
155,156
  
 
1.4.1 Protein Phosphatase Inhibition Assay 
The PPIA utilises the ability of microcystins to inhibit protein phosphatases in 
order to determine the quantity of microcystin present in a sample. The amount of 
microcystin is determined by comparison with a standard curve constructed using 
microcystin at known concentrations and assayed in the same manner. In the past, 
this technique was limited by the commercial unavailability of the protein 
phosphatase enzyme and the radioactively-labelled substrate.
155
 Nowadays, 
colorimetric (p-nitrophenyl phosphate)
82
 and fluorescent (4-methylumbelliferyl 
phosphate)
157
 substrates are available instead of the unstable and hazardous 
32
P-labelled alternative. High quality protein phosphatase enzyme is also available 
from several sources. 
 
This technique is very sensitive (low picomolar region),
157
 but cannot distinguish 
between microcystins and other protein phosphatase inhibitors, such as okadaic 
acid.
158
 It also gives no indication of the microcystin congeners present in the 
sample, however, an estimate of the overall toxicity is given by the strength of 
protein phosphatase inhibition.
82
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1.4.2 Adda-Specific Enzyme-Linked Immunosorbent Assay 
ELISA exploits the specific binding of an antibody with the antigen it was raised 
against in order to determine the quantity of antigen in a sample.
159
 Monoclonal 
and polyclonal antibodies have been raised against a variety of microcystin 
congeners
160-163
 and Adda-haptens.
164
 These antibodies have shown varied cross-
reactivity, some reacted uniformly with different microcystin congeners,
160
 whilst 
others reacted poorly to certain congeners.
163
 
 
A direct competitive ELISA for microcystin analysis involves attaching an 
Adda-specific antibody to a solid phase, for example, a microtitre plate.
165
 This is 
incubated with a mixture of samples/standards and a microcystin-peroxidase 
conjugate which competes for the binding sites of the antibody. After removing 
unbound microcystin and incubation with a peroxidase substrate, an inverse 
response is observed and a high level of colour formation is taken to indicate a 
low level of microcystin in the sample. 
 
Modern ELISA protocols have sensitivity comparable with the PPIA (low 
picomolar region),
164
 but are specific for Adda-containing compounds. As ELISA 
gives no indication of the microcystin congeners present, it provides no 
information on the toxicity of the sample. 
 
1.4.3 High Performance Liquid Chromatography-Ultraviolet Detection 
A microcystin-containing extract or water sample can be separated by HPLC in 
order to determine the microcystin congeners present and their concentration. 
Generally a reversed-phase C18 column with an acidic buffer is utilised.
166
 When 
coupled to a photo-diode array detector, the congeners present can be determined, 
to some degree, by the retention time on a C18 column and the UV spectrum.
167
 
However, this relies on the appropriate microcystin standard being available for 
comparison. Most microcystin congeners exhibit a UV maximum of 238 nm due 
to the conjugated diene group of the Adda moiety, although tryptophan-containing 
congeners also have a maximum at 222 nm.
153
 The quantity of microcystin 
present in a sample is determined by comparison of the UV absorbance (at 
238 nm) of the microcystin peaks with a standard curve.
167
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The sensitivity of this method of microcystin analysis is in the moderate 
nanomolar range.
168
 One disadvantage of HPLC quantification of microcystins is 
the long duration of both sample handling and analytical procedures, and the 
method has also been shown to be susceptible to matrix-effects from co-eluting 
extract components
169
 and plasticisers.
170
  
 
1.4.4 Liquid Chromatography-Mass Spectrometry Detection 
Liquid chromatography in combination with MS is the most robust of current 
methods used for microcystin analysis. It gives definitive information on the 
congeners present according to their retention time on a C18 column and their 
mass-to-charge ratio (m/z).
166
 Mass spectrometers equipped to perform MS/MS 
can further clarify any ambiguous identifications. Multiple reaction monitoring 
methods, which utilise MS/MS capabilities are often used to improve the 
selectivity and sensitivity of the method.
171
 Here, a target ion is isolated and 
fragmented, then the resulting fragments ions are used for quantification purposes. 
With microcystin analysis, the m/z 135 Adda sidechain fragment ion is commonly 
utilised, as it is seldom observed in other compounds.
172
 Due to a fast scan rate, 
mass spectrometers equipped with a triple quadrupole mass analyser are able to 
analyse multiple target ions within a given segment of an HPLC chromatogram, 
whereas ion trap mass spectrometers, which have a slower scan rate, can only 
manage several target ions. Despite the enhanced selectivity and sensitivity, the 
major limitation of MS detection is the high capital and running costs of the 
instrumentation. 
 
This method of microcystin analysis has a sensitivity in the low nanomolar 
range.
157
 As with HPLC-UV analysis, matrix effects are apparent and lengthy 
procedures can be a hindrance. However, recent advances in small particle and 
monolithic silica columns have decreased instrument run-times significantly from 
those achieved using conventional HPLC.
173,174
 
 
1.4.5 Matrix-Assisted Laser Desorption/Ionisation-Time of Flight Mass 
Spectrometry 
Matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) MS 
produces ions from laser irradiation of a sample co-crystallised with a matrix. The 
laser energy is absorbed by the matrix and passed to the analyte molecules.
175
 This 
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method of ionisation predominantly produces singly protonated ions to 
approximately m/z 5000 and allows complex mixtures to be analysed from a 
minute amount of sample without prior separation.
176
 
 
For qualitative analyses of microcystins, MALDI MS gives comparable 
information to LC-MS. By separating sample ions according to their m/z, it allows 
for the identification of most microcystin congeners. Instruments equipped to 
analyse post-source decay have the ability to further clarify any ambiguous 
identifications.
176
 Analysis times on a MALDI mass spectrometer are shorter than 
with LC-MS since sample components do not need to be separated on a 
C18 column and sample preparation is minimal. MALDI MS is also highly suited 
to automated high-throughput sample preparation and data acquisition,
177
 making 
it an ideal technology for analysing large numbers of samples quickly. 
 
Whilst MALDI MS has frequently been used for qualitative detection of 
microcystins in cyanobacterial samples,
44,178-183
 it has only recently been used as a 
quantitative tool.
184
 The low ‘spot-to-spot’ and ‘shot-to-shot’ reproducibility of 
MALDI MS analyses are the main impediments to its quantitative use.
185-187
 To 
overcome this, an internal standard is commonly added to the sample and to 
standard solutions prior to preparation of the MALDI target.
188-192
 The signal for 
the analyte is then assessed against the signal for the internal standard. An internal 
standard used for quantitative MALDI MS needs to have similar chemical 
properties to the target analyte, be separated in mass, ionise with a similar 
efficiency and, preferably, be commercially available.
193
 
 
Howard and Boyer
184
 investigated the suitability of four potential internal 
standards; angiotensin I, cyclosporine A, nodularin and 
15
N-MC-YR, for 
quantitative MALDI MS analyses of microcystins. Angiotensin I, cyclosporine A 
and nodularin are commercially available, however nodularin is considerably 
more expensive than the other alternatives (ca. 50-400 times). A stable isotope 
labelled internal standard is often the recommended choice of many 
researchers,
194,195
 however the 
15
N-MC-YR utilised in this study had to be 
prepared in-house. Of the four internal standards tested by Howard and Boyer,
184
 
nodularin gave the best quantitative performance. 
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Detection limits in the low micromolar region were achieved using this 
technique.
184
 However, ionisation suppression effects were observed when 
microcystins were analysed in a sample matrix which contained contaminating 
compounds,
184
 a problem which would need to be overcome or better understood 
before this technique could be used for routine analyses. Another drawback of the 
method is that the existing protocol is not well suited for automated sample 
preparation or for use in an instrument automatically acquiring data. In order for 
this emerging technique to reach its full potential, different protocols are required 
to allow automated sample preparation and data acquisition. 
 
 
1.5 STRUCTURAL CHARACTERISATION OF OLIGOPEPTIDES 
Multiple structural characterisation techniques were utilised during this study in 
order to acquire as much information as possible on the oligopeptides investigated. 
A short description of the techniques and the structural information they can 
supply is provided in this section. 
 
1.5.1 Mass Spectrometry 
Mass spectrometry involves the assessment of ions in the gas phase in order to 
determine their m/z. Deconvolution from the determined m/z can provide the mass 
of the analyte. Mass spectrometers consist of a method of sample introduction, an 
ion source to ionise sample component and a mass analyser which separates ions 
according to their m/z.
196
 
 
Mass spectrometers with multiple mass analysers in series (MS/MS) and ion-trap 
mass analysers can provide structural information on a compound. The first mass 
analyser is used to isolate the ion of interest, which is broken apart (generally 
through collision with an inert, heavy gas) and the m/z of the resulting fragments 
are assessed using the second mass analyser.
197
 The m/z of the fragment ions 
indicate how the parent compound was put together. In an ion-trap mass analyser, 
the ion of interest is trapped whilst the other ions are filtered out, the trap is then 
flooded with a collision gas, causing fragmentation of the parent ion and the m/z 
of the resulting fragments are assessed.
197
 Furthermore, the resulting fragment 
ions can be trapped and broken apart to provide additional structural information 
(MS
n
). 
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The ionisation techniques utilised during this study were MALDI and electrospray 
ionisation (ESI). Both are relatively ‘soft’, providing intact molecular ions for 
labile compounds such as peptides.
198
 As discussed in Section 1.4.5, MALDI 
produces ions from laser irradiation of a sample co-crystallised with a matrix.
175
 
This method of ionisation produces predominantly singly protonated ions and 
allows complex mixtures to be analysed without prior separation.
176
 ESI produces 
ions by passing a sample in solution through a charged capillary, from which it 
acquires a charge. As the solution exits the capillary, it is nebulised into a 
desolvation chamber where solvent is removed from the ionised analyte.
199
 This 
method of ionisation is pH dependent and requires complex mixtures first be 
separated by HPLC. It also has a propensity towards multiply charged ions when 
multiple ionisation points are available on a single compound.
200
 
 
These ionisation techniques were utilised in three different mass spectrometers; 
MALDI directly coupled to a TOF mass analyser (Bruker AutoFlex II), an 
LC-MS with HPLC coupled to ESI with an ion-trap mass analyser (Bruker 
AmaZon X) and ESI orthogonally coupled to a TOF mass analyser (Bruker 
MicrOTOF). 
 
1.5.2 Advanced Marfey’s Amino Acid Analysis 
In 1984, it was found that derivatisation of an amino acid with FDAA (1-difluoro-
2,4-dinitrophenyl-5-alanine amide) allowed for the separation of the D- and 
L-stereoisomers by conventional reversed-phase HPLC.
201
 However, the lack of 
standards for non-proteinogenic amino acids posed a problem for the analysis of 
cyanobacterial oligopeptides. To overcome this, two measures were undertaken; 
racemisation of the sample and coupling with MS, this technique was termed 
Advanced Marfey’s amino acid analysis.202 
 
Racemisation of the sample amino acids produces a mixture of both the D- and 
L-stereoisomers. When the derivatives of this mixture were compared to a 
non-racemised mixture of the sample amino acids, the configuration of the 
original amino acid could be determined. Racemisation of the sample amino acids 
was later replaced by derivatisation with D- and L-FDAA which facilitated the 
identification of the stereoisomer present in the sample.
203,204
 Coupling with MS 
allowed the mass of unconventional amino acids to be determined. For this, a 
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heavier derivatisation reagent (1-difluoro-2,4-dinitrophenyl-5-leucine amide; 
FDLA) was utilised, as it produced a more intense MS signal.
202,205
 
 
Advanced Marfey’s amino acid analysis of a cyanobacterial peptide is generally 
conducted on a pure sample which has been hydrolysed into its constituent amino 
acids. After derivatisation with L-FDLA or DL-FDLA, the products are analysed 
by LC-UV-MS.
205
 Comparison of the L-FDLA derivatives with those of standard 
amino acids allows the identification and determination of the configuration of 
some amino acids. Comparison of the L-FDLA derivatives of the sample 
hydrolysate with the DL-FDLA derivatives, indicates the configuration of the 
unconventional amino acids. 
 
1.5.3 Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance spectroscopy exploits the phenomenon where 
magnetic nuclei (such as 
1
H and 
13
C) absorb electromagnetic radiation at a 
frequency specific to the isotope.
206
 Modern NMR spectrometers use helium-
cooled superconducting magnets to generate a magnetic field which the sample is 
placed inside.
206
 Sample nuclei are simultaneously excited by a short, 
high-powered radio frequency pulse. The time of the resulting decay signals are 
measured and Fourier transform is used to convert the signals into a readable 
spectrum measured as a frequency (chemical shift).
207
 As the position of the 
resulting chemical shift is dependent upon the strength of the applied magnetic 
field, the frequency of the signal is often expressed as dimensionless numbers 
(δ or ppm) relative to a reference signal. 
 
Shielding by the electron cloud of a nucleus causes a single isotope to resonate at 
different frequencies.
206,208
 The presence of nearby electronegative environments 
draws the electron cloud away from the nucleus and causes it to become 
deshielded. The resulting chemical shifts are indicative of the chemical 
environment the nuclei are in and hence give an indication of the structural 
elements present in a compound. Coupling (J) between adjacent magnetic nuclei 
is observed in NMR spectra as splitting of the signals, the multiplicity of a signal 
therefore indicates the number of adjacent magnetic isotopes.
206,209
 Carbon spectra 
are generally acquired decoupled and each 
13
C nucleus in an unique chemical 
environment resonates as a single peak.
206
 Two-dimensional NMR experiments 
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plot data on two axes and show correlations between two magnetic nuclei.
206
 
Two-dimensional NMR experiments can allow correlations between different 
isotopes to be detected and give an indication of the proximity of other magnetic 
nuclei. 
 
 
1.6 OBJECTIVES, SCOPE AND OUTPUTS OF THIS RESEARCH 
This study had three distinct objectives:  
 
 To identify and characterise new microcystins, as well as other new 
cyanobacterial oligopeptides. 
 
 To improve an existing technique for the quantification of microcystins. 
 
 To examine how nitrogen supply can affect the abundance of different 
microcystin congeners. 
 
Chapter 2 of this thesis describes the MS/MS characterisation of a new 
anabaenopeptin from a New Zealand cyanobacterial bloom sample. This chapter 
is based on the article: Puddick, J. & Prinsep, M.R. MALDI-TOF mass 
spectrometry of cyanobacteria: A global approach to the discovery of novel 
secondary metabolites. Chemistry in New Zealand, 2008, 72, 68-71. 
 
Characterisation of 27 conventional microcystin congeners from a Microcystis 
strain isolated from Lake Hakanoa (Huntly, New Zealand) is described in 
Chapter 3. Ten of these microcystins have not been reported previously. This 
chapter is being written up as two papers; one article will detail the full structural 
characterisation of two of the new microcystins, the other will present the MS/MS 
characterisation of the remaining new variants and discuss the abundance of 
microcystin congeners produced by CYN06. Microcystins which contained 
oxidised tryptophan residues were also identified in this cyanobacterial strain and 
this is the first report of oxidised tryptophan residues in microcystins. This work is 
presented in Chapter 4 and is currently being developed into a scientific 
publication. 
 
Chapter 1 
30 
 
The structural characterisation of eight new microcystins and six novel linear 
peptides from an Antarctic cyanobacterial sample is described in Chapter 5. 
Portions of this chapter are based on the publication: Wood, S.A., Mountfort, D., 
Selwood, A.I., Holland, P.T., Puddick, J. and Cary, S.C. Widespread distribution 
and identification of eight novel microcystins in Antarctic cyanobacterial mats. 
Appl. Environ. Microbiol., 2008, 74, 7243-7251. This was the first report of 
microcystins which contain a position one glycine, as well as the first report of 
ADMAdda-containing microcystins from the Southern Hemisphere. The 
additional characterisation work presented in this chapter will be written up as a 
scientific publication. 
 
Chapter 6 of the thesis is based on the publication: Puddick, J., Prinsep, M.R., 
Wood, S.A., Cary S.C. and Hamilton, D.P. Enhanced sample preparation for 
quantitation of microcystins by matrix-assisted laser desorption/ionisation-time of 
flight mass spectrometry. Phytochemical Analysis, 2012, 23, 285-291. Here, the 
development of a sample preparation for use with quantitative MALDI-TOF 
analysis of microcystins is described. 
 
A preliminary investigation of microcystin congener abundance in response to 
nitrogen availability is presented in Chapter 7. This is the first study to show that 
microcystin congener abundance is affected by nitrogen supply and opens new 
research avenues for investigating the regulation of microcystin production. 
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CHAPTER 2 
 
Tandem Mass Spectrometry Characterisation 
of a New Anabaenopeptin from a 
New Zealand Microcystis Species 
 
 
2.1 INTRODUCTION 
Anabaenopeptins are cyclic peptides containing six amino acids. Each contains a 
D-lysine (Lys) in position two with a ureido bond to a carbonyl-linked sidechain 
amino acid in position one. The D-Lys also forms a secondary peptide bond which 
encloses the ring, as in anabaenopeptin A (2).
21
 The CO-linked sidechain and the 
ring amino acids vary, as does their degree of methylation, resulting in 39 
different anabaenopeptin structures being observed to date (2,120-157; Table 2.1).  
 
 
 
Anabaenopeptins are produced by a non-ribosomal peptide synthetase module 
similar to that of the microcystin synthase discussed in Section 1.3.1.  The 
multi-enzyme complex is genetically coded by a 32.5-kb gene cluster consisting 
of five open reading frames.
210
 The enzyme complex builds the structure from the 
position one sidechain amino acid by consecutive addition of amino acids via 
condensation, adenylation and thiolation domains. The ring is cyclised by 
condensation of the carboxyl group of the position six amino acid with the 
sidechain amine of the position two Lys. An epimerisation domain facilitates  
  
 
3
2
 
Table 2.1: Amino acid sequence, molecular masses and bioactivity data on the known anabaenopeptins.
a
 
Anabaenopeptin Mr (Da)
b
 1 3 4 5 6 Biological Activities
 d
 References 
Anabaenopeptin A (2) 843.4 Tyr Val Hty N-MeAla Phe rNEc 21 
Anabaenopeptin B (120) 836.5 Arg Val Hty N-MeAla Phe rNEc 21,211,212 
Anabaenopeptin B1 (121) 
c
 850.5 Har Val Hty MeAla Phe  213 
Anabaenopeptin C (122) 808.4 Lys Val Hty N-MeAla Phe  214 
Anabaenopeptin D (123) 827.4 Phe Val Hty N-MeAla Phe  214 
Anabaenopeptin E (124) 850.5 Arg Val Hty(OMe) N-MeAla Phe  212,215 
Anabaenopeptin F (125) 850.5 Arg Ile Hty N-MeAla Phe PPi  212,215,216 
Anabaenopeptin F1 (126) 
c
 864.5 Har Ile Hty MeAla Phe  213 
Anabaenopeptin G (127) 
c
 908.5 Arg Ile Hty MeLeu Tyr  181 
Anabaenopeptin G* (128) 929.5 Tyr Ile Hty N-MeHty Ile CPAi 212,217 
Anabaenopeptin H (129) 922.5 Arg Ile Hty N-MeHty Ile CPAi 212,217 
Anabaenopeptin I (130) 759.5 Ile Val Hty N-MeAla Leu CPAi 212 
Anabaenopeptin J (131) 793.4 Ile Val Hty N-MeAla Phe CPAi 212 
Anabaenopeptin T (132) 865.5 Ile Val Hty N-MeHty Ile CPAi 212,218 
Anabaenopeptin HU892 (133) 892.5 Arg Val Hph N-MeHty Ile  219 
Anabaenopeptin KT864 (134) 864.5 Har Ile Hty N-MeAla Phe  220 
Anabaenopeptin MM823 (135) 823.4 Glu(OMe) Val Hty N-MeAla Phe CHYi, ELAi 221 
Anabaenopeptin MM850 (136) 850.5 Arg(OMe) Val Hty N-MeAla Phe TRPi, CHYi, ELAi 221 
Anabaenopeptin MM913 (137) 913.5 Tyr Ile Hph N-MeHty Ile  221 
Anabaenopeptin NZ825 (138) 825.4 Phe Ile Hph N-MeGly Hph  222 
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Anabaenopeptin NZ841 (139) 841.4 Phe Ile Hty N-MeGly Hph  222 
Anabaenopeptin NZ857 (140) 857.4 Phe Ile Hty N-MeGly Hty  222 
Anabaenopeptin 820 (141) 
c
 820.5 Arg Val Hph MeAla Phe  183 
Anabaenopeptin 908 (142) 908.5 Arg Val Hty N-MeHty Ile CPAi 223 
Anabaenopeptin 915 (143) 915.5 Tyr Val Hty N-MeHty Ile  223 
Ferintoic Acid A (144) 866.4 Trp Val Hty N-MeAla Phe  224 
Ferintoic Acid B (145) 880.4 Trp Ile Hty N-MeAla Phe  224 
Lyngbyaureidamide A (146) 855.5 Phe Ile Hty N-MeAla Hph  22 
Lyngbyaureidamide B (147) 841.4 Phe Ile Hty N-MeAla Phe  22 
Nodulapeptin A (148) 929.4 Ile Met(O2) Hph N-MeHty Ser(OAc)  225 
Nodulapeptin B (149) 913.4 Ile Met(O) Hph N-MeHty Ser(OAc)  225 
Nodulapeptin 899 (150) 899.4 Phe Val Hph N-MeHty Met  226 
Nodulapeptin 901 (151) 901.4 Phe Val Hph N-MeHty Met(O)  226 
Nodulapeptin 917 (152) 917.4 Phe Val Hph N-MeHty Ser(OAc)  226 
Oscillamide B (153) 868.4 Arg Met Hty N-MeAla Phe PPi 216 
Oscillamide C (154) 956.5 Arg Ile Hty N-MeHty Phe PPi 216 
Oscillamide H (155) 929.5 Tyr N-MeIle Hty Hty Ile  227 
Oscillamide Y (156) 857.4 Tyr Ile Hty N-MeAla Phe CHYi 216,228 
Schizopeptin 791 (157) 791.5 Ile Ile Hph N-MeAla Phe TRPi 229 
a
 Amino acid numbering is as indicated in Anabaenopeptin A (2); D-Lys is omitted as it is always present in position two. 
b
 Masses are rounded to one decimal 
place. 
c
 Reported structure is based on tandem mass spectrometry data so identity of some amino acids is putative. 
d
 rNEc = Relaxation of norepinephrine-
induced contraction; CPAi = Inhibition of carboxypeptidase-A; PPi = Inhibition of protein phosphatases 1 & 2A; TRPi = Inhibition of trypsin; 
CHYi = Inhibition of chymotrypsin; ELAi = Inhibition of elastase. 
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isomerisation of L-Lys to D-Lys, whilst the presence of methyltransferase domains 
allows for the methylated variants sometimes observed.
29,210
 As with microcystin 
biosynthesis, the substrate specificity of the various adenylation domains 
determines which amino acid is incorporated at each position and a lack of 
specificity at a certain domain results in multiple anabaenopeptins being produced 
by a single cyanobacterial strain. 
 
To date, anabaenopeptins have been found in multiple cyanobacterial genera 
including; Anabaena,
21
 Aphanizomenon,
212
 Lyngbya,
22
 Microcystis,
219
 
Nodularia,
225
 Oscillatoria
215
 and Schizothrix.
229
 The varied structures of the 
anabaenopeptins, listed in Table 2.1, also have varied biological activities 
including; relaxation of norepinephrine-induced contraction,
21
 protein 
phosphatase inhibition,
216
 carboxypeptidase-A inhibition
217
 and protease 
inhibition.
228
 
 
Compounds structurally related to anabaenopeptins have been found in marine 
cyanobacteria
230
 and sponges,
231-235
 as well as terrestrial cyanobacteria.
236
 The 
structures are similar to that of an anabaenopeptin as they are D-Lys mediated 
cyclic pentapeptides which contain a CO-linked amino acid sidechain, as in 
mozamide A (158).
233
 However, they regularly contain modified tryptophan 
residues and almost all contain a leucine in position four instead of an aromatic 
amino acid. The presence of these compounds in sponges is assumed to be due to 
a symbiotic relationship with cyanobacteria.
231-235
 This assumption is supported 
by observations that the cyclic peptides patellamides A and C,
237
 which were 
initially isolated from an ascidian, were actually produced by its cyanobacterial 
symbiont Prochloron didemni.  
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This chapter details the partial characterisation of a new anabaenopeptin, found in 
an environmental sample collected from Lake Wiritoa (Manawatu, New Zealand) 
using matrix-assisted laser desorption/ionisation-time of flight mass spectrometry 
(MALDI-TOF MS). 
 
2.2 RESULTS 
The positive ion MALDI-TOF mass spectrum of the Lake Wiritoa sample 
(Figure 2.1) showed multiple peaks relating to the masses of various known 
oligopeptides including several anabaenopeptins (Table 2.2). Analysis of the 
daughter ion spectra collected by MALDI post source decay (PSD) confirmed 
these identifications and indicated the presence of an unknown metabolite with 
m/z 907. 
 
 
Figure 2.1: Positive ion MALDI-TOF mass spectrum of a methanol extract of 
the Lake Wiritoa sample. 
 
Table 2.2: Assignment of the ions observed in the MALDI-TOF mass spectrum 
of the Lake Wiritoa sample. 
m/z Assignment m/z Assignment 
742.4 Nostoginin BN741
238
 828.5 Anabaenopeptin D
214
 
846.5 Unknown compound 887.6 Microginin 299-A
239
 
893.5 Anabaenopeptin HU892
219
 907.6 New Anabaenopeptin 906 
923.6 Anabaenopeptin H
217
 953.6 MC-AR
38
 
975.6 Unknown compound 987.6 Micropeptin A
240
 or K139
241
 
995.6 MC-LR
31
 1015.6 Desmethyl MC-FR
58,59
 
1021.6 Unknown compound 1029.6 MC-FR
38
 
1038.6 MC-RR
70
 1045.6 MC-YR
31
 
1049.6 MC-(H4)YR
57
 1054.6 Desmethyl MC-WR
58
 
1068.6 MC-WR
38
 1084.6 Unknown microcystin 
1100.6 Unknown microcystin 1448.9 Unknown compound 
1672.7 Unknown compound 1732.1 Unknown compound 
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The MALDI PSD spectrum of the m/z 907 ion (Figure 2.2), in conjunction with 
the sequences of the presently known anabaenopeptins (Table 2.1), allowed for 
the postulation of the structure of the new anabaenopeptin 906 (159). The PSD 
spectrum showed the loss of a 200 Da fragment, which is diagnostic of an 
anabaenopeptin possessing an arginine (Arg) sidechain.
181
 The low m/z species 
(Table 2.3) indicated the presence of Arg (m/z 129), Lys (m/z 84), isoleucine (Ile; 
m/z 86), methylleucine (MeLeu; m/z 100), and methylhomotyrosine (MeHty; 
m/z 107, 164). Thus, five of the six amino acids present in the anabaenopeptin 
were identified and the missing mass entity correlated with that of a phenylalanine 
(Phe) residue. 
 
 
 
 
Figure 2.2: Tandem mass spectrum of anabaenopeptin 906. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
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Table 2.3: Tandem mass spectrometry fragment ions for anabaenopeptin 906 
observed by matrix-assisted laser desorption/ionisation post-source 
decay. 
m/z Fragment Assignment m/z Fragment Assignment 
84 Lys fragment 86 Ile immonium 
100 MeLeu immonium 107 Tyr sidechain 
112 Arg fragment 129 Arg immonium 
164 MeHty immonium 175 Arg + 2H 
201 CO-Arg 275 MeLeu-Phe + H 
305 Ile-MeHty + H 449 Arg-CO-Lys-Phe − CO + 2H 
466 MeHty-MeLeu-Phe + H 579 Ile-MeHty-MeLeu-Phe + H 
594 Lys-Phe-MeLeu-MeHty + 2H 603 Arg-CO-Lys-Phe-MeLeu + H 
707 Lys-Ile-MeHty-MeLeu-Phe + 2H 907 M + H 
 
 
The fragment ions which characterise the CO-linked Arg sidechain are displayed 
in Figure 2.3A.
181
 As well as being attached to the Arg sidechain, the Lys at 
position two is also attached to the positions three and six ring amino acids. The 
m/z 449 fragment showed that Phe was one of these amino acids, however, the 
fragment could represent Phe attached to the sidechain amine of Lys 
(Figure 2.3A), or to the backbone amine of Lys (Figure 2.3B). 
 
 
Figure 2.3: Fragment ions observed from the sidechain of 
anabaenopeptin 906 with phenylalanine present in position 
six (A) and position three (B). 
 
The higher mass fragments provide the sequence of the ring amino acids in 
anabaenopeptin 906 (Table 2.3). The m/z 275 fragment indicated that Phe was 
joined to MeLeu (Figure 2.4) and the m/z 449 fragment showed that Phe was also 
attached to Lys, placing it in either position three or six. The m/z 466 fragment 
therefore, showed that MeHty was attached to MeLeu since Phe was already 
attached to both Lys and MeLeu. This gave a final ring sequence of 
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Ile-MeHty-MeLeu-Phe, and supported the presence of the Ile-MeHty fragment at 
m/z 305. 
 
 
Figure 2.4: Tandem mass spectrometry fragment ions which indicate 
the ring amino acid sequence in anabaenopeptin 906. 
 
Although none of the observed fragments confirmed the order in which the amino 
acids were present in the ring or the identity of the Leu/Ile and MeLeu/MeIle 
residues present in positions three and five, the proposed structure 159 was 
constructed using the fragments listed in Table 2.3 in conjunction with the 
sequences of the presently known anabaenopeptins (Table 2.1). Here, Phe is 
commonly seen at position six and never in position three. Also, an aromatic 
amino acid, such as Hty, has always been present at position four. These 
observations suggested that the order of the ring amino acids is most likely 
Ile-MeHty-MeLeu-Phe instead of in the opposite order. According to the tandem 
MS (MS/MS) data, the position three amino acid could be either an Ile or a Leu, 
as these amino acids have an identical mass. However Ile is commonly observed 
in this position and Leu has never been reported. Similarly, MeLeu has been 
reported in position five once, but MeIle has not. 
 
 
2.3 DISCUSSION 
The proposed structure for anabaenopeptin 906 was constructed using MS/MS 
data and the amino acid sequences of the presently known anabaenopeptins. 
Whilst the MS/MS data indicated the amino acids present in anabaenopeptin 906 
and the order of these amino acids, it does not indicate their position in the 
structure. The presently known anabaenopeptin sequences provide a strong 
indication that Ile is more likely to be in position three than Phe, which enabled a 
sequence of Arg-Lys-Ile-MeHty-MeLeu-Phe to be postulated. 
 
Ile       MeHty       MeLeu       Phe
+H
+H
305
275
+H
466
+H
579
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The MS/MS data cannot confirm whether the extra 14 Da mass on two of the 
amino acids (MeHty and MeLeu) was an N-methylation of the amine in the 
backbone of the amino acid chain or an additional methylene in the branching arm 
of the amino acid sidechain. However, in the case of the MeHty in position four, 
the methylation cannot be attributed to an O-methylation of the hydroxyl group of 
the sidechain, as this would cause the observed Tyr sidechain fragment ion 
(m/z 107; Table 2.3) to be 14 Da heavier. 
 
Leu and Ile, which have identical masses, can in some cases be differentiated by 
MS/MS. The use of high-energy, collision-induced dissociation (CID) can yield 
sufficiently intense fragmentation that a portion of the Leu/Ile sidechain breaks 
off.
242,243
 As a result, the d- or w-fragment ions for Leu would be 42 Da less than 
the corresponding a- or z-ions, whilst those for Ile would show a reduction of 
28 Da (Figure 2.5).
242,243
 Neither of these fragment ions were observed in the 
MS/MS spectrum. The likely reason for their absence was the low abundance of 
these ions, combined with the “LIFT” technology used in this particular MALDI 
mass spectrometer. When MS/MS analyses are performed on an instrument 
operating without “LIFT”, multiple fragment ion spectra would be collected over 
different m/z ranges to obtain the complete spectrum. A consequential benefit of 
this is that a particular m/z region, where the fragment ions of interest were 
expected to be, can be focused upon and as a result, enhance the spectrum. Using 
an instrument equipped with “LIFT” technology, all the fragment ions were 
assessed simultaneously and a single region could not be focused on. 
 
 
Figure 2.5: Sidechain fragmentation of the amino acids isoleucine and 
leucine by high-energy, collision-induced dissociation. 
 
N
H
O
N
H
O
- 28 Da - 42 Da
Isoleucine Leucine
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As discussed in Section 2.1, various anabaenopeptins have been reported to have 
several different bioactivities including; relaxation of norepinephrine-induced 
contraction,
21
 protein phosphatase inhibition,
216
 carboxypeptidase inhibition
217
 
and protease inhibition.
228
 Utilising the structures and bioactivities of the known 
anabaenopeptins (Table 2.1) and comparing them with the proposed structure of 
anabaenopeptin 906, the potential activities of this new compound can be 
postulated. Several anabaenopeptins inhibit carboxypeptidase-A, however it is 
unlikely that anabaenopeptin 906 would prove an effective inhibitor, since 
anabaenopeptins possessing an Arg sidechain have been shown to be ineffective 
or less effective inhibitors of the enzyme.
212
 Anabaenopeptin 906 could inhibit 
protein phosphatases 1 and 2A, as an Arg sidechain has been shown to be 
important for inhibition of this enzyme.
216
  However, an N-MeHty in position five 
was shown to enhance this inhibition and this amino acid is absent in 
anabaenopeptin 906. Only two anabaenopeptins (anabaenopeptins A and B) have 
been assessed for relaxation of norepinephrine-induced contraction.
21
 Given that 
anabaenopeptin 906 shows some structural similarity to anabaenopeptin B, it 
could possibly exhibit the same effect. 
 
Since the putative structure of anabaenopeptin 906 was determined from a small 
environmental sample (≈ 0.5 mg), there was insufficient material to proceed with 
purification and further characterisation. In the following year, cyanobacterial 
blooms at Lake Wiritoa were monitored by MALDI-TOF MS for the presence of 
anabaenopeptin 906, but it was not observed. This study illustrates the power, and 
the limitations of characterising cyanobacterial secondary metabolites by 
MALDI-TOF MS. Whilst a putative structure was pieced together quickly from a 
small amount of sample, the identity of several of the amino acids present could 
not be confirmed and their stereochemistry would never be deduced by this 
technique. Ultimately, full characterisation of this novel compound would require 
purification of a larger sample and the use of other techniques such as nuclear 
magnetic resonance spectroscopy and amino acid analysis.  
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2.4 CONCLUSIONS 
A putative structure for anabaenopeptin 906 was constructed from MALDI 
MS/MS data, in conjunction with the sequences of the presently known 
anabaenopeptins. However, the identity and position of several amino acids 
cannot be stated with absolute certainty without the use of additional techniques. 
Unfortunately, the sample size did not allow for this, illustrating both the power, 
and the limitations of using such a sensitive technique for structural 
characterisation. 
 
 42 
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CHAPTER 3 
 
Structural Characterisation of New Microcystins 
from Microcystis CYN06  
 
 
3.1 INTRODUCTION 
Microcystins (MCs) are cyclic heptapeptides which can be toxic to mammals. 
They are generally composed of the unique β-amino acid Adda (3-amino-9-
methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid), D-glutamic acid (Glu), 
N-methyldehydroalanine (Mdha), D-alanine (Ala), D-erythro-β-methylaspartic 
acid (Masp) and two variable L-amino acids. To date, there have been at least 111 
different microcystin congeners characterised (Appendix A), mostly due to 
substitutions of the variable L-amino acids in positions two and four, although 
modifications have been reported for all of the amino acids.
33
 
 
The different microcystin congeners range in toxicity according to their ability to 
inhibit the important eukaryotic regulatory enzymes, serine/threonine protein 
phosphatases 1 and 2A.
82
 Microcystins predominantly affect the liver cells of 
mammals, where inhibition of the protein phosphatases in these cells results in 
excessive signalling due to a lack of regulation via the phosphatases 
(see Section 1.2.7).
244
  
 
Microcystins have been reported to be produced by numerous cyanobacterial 
genera when the necessary microcystin synthase genes are present. These 
non-ribosomal peptide synthetase (NRPS) and polyketide synthase (PKS) genes 
produce a multi-enzyme complex which sequentially adds onto phenylacetate to 
produce a peptide chain which is condensed to form the cyclic microcystin 
(see Section 1.3.1).
99-101
  
 
The occurrence of different microcystin congeners is due to differences in the 
coding of the microcystin synthase genes of different cyanobacterial strains. At 
times, the McyA1 N-methyltransferase domain can be inefficient or inactive, 
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which results in a position seven desmethyl variant. The amino acid specificity of 
the various adenylation domains is dependent upon their sequence. Changes to 
this sequence can cause the domains to be specific for a different amino acid or to 
recognise more than one amino acid.
110
 The substrate specificity of many of the 
adenylation domains is relatively conserved, whilst the substrate specificity of the 
position two and four adenylation domains are varied (see Section 1.3.2). 
 
A single strain of cyanobacteria can often produce more than one microcystin 
congener. This is mainly due to at least one adenylation domain possessing 
relaxed substrate specificity and being able to incorporate different amino acids 
into the structure.
110,114
 A cyanobacterial strain will generally produce around four 
microcystin congeners, in most cases; MC-LR, MC-RR and desmethyl analogues 
of each (Appendix C). Whilst uncommon, cyanobacterial strains which produce 
up to 47 microcystin congeners have been reported.
245
 
 
A Microcystis species (CYN06) isolated from Lake Hakanoa (Huntly, New 
Zealand) in 2005
246
 was investigated as it produced a large number of microcystin 
congeners, including ten new variants. As modern mass spectrometry (MS) based 
techniques for microcystin detection rely upon previous knowledge of the 
compounds (see Section 1.4), the structural characterisation of these new 
microcystins was conducted. 
 
 
3.2 RESULTS 
3.2.1 Oligopeptide Diversity of Microcystis CYN06  
A methanol extract of Microcystis CYN06 was analysed by matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) MS. The resulting spectrum 
contained multiple ions spanning a mass range of 600-1,800 Da (Figure 3.1). 
Further investigation of these ions by MALDI post source decay (PSD), indicated 
the presence of linear, cyclic and tricyclic oligopeptides including; aeruginosins, 
microcystins, microviridins and a group of unknown metabolites with molecular 
weights of approximately 1,500 Da. 
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Figure 3.1: Positive ion MALDI-TOF mass spectrum of a methanol extract of 
CYN06. 
 
The aeruginosins produced by CYN06 included the known aeruginosin 602,
183
 as 
well as several new aeruginosin analogues with masses of 604, 616, 618, 620, 634 
and 660 Da. The microviridins present may include the known microviridin I,
247
 
however the tandem MS (MS/MS) analysis could not confirm this. Several new 
microviridins with masses of 1779, 1745, 1780, 1759 and 1791 Da were also 
present in the extract. No attempt was made in the present study to purify and 
characterise the new aeruginosins and microviridins, but characterisation of these 
compounds form the basis of the current research in our group. 
 
The MALDI-TOF MS and MS/MS analysis of CYN06 also indicated the presence 
of a plethora of arginine-containing microcystins (Figure 3.2A). This included a 
new analogue of MC-RA with a position three aspartic acid (Asp; [Asp
3
] MC-RA; 
160). Since microcystins which do not contain an arginine residue have a low 
ionisation efficiency using MALDI,
184
 the microcystin diversity of CYN06 was 
further investigated using high performance liquid chromatography (HPLC) with 
electrospray ionisation (ESI) MS. The LC-MS analysis (Figure 3.2B) revealed the 
presence of fifteen microcystin congeners which were not evident from the 
MALDI-TOF MS analysis. In total, 27 microcystin congeners were detected, ten 
of which were new (160-169; Table 3.1). These microcystins ranged in polarity 
from hydrophilic (MC-RR) to slightly hydrophobic (MC-WL) and in size from 
895.5 Da ([Asp
3
] MC-LA) to 1067.5 Da (MC-WR). CYN06 also contained 
oxidised tryptophan microcystin congeners which are described in Chapter 4 of 
this thesis. 
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Figure 3.2: Positive ion MALDI-TOF mass spectrum of the microcystin-
containing region (m/z 850-1,150; A) and a liquid 
chromatography-mass spectrometry basepeak chromatogram 
(negative ion; m/z 850-1,150; B) of a methanol extract of CYN06. 
 
A microcystin containing a terminal alkene, as is found in Mdha and 
dehydroalanine (Dha), will readily react with β-mercaptoethanol under alkaline 
conditions.
41
 When dehydrobutyrine (Dhb) is present, this reaction rate is 
hundreds of times slower.
248
 A β-mercaptoethanol derivatisation of the CYN06 
extract underwent rapid reaction (t½ < 18 min) and all of the congeners were fully 
derivatised within four hours (see Appendix D.2). This indicated that each of the 
microcystins identified contained Dha or Mdha. Tandem MS analysis of each 
congener showed that an 83 Da moiety was present at position seven 
(Appendix E); therefore, each congener was designated as containing Mdha. 
 
The microcystin congeners produced by CYN06 show variability of the amino 
acids at both positions two and four. This indicates that the microcystin synthase 
in CYN06 has relaxed substrate specificity at McyB1 as well as at McyC 
(see Section 1.3.2). The presence of [Asp
3
] desmethyl congeners indicates that the 
adenylation domain of McyB2 recognises both Masp and Asp. This results in 
approximately 2.5% of each microcystin congener containing an Asp in position 
three. As the various substitutions occur at different levels, not all of the possible 
 
A 
B 
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Table 3.1: Structures, molecular masses and retention times of the microcystins 
observed in CYN06. 
 
Microcystin 
Mr
 a
 
(Da) 
RT 
b
 
(min) 
X Z R References 
MC-RRs 
[Asp
3
] MC-RR (67) 1023.6 6.32 Arg Arg H 60 
MC-RR (85) 1037.6 6.45 Arg Arg CH3 70,119,120 
MC-XRs 
MC-YR (97) 1044.5 7.20 Tyr Arg CH3 31 
[Asp
3
] MC-LR (30) 980.5 7.32 Leu Arg H 47,74 
MC-LR (7) 994.5 7.35 Leu Arg CH3 31,82 
[Asp
3
] MC-FR (59) 1014.5 7.52 Phe Arg H 58 
MC-FR (72) 1028.5 7.54 Phe Arg CH3 38 
[Asp
3
] MC-WR (105) 1053.5 7.56 Trp Arg H 58 
MC-WR (113) 1067.5 7.60 Trp Arg CH3 38 
MC-RZs 
[Asp
3
] MC-RA (160) 938.5 7.80 Arg Ala H This Study 
MC-RA (16) 952.5 7.84 Arg Ala CH3 39,41 
[Asp
3
] MC-RAba (161) 952.5 8.16 Arg Aba H This Study 
MC-RAba (19) 966.5 8.18 Arg Aba CH3 41 
MC-RL (41) 994.5 8.35 Arg Leu CH3 41 
MC-XAs 
MC-YA (17) 959.5 9.01 Tyr Ala CH3 31 
[Asp
3
] MC-LA (8) 895.5 9.12 Leu Ala H 34 
MC-LA (9) 909.5 9.29 Leu Ala CH3 32 
[Asp
3
] MC-FA (162) 929.5 9.46 Phe Ala H This Study 
MC-FA (163) 943.5 9.52 Phe Ala CH3 This Study 
[Asp
3
] MC-WA (164) 968.5 9.48 Trp Ala H This Study 
MC-WA (165) 982.5 9.54 Trp Ala CH3 This Study 
MC-XAbas 
MC-LAba (11) 923.5 9.69 Leu Aba CH3 34,35,249 
MC-FAba (166) 957.5 9.97 Phe Aba CH3 This Study 
MC-WAba (167) 996.5 10.24 Trp Aba CH3 This Study 
MC-XLs 
MC-LL (14) 951.5 10.50 Leu Leu CH3 37 
MC-FL (168) 985.5 10.71 Phe Leu CH3 This Study 
MC-WL (169) 1024.5 10.77 Trp Leu CH3 This Study 
a Molecular weights are rounded to one decimal place. b RT = Retention time on a C18 column as per 
Table 9.3. 
NH
O
Z
H
N
H
N X
HN
N
NH
HN
O
O
O
O O
O
O
HO O
OHO
R
CH2
2
1
3
4
76
5
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congeners have been observed in the present study, namely [Asp
3
] analogues 
of -RL, the -XAba, -XL and -YZ microcystin congeners. Tyrosine-containing 
analogues of the -XAba and -XL congeners were also not observed. 
 
On account of the difference in abundance of the various microcystins produced 
by CYN06, not all of the new microcystins were purified in adequate amounts to 
be fully characterised. MC-FA and MC-WA were isolated in sufficient quantities 
to undertake analysis by nuclear magnetic resonance (NMR) spectroscopy, MS 
and amino acid analysis. The other microcystins were present at lower levels and 
only MS characterisation could be performed. Whilst the characterisation of the 
known microcystins produced by CYN06 is not detailed in this chapter, the 
MS/MS characterisation of each microcystin listed in Table 3.1 can be found in 
Appendix E.  
 
3.2.2 Structural Characterisation of MC-FA from CYN06 
The presence and stereochemistry of several of the amino acids present in 
MC-FA (163) were determined by Advanced Marfey’s amino acid analysis.204,205 
Derivatisation of amino acids with L-FDLA allowed for the separation of both 
stereoisomers by reversed-phase C18 HPLC. LC-MS analysis of the L-FDLA 
derivatives of hydrolysed MC-FA indicated it comprised seven amino acids 
(Figure 3.3). The presence of D-Glu (m/z 440; 14.3 min), L-Ala (m/z 382; 
15.8 min), D-Ala (m/z 382; 18.6 min) and L-phenylalanine (Phe; m/z 458; 21.3 min) 
was determined by comparison with standard amino acids. The identities of the 
remaining peaks were determined by comparison with the L-FDLA derivatives of 
hydrolysed MC-LR (Appendix F.3). This indicated the presence of D-Masp 
(m/z 440; 15.9 min), N-methylamine (m/z 324; 19.6 min) and the methanol-loss 
product of 3(S)-Adda (m/z 592; 32.9 min). N-methylamine is produced during the 
breakdown of the Mdha or N-methyldehydrobutyrine observed in microcystins.
250
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Figure 3.3: Advanced Marfey’s amino acid analysis of MC-FA. Extracted ion 
chromatograms of hydrolysed MC-FA derivatised with L-FDLA. 
 
The high resolution MS (HRMS) analysis of 163 yielded a m/z of 966.4550, 
consistent with the sodium adduct ion of a cyclic peptide containing the six amino 
acids indicated by amino acid analysis (L-Ala, D-Ala, Glu, Masp, Phe, Adda) and 
Mdha (C49H65N7O12Na, m/z 966.4583, Δ −3.41 ppm). 
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The MS/MS spectrum of 163 (Figure 3.4) indicated that it was a microcystin with 
a structure similar to the majority of those previously characterised (Appendix A). 
The presence of Adda was indicated by the loss of 134 Da (m/z 810) and 313 Da 
(m/z 631).
34
 These fragments represented the loss of a portion of the Adda 
sidechain and the entire amino acid respectively (Figure 3.4). The mass difference 
between other fragment ions indicated the position of the amino acids in the 
structure (Table 3.2). 
 
 
Figure 3.4: Tandem mass spectrum of MC-FA and fragments commonly 
observed from the generic microcystin structure. Fragmentation 
induced by electrospray ionisation collision-induced dissociation. 
 
Table 3.2: Tandem mass spectrometry fragment ions for MC-FA observed by 
electrospray ionisation collision-induced dissociation. 
m/z Fragment Assignment
 a
 m/z Fragment Assignment
 a
 
348 Ala-Phe-Masp + H 365 Phe-Masp-Ala + NH4 
375 Adda’-Glu-Mdha + H 419 Ala-Phe-Masp-Ala + H 
436 Ala-Phe-Masp-Ala + NH4 446 Adda’-Glu-Mdha-Ala + H 
502 Mdha-Ala-Phe-Masp-Ala + H 509 Adda-Glu-Mdha – NH3 + H 
519 Mdha-Ala-Phe-Masp-Ala + NH4 580 Adda-Glu-Mdha-Ala – NH3 + H 
593 Adda’-Glu-Mdha-Ala-Phe + H 631 Glu-Mdha-Ala-Phe-Masp-Ala + H 
727 Adda-Glu-Mdha-Ala-Phe – NH3 + H 856 Adda-Glu-Mdha-Ala-Phe-Masp – NH3 + H 
792 M – Adda sidechain – H2O + H 810 M – Adda sidechain + H 
843 M – Mdha – H2O + H 926 M – H2O + H 
944 M + H   
a Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
 
The Adda’-Glu-Mdha fragment ion (m/z 375) commonly observed in 
microcystins
35,78
 was extended to include Ala and Phe (Figure 3.5A). This 
sequence was supported by a similar ion series containing Adda minus NH3 
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(m/z 509, 580, 727) and was extended to include Masp (Figure 3.5B). The 
fragment ion series which began with Phe-Masp-Ala (m/z 348) and extended in 
the opposite direction to include the second Ala residue, gave the complete amino 
acid sequence of Adda-Glu-Mdha-Ala-Phe-Masp-Ala. A fragment where Mdha 
and water were lost from the compound (m/z 843; Table 3.2) indicated that Adda 
and the second Ala residue were adjacent and that the structure was cyclic. 
 
 
Figure 3.5: Tandem mass spectrometry fragment ions indicating the amino 
acid sequence in MC-FA. 
 
The structures of several of the amino acids present in microcystins can only be 
confirmed by NMR spectroscopy. Interpretation of COSY, TOCSY, HSQC and 
HMBC spectra allowed for the assignment of the 
1
H and 
13
C NMR signals 
(Table 3.3). Several of the 
1
H signals overlapped in the spectrum acquired at 
400 MHz and the peak patterns had to be resolved using selective TOCSY 
experiments. Nuclear magnetic resonance spectra for MC-FA are presented in 
Appendix G. 
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Table 3.3: Nuclear magnetic resonance spectroscopy assignment of MC-FA at 
400 MHz in CD3OD. 
AA
a
 13C 
1
H 
Mult.
b
 
(J in Hz) 
AA
a
 13C 
1
H 
Mult.
b
 
(J in Hz)
 
D-Ala-1    Adda-5 cont.    
1 173.8 -  5 138.8 6.26 d (15.9) 
2 49.1
c
 4.45 q (7.3)
d
 6 134.0 -  
3 18.0 1.30 d (7.3) 7 137.1 5.45 d (11.6)
d
 
    8 37.8 2.59 m 
L-Phe-2    9 88.5 3.26 dt (5.9, 6.7)
d
 
1 178.9 -  10 39.1 2.67 dd (7.2, 14.0) 
2 59.7 4.35
c
 m   2.82 dd (4.7, 14.0) 
3 37.9 3.19 (2H) m 11 140.7 -  
4 139.5 -  12 & 16 130.7 7.18
c
 d (7.8) 
5 & 9 130.4 7.37 d (7.8) 13 & 15 129.3 7.25
c
 dd (7.3, 7.8) 
6 & 8 129.5 7.24 dd (6.8, 7.8)
d
 14 127.1 7.16
c
 t (7.3) 
7 127.7 7.17 t (6.8)
d
 17 16.4 1.06 d (6.8)
d
 
    18 13.0 1.63 s 
D-Masp-3    19 16.7 1.02 d (6.8) 
1 nd -  20 58.8 3.24 s 
2 57.9 4.41
c
 d (3.9)     
3 41.6 3.13 m D-Glu-6    
4 179.1 -  1 nd -  
5 15.7 1.05 d (7.3)
d
 2 55.3 4.33
c
 m 
    3 29.5 1.96 m 
L-Ala-4      2.22 m 
1 175.1 -  4 33.6 2.55 (2H) m 
2 49.3
c
 4.56 q (7.3)
d
 5 177.3 -  
3 17.5 1.25 d (7.3)     
    Mdha-7    
Adda-5    1 165.9 -  
1 176.8 -  2 146.6 -  
2 45.5 2.97 m 3 114.4 5.45 s
d
 
3 56.7 4.59 dd (9.7, 10.9)   5.89 s 
4 126.7 5.44 dd (10.9, 15.9)
d
 N-CH3 38.5 3.30
c
 s 
a AA = Amino acid (number indicates the position in the structure); nd = Not detected. b Mult. = Multiplicity of the 
proton signal; J = Coupling constant. c Signals were overlapped so chemical shifts were determined using correlations 
observed in 2D HSQC spectra. d Multiplicity and coupling constants were determined using 1D-selective TOCSY 
experiments. 
 
NMR Characterisation of the Adda residue in MC-FA 
The Adda residue in MC-FA was characterised by NMR spectroscopy through 
analysis of the results of 
1
H, 
13
C, DEPT, COSY, HSQC and HMBC experiments. 
The residue gave rise to sixteen proton signals; two singlets at 1.63 and 3.24 ppm, 
five doublets at 1.02, 1.06, 5.45, 6.26 and 7.18 ppm, a triplet at 7.16 ppm, five 
doublets of doublets at 2.67, 2.82, 4.59, 5.44 and 7.25 ppm, a doublet of triplets at 
3.26 ppm, and two multiplets at 2.59 and 2.97 ppm (Figure 3.6 and Table 3.3). 
The HSQC spectrum correlated these signals with fifteen carbon signals and 
indicated that the 2.67 and 2.82 ppm protons were both attached to a carbon atom 
which resonated at 39.1 ppm. The DEPT-135 indicated that this carbon was the 
only methylene present in the residue. 
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Figure 3.6: Structure of the Adda residue in MC-FA. Atoms are numbered 
according to Reference 111 and proton chemical shifts are 
indicated. 
 
The chemical shift and multiplicity of the doublet at 1.06 ppm (H17) indicated it 
was a methyl adjacent to a methine. This was coupled to a multiplet at 2.97 ppm 
(H2; Figure 3.7A) which, due to its chemical shift, was likely to be adjacent to a 
carbonyl and another carbon. This was reinforced by a correlation in the HMBC 
spectrum between the H17 signal and a carbonyl at 176.8 ppm (C1; Figure 3.7B). 
 
 
Figure 3.7: COSY (A) and HMBC (B) correlations for the C1-C6 portion of 
the Adda residue in MC-FA. 
 
The C2 methine was also coupled to the 4.59 ppm resonance (H3; Figure 3.7A), 
which was coupled to the signal at 5.44 ppm (H4), also coupled to the proton 
signal at 6.26 (H5). The downfield chemical shifts of the H4 and H5 signals 
indicated that they were part of an alkene. The slightly downfield chemical shift 
of the H3 signal suggested that it was adjacent to two electron-withdrawing 
environments (an amine and an alkene). The multiplicity of the H5 doublet 
indicated that it was adjacent to a quaternary carbon. These pieces of information 
were used to build up the substructure in Figure 3.7. HMBC correlations were 
observed between H17-C3 and H5-C3 (Figure 3.7B) which supports that 
substructure if 
3
J correlations were being observed. 
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The C6 quaternary terminated the COSY coupling beyond the C5 methine, 
however, multiple HMBC correlations to the C6 carbon re-established 
connectivity within the amino acid. HMBC 
3
J correlations were observed from the 
H4 signal, as well as from a multiplet at 2.59 ppm (H8; Figure 3.8B). HMBC 
2
J correlations were also observed from the H5 signal and a doublet at 
5.45 ppm (H7). The downfield resonance of the H7 doublet indicated that it was 
part of an alkene and a COSY coupling to the multiplet at 2.59 ppm (Figure 3.8A; 
H8) indicated the double bond was shared with the C6 quaternary (since the 
chemical shift of the H8 proton was too upfield to be part of an alkene). 
 
 
Figure 3.8: COSY (A) and selected HMBC (B) correlations for C4-C8 
portion of the Adda residue in MC-FA. 
 
An HMBC correlation to the C6 quaternary carbon was also observed from a 
singlet at 1.63 ppm (H18; Figure 3.8B). The HSQC spectrum indicated that it was 
attached to a carbon which resonated at 13 ppm, a signal which H5 showed an 
HMBC correlation to (Figure 3.7B). As the H18 signal was not split by any other 
protons, it was designated as a methyl attached to the C6 quaternary. The slightly 
downfield resonance was due to the double bond attached to the C6 carbon. The 
only COSY coupling observed for this signal was a 
4
J coupling with the H7 
doublet (Figure 3.8A). 
 
The H8 multiplet was also coupled to a doublet at 1.02 ppm (H19) and a doublet 
of triplets at 3.26 ppm (H9; Figure 3.9A). The H19 doublet was a methyl attached 
to the H8 methine. The HSQC spectrum correlated the H9 proton signal with a 
carbon which resonated at 88.5 ppm, which the DEPT analysis assigned as a 
methine. The COSY spectrum indicated that it was adjacent to the methylene with 
diastereotopic protons (C10), but the downfield chemical shift of the signal 
suggested that it was also adjacent to an electron-withdrawing environment. 
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Figure 3.9: COSY (A) and selected HMBC (B) correlations for the C7-C10 
portion of the Adda residue in MC-FA. 
 
A proton singlet at 3.24 ppm (H20) was shown to be attached to a carbon at 
58.8 ppm by the HSQC spectrum. The DEPT analysis designated it as a methyl 
and the downfield chemical shift indicated that it was adjacent to an electron-
withdrawing environment. HMBC correlations between it and the C9 methine 
showed that they were attached to the same electron-withdrawing environment 
(Figure 3.9B). This chemical environment was likely an oxygen, as the 3.24 ppm 
signal was a sharp peak indicating that there was no exchange of 
protons/deuterium with the solvent (which would be the case if it were a 
secondary amine). 
 
As the Adda aromatic proton signals overlapped with those of the Phe residue, 
resolved HSQC and HMBC experiments were required to assign the signals 
(Figure 3.10). The HMBC correlations were then used to assign the aromatic 
portion of the Adda residue. 
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Figure 3.10:HSQC (A) and HMBC (B) spectra of the MC-FA aromatic region. 
 
Both of the H10 methylene signals showed HMBC correlations with a quaternary 
carbon at 140.7 ppm (C11), as well as a carbon at 130.7 ppm (C12/16; 
Figure 3.11). The HSQC spectrum correlated the C12/16 signal with a proton 
doublet at 7.18 ppm which showed an HMBC correlation to a carbon at 
127.1 ppm (Figure 3.10A & B). As the HMBC correlation (in an aromatic ring) 
was likely to be a 
3
J coupling, this signal was assigned as the para-position (C14; 
Figure 3.11). The C14 signal was correlated with the proton triplet at 7.16 ppm by 
HSQC. This assignment was reinforced by the HMBC correlation observed 
between the doublet of doublets at 7.25 ppm (H13/15) and the C11 quaternary. 
Again assuming a 
3
J coupling, that would attribute this signal to the meta-position 
on the ring. 
 
 
Figure 3.11: Selected HMBC correlations for the aromatic portion of the Adda 
residue in MC-FA. 
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The ROESY spectrum of MC-FA showed many correlations throughout the Adda 
moiety (Figure 3.12), which indicated that there was a great deal of flexibility 
within the structure. The Adda residue contains two double bonds, the 
stereochemistry of which is important for the toxicity of the microcystin.
52,121
 
Generally the double bonds are both in the E-configuration, however exposure to 
ultraviolet light has been shown to isomerise the second double bond to the 
Z-configuration.
113
 The large coupling constant observed between the H4 and H5 
protons (15.9 Hz; Table 3.3) indicated that the C4 double bond was in the 
E-configuration. The C6 double bond was also determined to be in the 
E-configuration due to a correlation between the H5 and H7 signals in the 
ROESY spectrum. If it were in the Z-configuration, a correlation would have been 
observed between the H5 and H8 protons.
52
 
 
 
Figure 3.12: ROESY spectrum of MC-FA. Correlations for the Adda residue 
are indicated. 
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NMR Characterisation of the Mdha residue in MC-FA 
The Mdha residue in MC-FA gave rise to three proton singlets at 3.30, 5.45 and 
5.89 ppm (Table 3.3). The HSQC spectrum indicated that the 5.45 and 5.89 ppm 
protons were attached to a methylene carbon that resonated at 114.4 ppm. This 
and the downfield chemical shifts of these signals indicated that they were 
geminal alkene protons 
 
The COSY spectrum showed coupling between these two protons (Figure 3.13A), 
but no others. HMBC 
2
J correlations from each of the H3 proton signals indicated 
that they were attached to a quaternary carbon which resonated at 146.6 ppm (C2; 
Figure 3.13B). The HMBC spectrum also showed a 
3
J correlation between the H3 
protons and another quaternary carbon at 165.9 ppm (C1). Whilst this chemical 
shift was lower than expected for a carbonyl, conjugation with the nearby alkene 
has been shown to lower the chemical shift of a carbonyl by approximately 
10 ppm,
206
 which has been commonly observed in the Mdha residue of 
microcystins.
32,52,111,251
 
 
 
Figure 3.13: COSY (A) and HMBC (B) correlations for the N-methyl 
dehydroalanine residue in MC-FA. 
 
The HSQC spectrum indicated that the 3.30 ppm proton was attached to a carbon 
at 38.5 ppm. The DEPT analysis indicated it was a methyl carbon and the 
downfield chemical shift suggested it was attached to an electron-withdrawing 
environment. An HMBC correlation to C2 showed that both carbons were 
attached to the same environment (Figure 3.13B) and therefore this was assigned 
as the N-methylation observed in Mdha.
32,52,111,251
 The 3.30 ppm N-methyl signal 
also showed an HMBC correlation to the C5 carbonyl of Glu (Figure 3.13B). 
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NMR Characterisation of the Masp residue in MC-FA 
The Masp residue in MC-FA gave rise to three proton signals; a doublet at 
1.05 ppm and two multiplets at 3.13 and 4.41 ppm (Table 3.3). The COSY 
spectrum indicated that these protons were on three adjacent carbons 
(Figure 3.14A); the doublet at 1.05 ppm being coupled to the multiplet at 
3.13 ppm, which was in turn coupled to the doublet at 4.41 ppm. The HSQC 
spectrum correlated each of these signals with methyl or methine carbons at 15.7, 
41.6 and 57.9 ppm, respectively. 
 
 
Figure 3.14: COSY (A) and HMBC (B) correlations for the methylaspartic 
acid residue in MC-FA. 
 
The doublet at 1.05 ppm (H5) was a methyl adjacent to a methine. The slightly 
downfield chemical shift of this 3.13 ppm methine (H3) indicated it was adjacent 
to an electron-withdrawing environment. An HMBC correlation between the H5 
doublet and a carbon that resonated at 179.1 ppm (C4; Figure 3.14B) indicated 
that this environment was a carbonyl. Since the doublet at 4.41 ppm (H2) was 
already adjacent to the C3 methine, it could not be adjacent to any other protons. 
The chemical shift indicated it was most likely adjacent to two electronegative 
environments, an amine and a carboxylic acid, as would be observed in iso-Masp. 
However, no HMBC correlations to the carboxylic acid (C1) were observed. 
 
Masp contains two chiral centres at the C2 and C3 positions. Amino acid analysis 
indicated MC-FA contained D-Masp, demonstrating that the C2 carbon was in the 
R-configuration (Figure 3.15A). The rotational constriction of being part of a 
cyclic peptide then allowed the stereochemistry of the C3 asymetric carbon to be 
deduced by NMR spectroscopy. The small coupling constant observed in the H2 
doublet (3.9 Hz; Table 3.3) indicated that the H3 proton was syn to the H2 proton 
(Figure 3.15B), or in the β-configuration commonly observed in microcystins.14 
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Figure 3.15: Staggered sawhorse (A) and Newman (B) projections of the 
methylaspartic acid residue in MC-FA. 
 
NMR Characterisation of the Proteinogenic Amino Acids in MC-FA 
Amino acid analysis of MC-FA indicated the presence of L-Ala, D-Ala, L-Phe and 
D-Glu. As these amino acids were confirmed by comparison with standard amino 
acids, the NMR characterisation of these amino acids will only be discussed 
briefly. The chemical shifts, coupling patterns and HMBC correlations matched 
those reported previously,
32,50,206,226
 
 
Both alanine residues each gave rise to two proton signals; a doublet (≈ 1.3 ppm) 
and a quartet (≈ 4.5 ppm; Table 3.3). The multiplicity of the signals and a COSY 
coupling (Figure 3.16A) indicated that they were adjacent to each other and no 
other protons. The chemical shift of the methine indicated that it was close to 
electronegative nuclei, consistent with the carbonyl and amine groups of an intact 
peptide bond. HMBC correlations to a carbon with a downfield resonance 
(≈ 174 ppm; Figure 3.16B) confirmed the presence of the carbonyl. 
 
 
Figure 3.16: COSY (A) and HMBC (B) correlations for the alanine residues in 
MC-FA. 
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Comparison of the proton NMR spectrum of MC-FA with that of MC-LR 
facilitated assignment of the signals to each Ala residue. MC-LR contains one Ala 
residue located in position one. The methyl protons of the Ala in MC-LR 
resonated at 1.35 ppm (Figure 3.17A), slightly downfield from the methyl signals 
observed in MC-FA. Therefore, the more downfield signal in the spectrum of 
MC-FA (Figure 3.17B) was assigned as the position one Ala, and the upfield 
signal was assigned as the position four Ala. This was in accordance with 
previous NMR studies of microcystins in CD3OD, where the position one Ala 
methyl group frequently resonated around 1.3 ppm.
48,50,54,61
 Amino acid analysis 
of MC-FA indicated the presence of D- and L-Ala and since a D-amino acid has 
consistently been observed in position one of the microcystins,
31,32,68,72
 the D-Ala 
was assigned to position one and the L-Ala to position four. 
 
 
Figure 3.17: Proton nuclear magnetic resonance spectra of the methyl regions 
for MC-LR (A) and MC-FA (B). 
 
The Phe residue in MC-FA gave rise to five proton signals; a doublet at 7.37 ppm, 
a doublet of doublets at 7.24 ppm, a triplet at 7.17 ppm and two multiplets at 3.19 
and 4.35 ppm (Table 3.3). The H3 methylene (3.19 ppm) showed a COSY 
coupling to the H2 methine (4.35 ppm; Figure 3.18A). The chemical shift of the 
H2 signal indicated that it was most likely adjacent to a carbonyl and an amine 
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group, which was reinforced by an HMBC correlation to a carbon that resonated 
at 178.9 ppm (C1; Figure 3.18B).  
 
 
Figure 3.18: COSY (A) and HMBC (B) correlations for the phenylalanine 
residue in MC-FA. 
 
The remaining proton signals (7.17, 7.24 and 7.37 ppm) were aromatic. Due to the 
multiplicity of the 7.37 ppm doublet and an HMBC correlation to the C3 
methylene (Figure 3.18B), it was attributed to the H5/9 protons of the aromatic 
ring. The 7.37 ppm doublet showed an HMBC correlation to the C7 carbon, to 
which the 7.17 ppm proton was attached. This was assigned to the para-position 
as a 
3
J correlation was likely to be observed. The remaining proton signal 
(7.24 ppm) was assigned as the H6/8 signal, which was supported by an HMBC 
correlation to a quaternary carbon at 139.5 ppm (Figure 3.18B). A selective 
TOCSY experiment with variable mixing times confirmed these proton 
assignments (Appendix G.9). 
 
The Glu residue in MC-FA gave rise to four proton multiplets at 1.96, 2.22, 2.55 
and 4.33 ppm (Table 3.3). A combination of HSQC and DEPT analysis indicated 
that the 4.33 ppm proton was part of a methine (C2), that the 1.96 and 2.22 ppm 
protons were attached to the same methylene carbon (C3) and that the 2.55 ppm 
multiplet was attached to a different methylene carbon (C4). The COSY spectrum 
showed that these three carbon atoms were adjacent (Figure 3.19A). An HMBC 
correlation was observed from the Mdha N-methyl proton to a carbon signal at 
177.3 ppm, which was assigned as the C5 carbonyl of the Glu residue 
(Figure 3.19B). The chemical shift of the C2 methine indicated that it was 
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adjacent to an amine and a carboxylic acid, but no HMBC correlations to the 
carboxylic acid (C1) were observed. 
 
 
Figure 3.19: COSY (A) and HMBC (B) correlations for the glutamic acid 
residue in MC-FA. 
 
Structural Characterisation of [Asp
3
] MC-FA 
A microcystin with a similar reversed-phase C18 retention time to MC-FA but 
14 Da lower in mass (929.5 Da; Table 3.1) was present at low levels. The MS/MS 
spectrum of the m/z 930.5 ion (Figure 3.20) attributed this to Asp being present in 
position three instead of Masp. Assignment of the MS/MS spectrum showed that 
each fragment ion which contained Masp in MC-FA exhibited a loss of 14 Da in 
[Asp
3
] MC-FA (162; Appendix E.4). This modification is commonly observed in 
microcystins (Appendix A). 
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Figure 3.20: Tandem mass spectrum of [Asp
3
] MC-FA. Fragmentation induced 
by electrospray ionisation collision-induced dissociation. 
 
MC-FA (163) was characterised by a combination of amino acid analysis, MS and 
NMR spectroscopy. Amino acid analysis of 163 indicated the presence of L-Ala, 
D-Ala, D-Glu, D-Masp, L-Phe, N-methylamine and (3S)-Adda. MS/MS analysis 
suggested that the N-methylamine observed in the amino acid analysis was due to 
the breakdown of Mdha. The MS/MS also arranged the seven amino acids as a 
cyclic peptide with the sequence: Ala-Phe-Masp-Ala-Adda-Glu-Mdha. Nuclear 
magnetic resonance spectroscopy confirmed the structure of each of the amino 
acids indicated by amino acid analysis. It was also utilised to determine that the 
D-Masp was in the β-configuration and that both of the double bonds in Adda 
were in the E-configuration. The chemical shifts, coupling constants and 
correlation patterns observed for MC-FA were consistent with those observed for 
other microcystins characterised by NMR spectroscopy.
32,38,50-54
 Using MS/MS, a 
minor component 162 with 14 Da lower mass was determined to be 
[Asp
3
] MC-FA. Neither 162 or 163 have been reported previously. 
 
4.2.3 Structural Characterisation of MC-WA from CYN06 
The presence and stereochemistry of several of the amino acids present in 
MC-WA (165) were determined by Advanced Marfey’s amino acid analysis. 
LC-MS analysis of the L-FDLA derivatives of hydrolysed MC-WA indicated the 
presence of six amino acids (Figure 3.21). The presence of D-Glu (m/z 440; 
14.3 min), L-Ala (m/z 382; 15.8 min) and D-Ala (18.6 min), was determined by 
comparison with standard amino acids. Identification of D-Masp (m/z 440; 
15.9 min), 3(S)-Adda (m/z 592; 32.9 min) and N-methylamine (m/z 324; 
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19.6 min) was facilitated by comparison with the L-FDLA derivatives of 
hydrolysed MC-LR (Appendix F.3). 
 
 
Figure 3.21: Advanced Marfey’s amino acid analysis of MC-WA. Extracted 
ion chromatograms of hydrolysed MC-WA derivatised with 
L-FDLA. 
 
The HRMS for 165 yielded a m/z of 1005.4650, consistent with the sodium adduct 
ion of a cyclic peptide containing L-Ala, D-Ala, Glu, Masp, Mdha, Adda and a 
tryptophan (Trp; C51H66N8O12Na, m/z 1005.4692, Δ -4.25 ppm). As Trp residues 
break down during acid hydrolysis, it was not detected by amino acid analysis.
38
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The MS/MS spectrum for 165 (Figure 3.22) indicated that it was a microcystin 
with a structure similar to MC-FA but with a Trp residue in position two. The 
presence of Adda was indicated by the loss of 134 Da (m/z 849) and 313 Da 
(m/z 670). The mass difference between the other fragment ions indicated the 
position of the remaining amino acids in the compound (Table 3.4). 
 
 
Figure 3.22: Tandem mass spectrum of MC-WA. Fragmentation induced by 
electrospray ionisation collision-induced dissociation. 
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Table 3.4: Tandem mass spectrometry fragment ions for MC-WA observed by 
electrospray ionisation collision-induced dissociation. 
m/z Fragment Assignment 
a
 m/z Fragment Assignment 
a
 
387 Ala-Trp-Masp + H 404 Trp-Masp-Ala + NH4 
375 Adda’-Glu-Mdha + H 458 Ala-Trp-Masp-Ala + H 
475 Ala-Trp-Masp-Ala + NH4 446 Adda’-Glu-Mdha-Ala + H 
541 Mdha-Ala-Trp-Masp-Ala + H 509 Adda-Glu-Mdha – NH3 + H 
558 Mdha-Ala-Trp-Masp-Ala + NH4 580 Adda-Glu-Mdha-Ala – NH3 + H 
632 Adda’-Glu-Mdha-Ala-Trp + H 670 Glu-Mdha-Ala-Trp-Masp-Ala + H 
766 Adda-Glu-Mdha-Ala-Trp – NH3 + H 895 Adda-Glu-Mdha-Ala-Trp-Masp – NH3 + H 
831 M – Adda sidechain – H2O + H 849 M – Adda sidechain + H 
882 M – Mdha – H2O + H 965 M – H2O + H 
944 M + H   
a Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
 
The fragment ion series starting with Adda’-Glu-Mdha (m/z 375) was extended to 
include Ala and Trp (Figure 3.23A). This sequence was supported by the ion 
series containing Adda minus NH3 (m/z 509, 580, 766) which was extended to 
include Masp (Figure 3.23B). A fragment ion series which began with 
Trp-Masp-Ala (m/z 387; Figure 3.23B) and extended in the opposite direction to 
include a second Ala residue, gave the complete amino acid sequence of 
Adda-Glu-Mdha-Ala-Trp-Masp-Ala. A fragment where Mdha and water were lost 
from the compound (m/z 882; Table 3.4) indicated that Adda and the second Ala 
residue were joined and that the structure was cyclic. 
 
 
Figure 3.23: Tandem mass spectrometry fragment ions indicating the amino 
acid sequence in MC-WA. 
 
NMR spectroscopy was utilised for confirmation of the structure indicated by MS 
and amino acid analysis.  Interpretation of COSY, TOCSY, HSQC and HMBC 
spectra allowed for the assignment of the 
1
H and 
13
C signals (Table 3.5). Several 
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of the 
1
H signals overlapped at 400 MHz and the peak patterns were resolved 
using selective TOCSY experiments. Nuclear magnetic resonance spectra for 
MC-WA are presented in Appendix H. 
 
Table 3.5: Nuclear magnetic resonance spectroscopy assignment of MC-WA at 
400 MHz in CD3OD. 
AA
a
 13C 
1
H 
Mult.
b
 
(J in Hz) 
AA
a
 13C 
1
H
 Mult.
b
 
(J in Hz) 
D-Ala-1    Adda-5 cont.    
1 174.0 -  3 56.5 4.63 m 
2 49.1
c
 4.49 q (7.7)
d
 4 126.9 5.46
c
 m 
3 18.0 1.31 d (7.7)
d
 5 138.7 6.29 d (16.1) 
    6 134.0 -  
Trp-2    7 137.1 5.46
c
 d (10.4)
d
 
1 nd -  8 37.8 2.60 m 
2 58.2 4.47 m 9 88.5 3.26 m 
3 28.0 3.31 dd (1.7, 3.3)
d
 10 39.1 2.68 dd (7.5, 14.0) 
  3.38 m   2.83 dd (4.6, 14.0) 
4 111.5 -  11 140.7 -  
5 138.2 -  12 & 16 130.7 7.19
c
 d (8.1) 
6 112.3 7.31 d (8.7) 13 & 15 129.3 7.25 dd (7.4, 8.1) 
7 122.3 7.07 dd (7.4, 8.7) 14 127.2 7.17
c
 t (7.4) 
8 119.8 7.00 dd (7.4, 8.4) 17 16.2 1.08 d (6.7)
d
 
9 119.1 7.67 d (8.4) 18 13.0 1.64 s 
10 128.3 -  19 16.6 1.03 d (6.7) 
11 125.7 7.29 s 20 58.9 3.25 s 
        
D-Masp-3    D-Glu-6    
1 nd -  1 nd -  
2 58.8 4.36
c
 d (4.0) 2 55.9 4.32 m 
3 41.5 3.15 m 3 30.5 1.89 m 
4 179.1 -    2.23 m 
5 16.3 1.07 d (7.7)
d
 4 33.8 2.55 (2H) m 
    5 177.4 -  
L-Ala-4        
1 175.0 -  Mdha-7    
2 49.0
c
 4.60 q (7.7)
d
 1 166.0 -  
3 17.4 1.23 d (7.7)
d
 2 146.4 -  
    3 113.8 5.45
c
 s
d
 
Adda-5      5.87 s 
1 176.7 -  N-CH3 38.3 3.30
c
 s 
2 45.3 2.98 m     
a AA = Amino acid (number indicates position in the structure); nd = Not detected. b Mult. = Multiplicity of the proton 
signal; J = Coupling constant. c Signals were overlapped so chemical shifts were determined using correlations observed 
in 2D HSQC spectra. d Multiplicity and coupling constants were determined using 1D-selective TOCSY experiments. 
 
A large proportion of the structure of MC-WA is the same as that of MC-FA, and 
as a result, very similar chemical shifts and coupling constants were observed 
(Tables 3.3 and 3.5). The COSY coupling patterns and HMBC correlations 
observed in each of the common amino acids were also the same as those 
described for MC-FA, therefore only the NMR characteristics of the position two 
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Trp have been described. As with MC-FA, the Ala residue with the downfield 
methyl proton resonance was assigned to position one and designated as the D-Ala. 
 
NMR Characterisation of the Tryptophan Residue in MC-WA 
The Trp residue in MC-WA gave rise to eight proton signals; one singlet at 
7.29 ppm, two doublets at 7.31 and 7.67 ppm, two doublets of doublets at 7.00 
and 7.07 ppm, and three multiplets at 3.31, 3.38 and 4.47 ppm (Table 3.5). The 
HSQC spectrum indicated that the 3.31 and 3.38 ppm protons were attached to a 
single carbon that resonated at 28.0 ppm, which the DEPT-135 designated as a 
methylene (C3). These proton signals showed a COSY coupling to the 4.47 ppm 
multiplet (H2; Figure 3.24) which, due to its chemical shift, was adjacent to two 
electron-withdrawing environments. These were presumably a carbonyl and an 
amine, however, no HMBC correlations were detected between the H2 or H3 
protons and what was assumed to be the C1 carbonyl. 
 
 
Figure 3.24: COSY correlations for the tryptophan residue in MC-WA. 
 
Unlike MC-FA, the signals from the aromatic region of MC-WA showed little 
overlap and were resolved in an HSQC experiment. The three Adda aromatic 
signals at 7.17, 7.19 and 7.25 ppm and five downfield signals from the Trp residue 
were evident in the HSQC spectrum (Figure 3.25A). 
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Figure 3.25: HSQC (A) and HMBC (B) spectra of the MC-WA aromatic 
region. 
 
The doublet at 7.67 ppm (H9) showed a COSY coupling to a doublet of doublets 
at 7.00 ppm (H8), which was in turn coupled to a doublet of doublets at 7.07 ppm 
(H7), coupled to a doublet at 7.31 ppm (H6; Figure 3.26). Each of the Trp 
aromatic protons were in unique chemical environments, which indicated 
asymmetric substitution of the aromatic ring. 
 
Figure 3.26: COSY spectrum displaying the aromatic region of MC-WA. 
Lines indicate proton coupling within the tryptophan residue. 
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The H6 and H8 protons showed HMBC 
3
J correlations to a quaternary carbon that 
resonated at 128.3 ppm (C10; Figure 3.27) and the H7 and H9 protons showed 
correlations to another quaternary carbon at 138.2 ppm (C5). The singlet at 
7.29 ppm (H11) also showed an HMBC correlation to the C5 quaternary carbon, 
as well as to a third quaternary carbon which resonated at 111.5 ppm (C4). This 
pattern of correlations between the H7, H9 and H11 protons and the C5 
quaternary carbon suggested that the H11 proton had a 
3
J correlation to the C5 
quaternary and a 
2
J correlation to the C4 quaternary (Figure 3.27). The downfield 
chemical shift of the H11 signal indicated that it was in a very electron-
withdrawing environment, which would be accounted for by being part of a 
double bond and adjacent to an amine, as observed in the indole ring of a 
tryptophan.
206
 
 
 
Figure 3.27: HMBC correlations for the tryptophan residue in MC-WA. 
 
Structural Characterisation of [Asp
3
] MC-WA 
A microcystin with a similar reversed-phase C18 retention time to MC-WA, but 
with 14 Da lower mass (968.5 Da; Table 3.1) was present in CYN06. The MS/MS 
spectrum of the m/z 969.5 ion (Figure 3.28) attributed the 14 Da mass difference 
to Asp being present in position three instead of Masp ([Asp
3
] MC-WA; 164; 
Appendix E.4). 
Chapter 3 
72 
 
 
 
 
Figure 3.28: Tandem mass spectrum of [Asp
3
] MC-WA. Fragmentation 
induced by electrospray ionisation collision-induced dissociation. 
 
MC-WA (165) was characterised by a combination of amino acid analysis, MS 
and NMR spectroscopy. Amino acid analysis of 165 indicated the presence of 
L-Ala, D-Ala, D-Glu, D-Masp, N-methylamine and (3S)-Adda. Tandem MS 
analysis suggested that the N-methylamine was due to the breakdown of Mdha 
and that the compound also contained a Trp residue. The MS/MS arranged the 
seven amino acids as a cyclic peptide with the sequence: Ala-Trp-Masp-Ala-
Adda-Glu-Mdha. As with MC-FA, NMR spectroscopy was used to confirm the 
structure and some of the stereochemistry of several of the amino acids in 
MC-WA. The signals and coupling patterns observed in the position two residue 
confirmed it was Trp, however, no connectivity was observed between the 
backbone and the sidechain portions. A minor component 164 with 14 Da less 
mass, was determined to be [Asp
3
] MC-WA using MS/MS. Both 164 and 165 are 
new microcystin congeners. 
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3.2.4 Structural Characterisation of the -RZ Microcystins from CYN06 
The -RZ microcystin congeners observed in CYN06 were MC-RA, 
[Asp
3
] MC-RA, MC-RAba, [Asp
3
] MC-RAba and MC-RL (Table 3.1). Only 
[Asp
3
] MC-RA and [Asp
3
] MC-RAba are new microcystin congeners, however, 
they were only present in sufficient quantities to conduct MS/MS analysis. 
Therefore, amino acid analysis of MC-RA and MC-RAba was conducted to 
facilitate the characterisation of the [Asp
3
] analogues. 
 
Structural Characterisation of MC-RA 
As with MC-FA and MC-WA, the presence and stereochemistry of the amino 
acids in MC-RA (16) were determined by Advanced Marfey’s amino acid 
analysis. LC-MS analysis of the L-FDLA derivatives of hydrolysed MC-RA 
indicated the presence of seven amino acids (Figure 3.29). The presence of 
D-Glu (m/z 440; 14.3 min), L-Ala (m/z 382; 15.8 min) and D-Ala (18.6 min), was 
 
 
Figure 3.29: Advanced Marfey’s amino acid analysis of MC-RA. Extracted ion 
chromatograms of hydrolysed MC-RA derivatised with L-FDLA. 
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determined by comparison with standard amino acids. The D-Masp (m/z 440; 
15.9 min), N-methylamine (m/z 324; 19.6 min) and 3(S)-Adda (m/z 592; 32.9 min) 
derivatives observed in MC-LR (Appendix F.3) were also present. 
 
A peak was present at 27.2 min with m/z 719, which could be indicative of an 
ornithine (Orn) bonded to two FDLA.
205
 However, it could also represent an 
arginine (Arg) residue which has lost the guanidinium group from the sidechain 
and become an Orn. This was consistently observed using standard Arg and the 
protocol followed during this work (Appendix F.2). Comparison of the retention 
time of the Orn/Arg derivative from MC-RA with standard L-Arg derivatised with 
L-FDLA did indicate that the Orn/Arg present in MC-RA was in the 
L-configuration. 
 
The HRMS for 16 yielded a m/z of 953.5122, consistent with the protonated ion of 
a cyclic peptide consisting of the amino acids indicated by the amino acid analysis 
(L-Ala, D-Ala, Glu, Masp, Mdha, Adda) and an Arg residue (C46H69N10O12, 
m/z 953.5091, Δ +3.28 ppm). 
 
 
 
The major ionisation point on an Arg-containing microcystin is the guanidinium 
group of the Arg residue, so an alteration of the position in the structure 
dramatically altered the MS/MS fragment ions observed. Where the m/z 599 ion 
(Arg-Adda-Glu)
78
 is one of the major fragment ions in a -XR microcystin 
congener, a m/z 440 ion (Glu-Mdha-Ala-Arg and Mdha-Ala-Arg-Masp) was 
present in the -RZ congeners.
66
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Due to the presence of an Arg residue, MC-RA ionised very efficiently by 
MALDI, therefore, MALDI PSD was also utilised for the MS/MS characterisation. 
For MC-RA (and other arginine-containing microcystins), both the MALDI PSD 
and ESI CID produced similar fragment ion series, however MALDI PSD 
produced lower mass fragment ions whilst ESI CID yielded information on the 
higher mass fragments. The MS/MS spectra for MC-RA (Figure 3.30) indicated 
that it was a microcystin which possessed the unusual mass spectrometric 
characteristics described previously. The presence of Adda was indicated by loss 
of the 134 Da sidechain fragment (m/z 819), the protonated Adda sidechain 
(m/z 135) and the m/z 163 fragment ion (Adda’). The mass difference between the 
other fragment ions indicated the position of the remaining amino acids in the 
compound (Table 3.6). 
 
 
Figure 3.30: Tandem mass spectra of MC-RA. Fragmentation induced by 
matrix-assisted laser desorption ionisation post-source decay (A) 
and electrospray ionisation collision-induced dissociation (B). 
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Table 3.6: Tandem mass spectrometry fragment ions for MC-RA observed by 
matrix-assisted laser desorption ionisation post-source decay and 
electrospray ionisation collision-induced dissociation. 
m/z Fragment Assignment
 a
 m/z Fragment Assignment
 a
 
70 Arg fragment 84 Arg fragment 
112 Arg fragment 135 Adda sidechain 
155 Mdha-Ala + H 201 Masp-Ala + H 
163 Adda’ + H 213 Glu-Mdha + H 
311 Mdha-Ala-Arg + H 329 Arg-Masp-Ala – CO + H 
357 Arg-Masp-Ala + H 368 Glu-Mdha-Ala-Arg – CH2NHCN2H3 + H 
368 Mdha-Ala-Arg-Masp – CH2NHCN2H3 + H 375 Adda’-Glu-Mdha + H 
395 Glu-Mdha-Ala-Arg – COOH + H 423 Mdha-Ala-Arg-Masp – NH3 + H 
428 Ala-Arg-Masp-Ala + H 440 Glu-Mdha-Ala-Arg + H 
440 Mdha-Ala-Arg-Masp + H 466 Mdha-Ala-Arg-Masp-Ala – COOH + H 
494 Mdha-Ala-Arg-Masp-Ala – NH3 + H 510 Mdha-Ala-Arg-Masp-Ala – H2O + NH4 
511 Mdha-Ala-Arg-Masp-Ala + H 528 Mdha-Ala-Arg-Masp-Ala + NH4 
819 M – Adda sidechain + H 824 M – Glu or Masp + H 
881 M – CH2NHCN2H3 + H 882 M – Ala + H 
908 M – COOH + H 935 M – H2O + H 
953 M + H   
a Adda’ = Adda minus NH2 and the sidechain (C9H11O); CH2NHCN2H3 is a fragment of the Arg sidechain. 
 
A fragment ion series beginning with Mdha-Ala (m/z 155; Figure 3.31A) which 
extended to include Arg, Masp and Ala indicated much of the amino acid 
sequence. Another ion series which extended in the opposite direction supported 
this partial sequence of Mdha-Ala-Arg-Masp-Ala. A Glu-Mdha fragment (m/z 213; 
Figure 3.31B) showed that Glu was attached to Mdha. The m/z 375 fragment 
(Adda’-Glu-Mdha) commonly observed in Adda-containing microcystins, showed 
that Adda was attached to Glu, which yielded the complete amino acid sequence 
of Adda-Glu-Mdha-Ala-Arg-Masp-Ala. The peptide was shown to be cyclic by 
the loss of Glu or Masp (m/z 824; Table 3.6), which indicated that Adda was 
attached to Ala. 
 
 
Figure 3.31: Tandem mass spectrometry fragment ions indicating the amino 
acid sequence in MC-RA. 
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Structural Characterisation of [Asp
3
] MC-RA 
The reversed-phase C18 retention time of [Asp
3
] MC-RA (160) was similar to 
MC-RA (Table 3.1), but the compound was 14 Da lower in mass (938.5 Da). The 
MS/MS spectra of 160 (Figure 3.32) attributed this to Asp being present in 
position three instead of Masp (Appendix E.3). Of note was the m/z 426 ion 
(Mdha-Ala-Arg-Asp) in the ESI CID MS/MS spectrum (Figure 3.32B), which 
demonstrates that both of the isometric fragments (Glu-Mdha-Ala-Arg and 
Mdha-Ala-Arg-Masp) from MC-RA were present in the m/z 440 peak. 
 
 
 
 
Figure 3.32: Tandem mass spectra of [Asp
3
] MC-RA. Fragmentation induced 
by matrix-assisted laser desorption ionisation post-source decay 
(A) and electrospray ionisation collision-induced dissociation (B). 
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Structural Characterisation of MC-RAba 
The presence and stereochemistry of the amino acids in MC-RAba (19) were 
determined by Advanced Marfey’s amino acid analysis. Comparison with 
standard amino acids facilitated the identification of D-Glu (m/z 440; 14.3 min), 
L-2-aminobutanoic acid (Aba; m/z 396; 17.4 min) and D-Ala (m/z 382; 18.6 min; 
Figure 3.33). Comparison with FDLA derivatives of hydrolysed MC-LR 
(Appendix F.3) led to the identification of D-Masp (m/z 440; 15.9 min), 
N-methylamine (m/z 324; 19.6 min) and 3(S)-Adda (m/z 592; 32.9 min). As with 
MC-RA, the m/z 719 derivative representing either L-Arg or L-Orn (27.2 min) 
was observed. 
 
 
Figure 3.33: Advanced Marfey’s amino acid analysis of MC-RAba. Extracted 
ion chromatograms of hydrolysed MC-RAba derivatised with 
L-FDLA. 
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HRMS of 19 yielded a m/z of 967.5259, consistent with the protonated ion of a 
cyclic peptide consisting of the amino acids indicated by the amino acid analysis 
(Ala, Aba, Glu, Masp, Mdha, Adda) and an Arg residue (C47H71N10O12, 
m/z 967.5247, Δ +1.15 ppm). 
 
 
 
The MS/MS spectra of 19 (Figure 3.34) were very similar to those of MC-RA, 
except that the fragments attributed to the position four amino acid contained 
14 Da more mass (Appendix E.3). This indicated that the L-Aba detected by 
amino acid analysis was present in position four instead of L-Ala. 
 
 
Figure 3.34: Tandem mass spectra of MC-RAba. Fragmentation induced by 
matrix-assisted laser desorption ionisation post-source decay (A) 
and electrospray ionisation collision-induced dissociation (B). 
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Structural Characterisation of [Asp
3
] MC-RAba 
[Asp
3
] MC-RAba (161) had a similar reversed-phase C18 retention time to 
MC-RAba (Table 3.1) but 14 Da lower mass (952.5 Da). The MS/MS spectrum of 
161 (Figure 3.35) indicated that the 14 Da mass loss was due to Asp being present 
in position three instead of Masp (Appendix E.3). Since this microcystin has the 
same mass as MC-RA, the two compounds were not resolved by MALDI MS, 
therefore, only LC-MS/MS was utilised for characterisation of this minor 
component. 
 
 
 
 
Figure 3.35: Tandem mass spectrum of [Asp
3
] MC-RAba. Fragmentation 
induced by electrospray ionisation collision-induced dissociation. 
 
A combination of amino acid analysis and MS was used to characterise 
MC-RA (16) and MC-RAba (19). Amino acid analysis of 16 indicated the 
presence of D-Ala, L-Ala, D-Glu, D-Masp, N-methylamine and (3S)-Adda, with 
either L-Arg or L-Orn. Tandem MS analysis suggested that the N-methylamine 
was due to the breakdown of Mdha and that Arg, not Orn, was present. The 
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MS/MS also indicated that the amino acids formed a cyclic peptide with the 
sequence: Ala-Arg-Masp-Ala-Adda-Glu-Mdha. Amino acid analysis of 19 yielded 
very similar results except that L-Aba was present in position four instead of L-Ala. 
Using MS/MS, two minor components were determined to be the new 
microcystins; [Asp
3
] MC-RA (160) and [Asp
3
] MC-RAba (161). Whilst only 160 
and 161 are new microcystin congeners, the information garnered from the 
structural characterisation of 16 and 19 was used to characterise the new 
analogues. 
 
3.2.5 Structural Characterisation of the -XAba Microcystins from CYN06 
The -XAba microcystin congeners observed in CYN06 were MC-LAba (11), 
MC-FAba (166) and MC-WAba (167). MC-LAba has been reported 
previously,
34,35,249
 but MC-FAba and MC-WAba are new variants. MC-FAba and 
MC-WAba were present at very low levels in CYN06, therefore, no desmethyl 
analogues were observed and the amount of material obtained was only sufficient 
to undertake MS/MS and HRMS analyses. Amino acid analysis of MC-RAba 
confirmed that the Aba utilised by CYN06 was not the isomeric version (2-amino-
iso-butanoic acid; Aib). As insufficient quantities were present to undertake 
amino acid analysis on MC-FAba and MC-WAba, it has been assumed that Aba 
was also present in these microcystins. 
 
 
 
The MS/MS spectra of 166 and 167 (Figure 3.36) indicated that they were 
microcystins with structures similar to MC-LAba. However, the fragments 
attributed to the position two amino acid contained either 34 or 73 Da additional 
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mass (Table 3.7). This was postulated to be due to Phe or Trp being present in 
position two instead of Leu. 
 
 
Figure 3.36: Tandem mass spectra of MC-FAba (A) and MC-WAba (B). 
Fragmentation induced by electrospray ionisation collision-
induced dissociation. 
 
Table 3.7: Tandem mass spectrometry fragment ions for the -XAba 
microcystin congeners observed by electrospray ionisation 
collision-induced dissociation. 
Fragment Assignment 
a MC-LAba 
X = 113 Da
 
MC-FAba 
X = 147 Da 
MC-WAba 
X = 186 Da 
M + H 924 958 997 
M – H2O + H 906 940 979 
M – Mdha – H2O + H 823 957 896 
M – Adda sidechain + H 790 824 863 
M – Adda sidechain – H2O + H 772 806 845 
M – Adda + H 611 645 684 
M – Adda – H2O + H 593 627 666 
Adda-Glu-Mdha-Ala-X – NH3 + H 693 727 766 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Adda’-Glu-Mdha-Ala-X + H 559 593 632 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Mdha-Ala-X-Masp-Aba + NH4 499 533 572 
Ala-X-Masp-Aba + NH4 416 450 489 
X-Masp-Aba + NH4 345 379 418 
Mdha-Ala-X-Masp-Aba + H 482 516 555 
Ala-X-Masp-Aba + H 399 433 472 
X-Masp-Aba + H 328 362 401 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
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The HRMS for MC-FAba and MC-WAba yielded m/z of 980.4744 and 1019.4836, 
consistent with the sodium adduct ions of the structures 166 and 167 
(C50H67N7O12Na, m/z 980.4740, Δ +0.4 ppm; C52H68N8O12Na, m/z 1019.4849, 
Δ -1.3 ppm). 
 
3.2.6 Structural Characterisation of the -XL Microcystins from CYN06 
The -XL microcystin congeners observed in CYN06 were MC-LL (14), 
MC-FL (168) and MC-WL (169). Whilst MC-LL has been reported previously,
37
 
MC-FL and MC-WL are new analogues. MC-FL and MC-WL have the same 
mass as the known microcystins MC-LF and MC-LW,
37,45
 however the MS/MS 
spectra from each indicated that the position two and four amino acids were 
inverted. Both of these microcystins were present at low levels, therefore only 
MS/MS characterisation was undertaken on the parent congeners and no 
desmethyl analogues were observed. 
 
 
 
The MS/MS spectra of 168 and 169 (Figure 3.37) indicated that they were 
microcystins with structures similar to MC-LL. However, the fragments attributed 
to the position two amino acid contained either 34 or 73 Da additional mass 
(Table 3.8). Again, this was postulated to be due to Phe or Trp being present in 
position two instead of Leu. 
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Figure 3.37: Tandem mass spectra of MC-FL (A) and MC-WL (B). 
Fragmentation induced by electrospray ionisation collision-
induced dissociation. 
 
Table 3.8: Tandem mass spectrometry fragment ions for the -XL microcystin 
congeners observed by electrospray ionisation collision-induced 
dissociation. 
Fragment Assignment 
a MC-LL 
X = 113 Da
 
MC-FL 
X = 147 Da 
MC-WL 
X = 186 Da 
M + H 952 986 1025 
M – NH3 + H 935 969 1008 
M – H2O + H 934 968 1007 
M – Glu or Masp + H 823 857 896 
M – Adda sidechain + H 818 852 891 
M – Adda sidechain – H2O + H 800 834 873 
M – Adda + H 639 673 712 
M – Adda – H2O + H 621 655 694 
Adda-Glu-Mdha-Ala-X – NH3 + H 693 727 766 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Glu-Mdha-Ala-X + H 397 431 470 
Adda’-Glu-Mdha-Ala-X + H 559 593 632 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Unassigned fragment ion 440 474 513 
Unassigned fragment ion 535 535 535 
Mdha-Ala-X-Masp-Leu + H 509 544 583 
Ala-X-Masp-Leu + H 426 461 500 
X-Masp-Leu + H 355 390 429 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
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An intense fragment ion that could not be assigned (m/z 535) was present in each 
of the MS/MS spectra from the -XL microcystin congeners (Figure 3.37). As this 
fragment had the same m/z in each of the -XL microcystin congeners, it would be 
attributed to a common portion of the structure. With another unassigned fragment 
ion, the mass deviated in each of the microcystins; m/z 440 in MC-LL, m/z 474 in 
MC-FL and m/z 513 in MC-WL. The mass increments between each of these 
fragments are the same as the mass increments between Leu, Phe and Trp. These 
fragments would therefore be attributed to a portion of the structure which 
contained the position two amino acid. 
 
 
3.3 DISCUSSION 
3.3.1 Microcystin Diversity of CYN06 
In this study, 27 different microcystin congeners were detected in cultures of 
CYN06. This was due to relaxed substrate specificity at positions two, three and 
four. Five different amino acids were observed to be incorporated into position 
two of the structure, two amino acids were observed in position three and four 
amino acids were observed in position four. This equates to a potential 40 
microcystins which could be produced by CYN06. This value would increase if 
the CYN06 microcystin synthase was shown to be able to incorporate more amino 
acids than reported in the present study. 
 
In order to better understand whether the number of microcystin congeners 
observed in CYN06 was unique, relevant literature was surveyed to assess the 
diversity of congeners produced by isolated cyanobacterial strains (Appendix C). 
In several cases, researchers were not able to identify all the microcystins present 
and listed these as unknown microcystins.
35,245,252
 These unidentified microcystins 
skew the analysis slightly as it cannot be predicted whether these congeners were 
similar analogues to those identified or whether they were structurally different. 
The investigation revealed that the median number of microcystin congeners 
produced by a cyanobacterial strain was between four and five. When assessing 
the number of congeners identified, the median was slightly lower (Median = 4.5; 
Figure 3.38A) than assessments based on the number of congeners observed 
(Median = 5; Figure 3.38B). The range of the number of microcystin congeners 
identified in a single cyanobacterial strain spanned from 1 to 16 (Figure 3.38A), 
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but could be extended to 47 when the unidentified congeners were taken into 
account (Figure 3.38B). 
 
 
Figure 3.38: Box plots representing the spread in the number of microcystin 
congeners produced by reported cyanobacterial strains. Plots 
depict the number of microcystin congeners identified; n = 42 (A), 
the number of microcystin congeners observed; n = 42 (B) and 
the potential number of congeners which could be produced 
according to the reported data; n = 33 (C). 
 
When there were no unidentified microcystin congeners present in a 
cyanobacterial strain, the potential number of congeners which could be produced 
was calculated. This took account of all of the combinations of the amino acids 
incorporated into positions two and four, as well as the variable modifications 
observed. Values ranged from 1 to 72, but there was a slightly lower median of 4 
microcystin congeners produced by a cyanobacterial strain (Figure 3.38C). As 
expected, the range for the potential number of microcystins was higher than that 
based on the microcystins identified/observed. This was due to some congeners 
occurring at lower levels and not being detected in the study. The lower median 
value for the potential number of microcystins compared with the microcystins 
identified was due to the reduced number of cyanobacterial strains being assessed. 
 
The number of microcystins identified in CYN06 (27 congeners) and the potential 
number of microcystins which could be produced (40 congeners), positioned 
CYN06 in the top ten percentile in the distribution of strains assessed. Other 
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strains in the top ten percentile included Anabaena 66A,
245
 Microcystis viridis 
NIES102
245
 and Nostoc 152.
55,56,72,245
 These cyanobacterial strains were able to 
incorporate an array of amino acids into position two and produced variable 
modifications at other positions in the structure (Appendix C). The strains did not 
show much variability at the position four amino acid as Anabaena 66A and 
Microcystis viridis NIES102 could only incorporate Arg, whilst Nostoc 152 was 
able to incorporate Arg and homoarginine. 
 
In general, the cyanobacterial strains assessed showed a lesser degree of 
variability in the amino acid incorporated into position four of the structure. The 
majority of the strains assessed were only able to incorporate one or two amino 
acids into position four (Appendix C). Interestingly, when strains did exhibit high 
levels of amino acid variability at position four, they tended to exhibit a high 
degree of substrate specificity at position two. CYN06 however, showed relaxed 
substrate specificity at both positions two and four. As a result, CYN06 produced 
microcystin congeners which contained no arginine residues, a single arginine 
residue and two arginine residues. Most of the other cyanobacterial strains 
assessed produced congeners containing one or two arginine residues or 
congeners that contained one or no arginine residues. None of these strains 
simultaneously produced microcystin congeners which contained one, two and no 
arginine residues. As CYN06 produces such a diverse range of microcystin 
congeners, it provides a useful cyanobacterial strain for culturing experiments to 
investigate parameters which cause the modulation of microcystin congeners. 
 
3.3.2 Discovery of Ten New Microcystin Congeners 
The discovery of ten new microcystins 160-169 in CYN06 is a substantial 
contribution to the 111 microcystins already characterised (Appendix A). The ten 
new congeners were present in varying quantities and only MC-FA (163) and 
MC-WA (165) were purified in sufficient quantities to undertake structural 
characterisation with NMR spectroscopy. The other new microcystin congeners 
were characterised using MS/MS and chemical derivatisation. 
 
Six of the new microcystins 163 and 165-169 followed the general structure of a 
microcystin; consisting of Adda, Glu, Mdha, Ala and Masp with variable amino 
acids in positions two and four.
11
  These congeners contained either Phe or Trp in 
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position two with Ala, Aba or Leu in position four. The remaining four new 
microcystins 160-162 and 164 were [Asp
3
] desmethyl analogues of other 
congeners produced by CYN06. A recently developed thiol derivatisation 
technique
248
 indicated that all of the new microcystin congeners contained Mdha 
in position seven. This was also indicated during amino acid analysis (for several 
of the CYN06 microcystins) by the presence of N-methylamine.
205
 However, the 
thiol derivatisation (see Section 9.1.5) consumes much less sample and unlike 
amino acid analysis, it is able to discriminate between Mdha and Mdhb, which 
both break down to N-methylamine upon acid hydrolysis.
250
 
 
Eight of the new congeners 162-169 were hydrophobic microcystins containing 
neutral amino acids in positions two and four. As the structures of these 
microcystin congeners are relatively conventional, it is surprising that they have 
not been observed previously. However, this could be due to the lower occurrence 
of hydrophobic microcystins compared with arginine-containing variants.
12
 The 
presence of Aba-containing microcystins is relatively uncommon, with only four 
congeners having been reported (Appendix A). Amino acid analysis of MC-RAba 
indicated that the Aba utilised by CYN06 was the straight chain version in the 
L-configuration. This was consistent with the only other study of an 
Aba-containing microcystin, where discrimination was made between Aba and 
Aib.
36
 
 
Two of the new congeners 160 and 161 contained position two arginine residues 
in conjunction with a neutral amino acid in position four (MC-RZs). Until 
recently,
41,66,77
 these types of microcystin congeners were rare, with only MC-RA 
having been reported.
39
 An interesting feature of the -RZ microcystin congeners is 
that whilst the amino acid composition may be identical to an -XR microcystin, 
the -RZ congeners are retained for longer during reversed-phase 
C18 chromatography (MC-LR = 7.35 min; MC-RL = 8.35 min). This observation 
has been noted by others,
39,66
 and enables a very straightforward means of 
differentiating between -XR and -RZ microcystin congeners. 
 
The change in retention time of the -RZ microcystins is most likely due to the 
position five Adda moiety being the major hydrophobic region of a microcystin. 
As a result, the alkyl chains of the C18 column packing are likely to interact 
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predominantly with this region of the compound. When an Arg residue is present 
in position four (MC-XRs) next to the Adda moiety, it would also be likely to 
interact substantially with the alkyl chains of the packing material. When an Arg 
residue is present in position two (MC-RZs) and is no longer located next to the 
Adda moiety, the hydrophilic effect of the protonated guanidinium group would 
not be as pronounced and the microcystin would be retained on the column for 
longer. 
 
Whilst the isolated quantities of MC-FA and MC-WA were sufficient to conduct 
toxicology or protein phosphatase inhibition studies, the purity of the samples was 
not. Further HPLC purification of the samples could yield enough material of 
sufficient purity to conduct this work; however, there was inadequate time for the 
additional purification during the present study. However,  the Adda-Glu portion 
of the microcystin structure, which has previously been shown to be important for 
protein phosphatase inhibition,
33
 is not modified in these congeners. Therefore it 
is likely that the two microcystins would inhibit protein phosphatases and pose a 
health risk to humans and animals. 
 
 
3.4 CONCLUSIONS 
Assessment of Microcystis CYN06 indicated the presence of numerous 
oligopeptides including aeruginosins, microviridins and microcystins. Further 
investigation of the microcystin diversity indicated that CYN06 produced at least 
27 microcystin congeners, of which, ten had not been reported previously. The 
structures of MC-FA and MC-WA were determined by NMR spectroscopy whilst 
the other new variants were characterised by MS/MS. The number of microcystin 
congeners produced by CYN06 was in the upper ten percentile of the 
cyanobacterial strains assessed. The relaxed substrate specificity observed in this 
cyanobacterial strain provides a unique opportunity to investigate the influence of 
environmental parameters on the abundance of microcystin congeners. 
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CHAPTER 4 
 
Characterisation of Oxidised Tryptophan 
Microcystins from Microcystis CYN06  
 
 
4.1 INTRODUCTION 
The oxidation of tryptophan (Trp) residues was first reported in 1903
253
 and in 
1931 kynurenine (Kyn) was identified as a by-product of the biological oxidation 
of Trp.
254
 Since then, the pathway for the enzymatic degradation of Trp has been 
expanded to include four intermediates which result in either kynurenic acid or 
quinolinic acid.
255
 Whilst the function of this oxidative pathway is to degrade Trp 
residues, the oxidation of Trp in intact polypeptides is also apparent.
256-259
 The 
major products of this oxidation are oxindolyalanine (Oia), N-formylkynurenine 
(Nfk) and Kyn (Figure 4.1), with Nfk being the most abundant.
256,257
 
 
 
Figure 4.1: Products of the chemical oxidation of tryptophan (Trp).
256
 Oia is 
oxindolyalanine, Nfk is N-formylkynurenine and Kyn is 
kynurenine.  
 
It is still unclear as to whether the oxidation of Trp residues in polypeptides is due 
to natural levels of reactive oxygen species in the cell,
260
 oxidative stress in the 
cell,
261
 post-translational modification of the Trp,
256
 or is an artefact of sample 
handling. It has been shown that the production of Trp oxidation products is 
intensified by increased levels of reactive oxygen species,
257,262
 therefore 
oxidation of Trp may be an artefact of sample handling, although, this does not 
disprove the natural intracellular occurrence of oxidised Trp residues. 
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The oxidation of methionine is also observed in proteins,
261,263,264
 and the presence 
of oxidised methionine-containing microcystins has been reported on two 
occasions.
38,67
 Whilst five Trp-containing microcystins have been reported 
previously,
38,44,45,49,58
 the presence of oxidised Trp residues in microcystins has 
not. As discussed in Section 3.2.1, CYN06 produces at least six Trp-containing 
microcystins, four of which are new. Analogues which contained oxidised Trp 
residues were also present. The characterisation of these microcystins will be 
presented in this chapter. 
 
 
4.2 RESULTS 
4.2.1 LC-MS Identification of Oxidised Tryptophan Microcystins from 
Microcystis CYN06  
LC-MS analysis of a CYN06 extract showed the presence of 27 conventional 
microcystin congeners (see Table 3.1), as well as nine microcystins which 
contained oxidised Trp residues in position two (170-178; Table 4.1). The 
presence of Kyn, Oia and Nfk was observed in place of Trp, with an arginine (Arg; 
MC-XRs), alanine (Ala; MC-XAs) and 2-aminobutanoic acid (Aba; MC-XAbas). 
It is likely that oxidised Trp congeners containing a position four leucine (Leu; 
MC-XLs) were also present, but were not observed due to low abundance. 
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Table 4.1: Structure, molecular masses and retention times of the tryptophan- 
and oxidised tryptophan-containing microcystins found in CYN06. 
 
Microcystin 
Mr
 a
 
(Da) 
RT
b
 
(min) 
X Z 
MC-XRs 
MC-WR (113) 1067.5 7.60 Trp Arg 
MC-KynR (170) 1071.5 7.45 Kyn Arg 
MC-OiaR (171) 1083.5 7.37 Oia Arg 
MC-NfkR (172) 1099.5 7.32 Nfk Arg 
MC-XAs 
MC-WA (165) 982.5 9.54 Trp Ala 
MC-KynA (173) 986.5 9.41 Kyn Ala 
MC-OiaA (174) 998.5 9.31 Oia Ala 
MC-NfkA (175) 1014.5 9.07 Nfk Ala 
MC-XAbas 
MC-WAba (167) 996.5 10.24 Trp Aba 
MC-KynAba (176) 1000.5 9.80 Kyn Aba 
MC-OiaAba (177) 1012.5 9.58 Oia Aba 
MC-NfkAba (178) 1028.5 9.46 Nfk Aba 
a Molecular weights are rounded to one decimal place. b RT = Retention time on a C18 column as per 
Table 9.3. 
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4.2.2 Structural Characterisation of MC-NfkA 
MC-NfkR (172) and MC-NfkA (175) were the most abundant of the oxidised Trp 
microcystins. Whilst MC-NfkR was not able to be separated from MC-LR using 
the current fractionation procedure, sufficient MC-NfkA was purified in order to 
conduct structural characterisation by nuclear magnetic resonance (NMR) 
spectroscopy. 
 
 
 
The electrospray ionisation collision-induced dissociation (ESI CID) tandem mass 
spectrometry (MS/MS) of 175 (Figure 4.2) indicated that it was a microcystin 
with a structure similar to MC-WA, but containing a position two amino acid with 
a mass 32 Da greater than Trp (Nfk, 218 Da; Table 4.2). MC-NfkA also eluted 
earlier from a reversed-phase C18 column than MC-WA (Table 4.1). The presence 
of an amidoaldehyde like that observed in Nfk would account for this reduced 
retention time.
257
 
 
 
Figure 4.2: Tandem mass spectrum of MC-NfkA. Fragmentation induced by 
electrospray ionisation collision-induced dissociation. 
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Table 4.2: Tandem mass spectrometry fragment ions for MC-NfkA observed 
by electrospray ionisation collision-induced dissociation. 
m/z Fragment Assignment 
a
 m/z Fragment Assignment
 a
 
373 Mdha-Ala-Nfk + H 375 Adda’-Glu-Mdha + H 
419 Nfk-Masp-Ala + H 446 Adda’-Glu-Mdha-Ala + H 
490 Ala-Nfk-Masp-Ala + H 509 Adda-Glu-Mdha – NH3 + H 
573 Mdha-Ala-Nfk-Masp-Ala + H 580 Adda-Glu-Mdha-Ala – NH3 + H 
664 Adda’-Glu-Mdha-Ala-Nfk + H 684 M – Adda – H2O + H 
702 M – Adda + H 798 Adda-Glu-Mdha-Ala-Nfk – NH3 + H 
863 M – Adda sidechain – H2O + H 881 M – Adda sidechain + H 
914 M – Mdha – H2O + H 997 M – H2O + H 
1015 M + H   
a Fragments containing NH4
+ adducts were not included; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
 
The Adda’-Glu-Mdha fragment ion (m/z 375) commonly observed in 
microcystins
265
 was extended to include Ala and Nfk (Figure 4.3A). This 
sequence was supported by the ion series containing Adda minus NH3 (m/z 509, 
580, 798; Figure 4.3B). A fragment ion series which began with Nfk-Masp-Ala 
(m/z 419; Figure 4.3B) and extended in the opposite direction to include a second 
Ala residue gave the complete amino acid sequence of Adda-Glu-Mdha-Ala-Nfk-
Masp-Ala. A fragment where Mdha and water were lost from the compound 
(m/z 914; Table 4.2) indicated that Adda and the second Ala residue were joined 
and that the structure was cyclic. 
 
 
Figure 4.3: Tandem mass spectrometry fragment ions indicating the amino 
acid sequence in MC-NfkA. 
 
High resolution mass spectrometry (HRMS) of MC-NfkA yielded a 
m/z of 1037.4598, consistent with the sodium adduct ion of the proposed 
structure 175 (C51H66N8O14Na, m/z 1037.4591, Δ −0.75 ppm). 
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The structure suggested by the MS/MS analysis was investigated further by NMR 
spectroscopy. Interpretation of COSY, TOCSY, ROESY, HSQC and HMBC 
spectra allowed for the assignment of the 
1
H and 
13
C signals (Table 4.3). These 
spectra were acquired in a solvent which allowed exchangeable protons to be 
detected (CD3OH) and on a 600 MHz instrument. Nuclear magnetic resonance 
spectra for MC-NfkA are presented in Appendix I. 
 
Table 4.3: Nuclear magnetic resonance spectroscopy assignment of MC-NfkA at 
600 MHz in CD3OH. 
AA
a
 13C 
1
H 
Mult.
b
 
(J in Hz) 
AA
a
 13C 
1
H 
Mult.
b
 
(J in Hz) 
Ala-1    Adda-5    
1 175.7 -  1 176.5 -  
2 49.9 4.54 m 2 44.6 3.16 m 
3 17.1 1.40 d (7.3) 3 56.7 4.57 m 
NH - 8.22 d (8.5) 4 127.3 5.58 dd (9.3, 15.5) 
    5 138.6 6.24 d (15.5) 
Nfk-2    6 136.0 -  
1 nd -  7 136.4 5.41 d (10.0) 
2 55.9 4.26 m 8 37.7 2.59 m 
3 29.1 2.02 (2H) m 9 88.4 3.25
c
 m 
4 nd -  10 39.3 2.68 dd (7.4, 14.0) 
5 124.9 -    2.82 dd (4.7, 14.0) 
6 132.4 8.06 d (7.2)
d
 11 140.3 -  
7 125.5 7.24
 
dd (7.2, 8.6)
d 
12 & 16 130.1 7.19 d (7.8) 
8 134.6 7.49 dd (8.0, 8.6) 13 & 15 128.7 7.24 dd (7.4, 7.8) 
9 122.2 8.49 d (8.0) 14 126.9 7.16 t (7.4) 
10 139.5 -  17 15.9 1.07 d (6.7) 
11 162.5 8.43 s 18 12.9 1.64 s 
CHO-NH - 8.93 br s 19 16.4 1.00 d (6.9) 
NH - 8.32 d (6.8) 20 58.7 3.24 s 
    NH - 8.01 d (9.2) 
Masp-3        
1 nd -  Glu-6    
2 58.5 4.36 m 1 nd -  
3 42.3 3.14 m 2 56.5 4.06 m 
4 177.8 -  3 29.7 1.93 m 
5 15.8 1.06 d (6.9)   2.22 m 
NH - 8.06 d (8.3) 4 33.5 2.48 m 
      2.66 m 
Ala-4    5 177.1 -  
1 172.5 -  NH - 8.39 d (7.2) 
2 49.0 4.41 m     
3 17.5 1.26 d (7.3) Mdha-7    
NH - 8.72 d (9.2) 1 165.9 -  
    2 146.3 -  
    3 113.6 5.27 s 
      5.71 s 
    N-CH3 38.2 3.28
c 
s 
a AA = Amino acid (number indicates the position in the structure); nd = Not detected; br = Broad signal. 
b Mult. = Multiplicity of the proton signal; J = Coupling constant. c Signals were overlapped so chemical shifts were 
determined using correlations observed in 2D HSQC spectra. d Multiplicity and coupling constants were determined using 
1D-selective TOCSY experiments. 
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Much of the structure of MC-NfkA was the same as those of MC-FA and 
MC-WA and, as a result, similar chemical shifts and coupling constants were 
observed for the corresponding parts of the structure (Tables 3.2, 3.4 and 4.3). The 
differences resulted from use of a solvent which allowed exchangeable protons to 
be detected, and hence the amine proton signals were observed in the spectrum. 
These signals overlapped with the aromatic signals from Nfk, however the 
identity of the signals was easily determined by comparing the proton spectrum 
acquired in CD3OD with that acquired in CD3OH (Figure 4.4). Analysis of the 
COSY coupling between the amine protons and the adjacent methines allowed 
each of the amine proton signals to be attributed to one of the amino acids present 
in MC-NfkA. 
 
 
Figure 4.4: Proton nuclear magnetic resonance spectra of the downfield 
region of MC-NfkA in CD3OD (A) and CD3OH (B). 
 
The presence of the amide protons caused additional 
1
H-
1
H coupling, which led to 
splitting of the adjacent methine proton signals. As a result, the multiplicities of 
these signals were no longer able to be discerned (Table 4.3). The ROESY 
correlations observed from the amine protons showed connectivity between 
several of the amino acids in the microcystin. The ROESY spectrum of MC-NfkA 
showed an interaction between the Glu amine and the Adda H2 (Figure 4.5), 
which indicated these two amino acids were adjacent. Several ROESY 
correlations between the Adda amine and the Ala residue with the more upfield 
H11 
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methyl proton resonance (1.26 ppm), placed this Ala in position four. This 
reinforced the assertion made with MC-FA and MC-WA, that the Ala with the 
more upfield methyl proton resonance was in position four (see Section 3.2.2). A 
correlation between the amine of the position four Ala and the Masp H3 
confirmed that Masp was in position three. Another ROESY correlation between 
one of the Nfk aromatic protons and the Masp amine, reinforced its placement in 
position two. An HMBC correlation between the N-methyl of Mdha and the Glu 
C5 carbonyl confirmed that these two amino acids were also adjacent. 
 
 
Figure 4.5: Connectivity within MC-NfkA shown by nuclear magnetic 
resonance spectroscopy correlations. Double-headed arrows are 
ROESY correlations and the single-headed arrow is an HMBC 
correlation. 
 
NMR Characterisation of the N-formylkynurenine residue in MC-NfkA 
The Nfk residue gave rise to nine proton signals; a sharp singlet at 8.43 ppm, a 
broad singlet at 8.93 ppm, three doublets at 8.06, 8.49 and 8.32 ppm, two doublets 
of doublets at 7.24 and 7.49 ppm, and two multiplets at 2.02 and 4.26 ppm 
(Table 4.3). The HSQC spectrum indicated that the 8.32 and 8.93 ppm signals 
were not attached to a carbon, which suggested they were amine proton signals. 
The HSQC spectrum also correlated the 2.02 ppm proton signal to a carbon 
resonance at 29.1 ppm, which the DEPT-135 designated as the only methylene in 
the structure (C3). This proton signal showed a COSY coupling to the multiplet at 
4.26 ppm (H2; Figure 4.6) which, due to its chemical shift, was adjacent to two 
electron withdrawing environments. One of these environments was shown to be 
an amine, as there was a COSY coupling between the 4.26 ppm signal and the 
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8.32 ppm amine doublet. The other environment was most likely the carbonyl of 
an intact peptide bond, although an HMBC correlation to this was not observed. 
 
 
Figure 4.6: COSY correlations for the N-formylkynurenine residue in 
MC-NfkA. 
 
As with the Trp residue in MC-WA, the aromatic signals in MC-Nfk were in an 
asymmetric environment and produced individual resonances. However, the 
chemical shifts of the aromatic proton signals in Nfk were more downfield than 
those observed in Trp (7.24-8.49 ppm as opposed to 7.00-7.67 ppm; Tables 3.5 
and 4.3). The 8.49 ppm doublet (H9) in Nfk showed a COSY coupling to the 
7.49 ppm signal (H8; Figure 4.7), which was coupled to the signal at 
7.24 ppm (H7) which was in turn coupled to the 8.06 ppm doublet (H6). This 
1
H-
1
H coupling pattern indicated an intact aromatic ring, however, the more 
downfield chemical shifts compared to MC-WA, suggested that two electron-
withdrawing substituents were located on the two remaining carbons. 
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Figure 4.7: COSY spectrum for the N-formylkynurenine aromatic protons in 
MC-NfkA. Lines indicate coupling between proton signals. 
 
A 
3
J HMBC correlation between the H6 doublet and a quaternary carbon signal at 
139.5 ppm indicated that it was the C10 quaternary carbon. Another 
3
J HMBC 
correlation between the H9 doublet and a quaternary carbon which resonated at 
124.9 ppm indicated that the latter arose from the C5 quaternary carbon 
(Figure 4.8). 
 
 
Figure 4.8: HMBC correlations for the N-formylkynurenine residue in 
MC-NfkA. 
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The chemical shift of the singlet at 8.43 ppm (H11) indicated that the proton was 
in a very electron-withdrawing environment, but it was not as downfield as would 
be expected for an aldehyde. In a ROESY experiment this peak showed a proton 
exchange with a broad peak at 8.93 ppm. The downfield chemical shift and the 
broad appearance of the 8.93 ppm peak could be due to an amine rapidly 
exchanging a proton. The presence of an amidoaldehyde would also explain the 
upfield chemical shift of the H11 signal.
266
 The H11 singlet also showed an 
HMBC correlation to a quaternary carbon (C10). Assuming a 
3
J coupling; this 
indicated that the amidoaldehyde was the C10 substituent of the aromatic ring 
(Figure 4.8). The presence of this electron-withdrawing environment would, to 
some degree, explain the more downfield chemical shifts observed for the 
aromatic protons (H6-H9). 
 
N-Formyl moieties can form rotational isomers, which are able to be distinguished 
by NMR spectroscopy.
267
 When in the trans-configuration, the amidoaldehyde 
proton signal (H11) is coupled to the amide proton with a coupling constant of 
ca. 10 Hz. In the cis-configuration, this 
1
H-
1
H coupling is not evident.
267
 As the 
H11 signal in MC-NfkA resonated as a singlet, the N-formyl moiety was 
determined to be in the cis-configuration. 
 
MS/MS analysis of MC-NfkA indicated that it possessed a structure similar to 
MC-WA, but with an amino acid which was 32 Da larger in position two. This 
mass increase correlated well with the presence of Nfk instead of Trp and was 
supported by a reduced retention time on reversed-phase C18.
257
 The NMR data 
matched that reported for Nfk.
266
 Due to restricted amounts of sample, the C1 and 
C4 carbonyls were not detected, however the mass of the amino acid at position 
two indicated by the MS/MS analysis, supported the inclusion of these two 
carbonyls in the structure. 
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4.2.3 Identification of Two Further -XA Oxidised Tryptophan Congeners 
The oxidation of Trp residues yields several major oxidation products (Kyn, Oia 
and Nfk), as well as other minor components.
257
  Whilst MC-NfkA was present in 
large enough quantities to purify and characterise by NMR spectroscopy, the 
presence of -XA microcystins containing Kyn (173) and Oia (174) was also 
apparent. 
 
 
 
The MS/MS spectra of 173 and 174 (Figure 4.9) indicated that they were 
microcystins very similar to MC-WA, but containing a position two amino acid 
with additional mass of 4 or 16 Da, respectively (Table 4.4). These amino acids 
were postulated to be the Trp oxidation products, Kyn and Oia, due to their mass 
and the presence of MC-NfkA in CYN06.  
 
The HRMS of MC-KynA and MC-OiaA yielded m/z 1009.4670 and 1021.4634, 
consistent with sodium ions of the proposed structures 173 and 174 
(C50H66N8O13Na, m/z 1009.4642, Δ +2.82 ppm; C51H66N8O13Na, m/z 1021.4642, 
Δ −0.76 ppm). 
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Figure 4.9: Tandem mass spectra of MC-KynA (A) and MC-OiaA (B). 
Fragmentation was induced by electrospray ionisation collision-
induced dissociation. 
 
Table 4.4: Tandem mass spectrometry fragment ions for the -XA oxidised 
tryptophan microcystin congeners observed by electrospray ionisation 
collision-induced dissociation. 
Fragment Assignment 
a MC-WA 
X = 186 Da 
MC-KynA 
X = 190 Da
 
MC-OiaA 
X = 202 Da 
M + H 983 987 999 
M – H2O + H 965 969 981 
M – Mdha – H2O + H 882 886 898 
M – Adda sidechain + H 849 853 865 
M – Adda sidechain – H2O + H 831 835 847 
M – Adda + H 670 674  
M – Adda – H2O + H 652 656 668 
Adda-Glu-Mdha-Ala-X-Masp – NH3 + H 895 899 911 
Adda-Glu-Mdha-Ala-X – NH3 + H 766 770 782 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Adda’-Glu-Mdha-Ala-X + H 632 636 648 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Mdha-Ala-X-Masp-Ala + H 541 545 557 
Ala-X-Masp-Ala + H 458 462 474 
X-Masp-Ala + H 387 391  
Mdha-Ala-X + H 341 345 357 
a Fragments containing NH4
+ adducts were not included; X = Position two amino acid; Adda’ = Adda 
minus NH2 and the sidechain (C9H11O). 
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4.2.4 Identification of Three -XR Oxidised Tryptophan Congeners 
Three microcystins in Microcystis CYN06 contained Arg at position four with a 
position two amino acid consistent with Kyn (170), Oia (171) or Nfk (172). 
 
 
 
As each of these microcystins 170-172 contained an Arg residue, they ionised 
well using matrix-assisted laser desorption/ionisation (MALDI) MS. Therefore, 
both MALDI post-source decay (PSD) and ESI CID MS/MS were utilised for 
their characterisation. The MS/MS spectra of 170-172 (Figure 4.10) indicated they 
had structures very similar to MC-WR, but containing an amino acid in position 
two with additional mass of 4, 16 or 32 Da, respectively (Table 4.5). These amino 
acids were postulated to be Kyn, Oia and Nfk.  
 
The HRMS of MC-KynR, MC-OiaR and MC-NfkR yielded m/z of 1072.5431, 
1084.5449 and 1100.5548, consistent with protonated ions of the proposed 
structures 170-172 (C53H73N11O13, m/z 1072.5431, Δ −2.93 ppm; C54H73N11O13, 
m/z 1084.5462, Δ −1.24 ppm; C54H73N11O14, m/z 1100.5411, Δ +3.42 ppm). 
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Figure 4.10: Tandem mass spectra of MC-KynR (A), MC-OiaR (B) and 
MC-NfkR (C). Fragmentation was induced by electrospray 
ionisation collision-induced dissociation. 
 
  
 
1
0
6
 
Table 4.5: Tandem mass spectrometry fragment ions for the -XR oxidised tryptophan microcystin congeners observed by electrospray 
ionisation collision-induced dissociation and matrix-assisted laser desorption/ionisation post-source decay. 
Fragment Assignment 
a MC-WR 
X = 186 Da 
MC-KynR 
X = 190 Da
 
MC-OiaR 
X = 202 Da 
MC-NfkR 
X = 218 Da 
M + H 1068 1072 1084 1100 
M – H2O + H 1050 1054 1066 1082 
M – Ala + H 997 1001 1013 1029 
M – CH2NHCN2H3 + H 996 1000 1012 1028 
M – Glu or Masp + H 939 943 955 971 
M – Adda sidechain + H 934 938 950 966 
M – Adda + H 755 759 771 787 
Arg-Adda-Glu – NH3 + H 582 582 582 582 
Arg-Adda – NH3+ H 453 453 453 453 
Masp-Arg-Adda – CO + H or Arg-Adda-Glu – CO + H 571 571 571 571 
Masp-Arg-Adda-Glu + H 728 728 728 728 
Masp-Arg-Adda + H or Arg-Adda-Glu + H 599 599 599 599 
Arg-Adda + H 470 470 470 470 
Mdha-Ala-X-Masp-Arg + H 626 630 642 658 
Ala-X-Masp-Arg + H 543 547 559 575 
X-Masp-Arg + H 472 476 488 504 
Mdha-Ala-X-Masp + H 470 474 486 502 
Mdha-Ala-X + H 341 345 357 373 
Mdha-Ala + H 155 155 155 155 
Adda’-Glu-Mdha-Ala + H 446 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 375 
Glu-Mdha + H 213 213 213 213 
ADDA’ + H 163 163 163 163 
ADDA sidechain 135 135 135 135 
Arg related ions 70/84/112/174 70/84/112/174 70/84/112/174 70/84/112/174 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O); CH2NHCN2H3 is a fragment of the Arg sidechain. 
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4.2.5 Identification of -XAba Oxidised Tryptophan Congeners 
Two microcystins in Microcystis CYN06 contained Aba at position four and a 
position two amino acid consistent with Oia (177) or Nfk (178). A further 
compound possessing a molecular mass consistent with that of MC-KynAba (176) 
was also observed. 
 
 
 
The MS/MS spectra of 177 and 178 (Figure 4.11) indicated that they were 
microcystins very similar to MC-WAba, but contained an amino acid at position 
two with additional mass of 16 or 32 Da, respectively (Table 4.6). These amino 
acids were postulated to be Oia and Nfk according to their mass and the presence 
of MC-NfkA. Because the -XAba microcystins were present in such low 
quantities, the presence of an [M+H]
+
 1001.5 ion was the only indication of 
MC-KynAba (176). This also meant there were not sufficient quantities to 
undertake purification and HRMS analysis of MC-OiaAba and MC-NfkAba. 
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Figure 4.11: Tandem mass spectra of MC-OiaAba (A) and MC-NfkAba (B). 
Fragmentation was induced by electrospray ionisation collision-
induced dissociation. 
 
Table 4.6: Tandem mass spectrometry fragment ions for the -XAba oxidised 
tryptophan microcystin congeners observed by electrospray 
ionisation collision-induced dissociation. 
Fragment Assignment 
a MC-WAba 
X = 186 Da 
MC-OiaAba 
X = 202 Da 
MC-NfkAba 
X = 218 Da 
M + H 997 1013 1029 
M – H2O + H 979 995 1011 
M – Mdha – H2O + H 896  928 
M – Aba – H2O + H  910  
M – Glu or Masp – H2O + H 850 866 878 
M – Adda sidechain + H 863 879 895 
M – Adda sidechain – H2O + H 845 861 877 
M – Adda + H 684 700 716 
M – Adda – H2O + H 666  698 
Adda-Glu-Mdha-Ala-X-Masp – NH3 + H 895 911  
Adda-Glu-Mdha-Ala-X – NH3 + H 766 782 798 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Adda’-Glu-Mdha-Ala-X + H 632 648 664 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Mdha-Ala-X-Masp-Aba + H 555 571 587 
Ala-X-Masp-Aba + H 472  504 
X-Masp-Aba + H 401 417 433 
a Fragments containing NH4
+ adducts were not included; X = Position two amino acid; Adda’ = Adda minus NH2 and 
the sidechain (C9H11O). 
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4.2.6 Oxidation of Tryptophan-Containing Microcystins 
Several experiments were conducted in order to determine if the oxidised Trp 
microcystins could be produced via oxidation of existing Trp microcystins. An 
extract of CYN06 was shielded from light and exposed to atmospheric oxygen 
while sub-samples were analysed periodically by LC-MS (Figure 4.12A). After 
124 h, the level of Trp-containing microcystins (for example, MC-WA) had  
 
 
Figure 4.12: Oxidation of a tryptophan-containing microcystin from a CYN06 
extract. Graphs depicting the oxidation of MC-WA into 
MC-KynA, MC-OiaA and MC-NfkA through diffusion with 
atmospheric oxygen (A), the application of stirring (B) and the 
application of hydrogen peroxide (C). 
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dropped by ca. 4%. In-turn, the level of the oxidised Trp microcystins (for 
example, MC-NfkA) had increased. Stirring at ca. 250 rpm did not have any effect 
on the rate of Trp oxidation. After 124 h of stirring, the levels of Trp- and 
oxidised Trp-containing microcystin were the same as observed through diffusion 
alone (Figure 4.12B). Addition of an oxidising agent (hydrogen peroxide) 
increased the rate of Trp oxidation and after 124 h, the level of oxidised Trp 
microcystins had increased by ca. 28% (Figure 4.12C). 
 
4.2.6 Presence of Oxidised Tryptophan Microcystins inside CYN06 Cells 
A healthy culture of CYN06 was harvested on nylon net, washed with fresh media 
and extracted in degassed 70% MeOH (v/v). The duration of the concentration 
and extraction procedure was 50 min and LC-MS analysis of the extract revealed 
the conventional microcystins produced by CYN06 as well as low levels of 
Nfk-containing microcystins (Figure 4.13).  
 
 
Figure 4.13: Negative ion mass spectra of a mild extraction of CYN06. Spectra 
focussing on the -XR congeners (A), the -XA congeners (B) and 
the -XAba congeners (C). 
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4.3 DISCUSSION 
Whilst oxidised Trp residues have been noted in polypeptides,
256-259
 their presence 
in microcystins has not. LC-MS analysis of nine unknown microcystins observed 
in CYN06 indicated the presence of position two amino acids with the mass of 
known Trp oxidation products (Kyn, Oia and Nfk). A sufficient quantity of one of 
the microcystins (MC-NfkA) was purified in order to characterise it by NMR 
spectroscopy. This demonstrated that Nfk was present in position two of the 
microcystin. 
 
It is likely that some of these microcystin congeners have been encountered 
previously, as mass-to-charge ratios consistent with MC-OiaR and MC-NfkR 
were observed in the Lake Wiritoa sample which contained anabaenopeptin 906 
(see Section 2.2). A microcystin with m/z 1100.6 has also been reported 
previously which could have been MC-NfkR.
265
 In both of these studies, MC-WR 
was present in the samples, making it likely that oxidised Trp microcystins would 
also be observed. The findings of this study will allow researchers working with 
samples of Trp-containing microcystins to assign the previously unidentified 
oxidised analogues. 
 
The oxidation of Trp-containing microcystins into the oxidised analogues poses a 
concern for researchers quantifying microcystins in samples which include 
Trp-containing microcystins. Whilst the rate of oxidation under normal storage 
conditions is unknown, it is likely that during prolonged storage of a 
Trp-containing microcystin standard or sample, some of the microcystin will 
become oxidised. This would result in a lower than expected signal from the 
sample or standard and cause inaccurate measurements. Further investigation into 
storage procedures to minimise the oxidation of Trp microcystins will need to be 
performed. 
 
Whilst the oxidation of Trp-containing microcystins into Kyn-, Oia- and 
Nfk-containing microcystins was apparent over a long time period (124 h), over a 
short period of time (2 h), Trp-oxidation was only detected when hydrogen 
peroxide was present. A mild extraction of Microcystis CYN06, where colonies 
were concentrated on nylon net and washed with fresh medium, revealed the 
presence of Nfk-containing microcystins. As this extraction was completed in less 
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than 2 h, the oxidised Trp microcystins observed were most likely present inside 
the cells.  It is not clear how the oxidised Trp-containing microcystins are 
produced in cyanobacteria. Whilst it is possible that Kyn, Oia and Nfk could be 
incorporated into the structure, it is more likely that the oxidation occurs post-
synthesis. Whether the oxidation was due to natural oxygen levels, reactive 
oxygen species or is enzymatically driven, remains to be elucidated. 
 
During the purification of 175 it is probable that some MC-WA was oxidised to 
form MC-NfkA. However, such oxidation artefacts still pose a potential health 
concern when produced in the environment. As with other microcystin congeners, 
it is very likely that these microcystins will inhibit protein phosphatases 1 and 2A 
and pose a health threat to animals. Unfortunately, the material isolated for 
characterisation was insufficiently pure to proceed with toxicology or protein 
phosphatase inhibition studies. 
 
 
4.4 CONCLUSIONS 
A combination of MS/MS and NMR spectroscopy was used to investigate the 
structure of an unknown microcystin (MC-NfkA) and demonstrated that the 
microcystin contained Nfk; a known oxidation product of Trp. Tandem MS 
analysis of other microcystins observed in CYN06 indicated the presence of 
further known oxidation products of Trp (Kyn and Oia). This resulted in the 
identification of nine new microcystin analogues and is the first report of a 
microcystin containing an oxidation product of Trp. 
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CHAPTER 5 
 
Characterisation of New Oligopeptides from an 
Antarctic Cyanobacterial Sample 
 
 
5.1 INTRODUCTION 
The McMurdo Dry Valleys in Eastern Antarctica form the largest ice-free region 
on the continent and are characterised by low temperatures, minimal precipitation, 
strong winds,
268
 and high salinity.
269
 Despite these harsh conditions, life is still 
present in this arid environment in the form of microbial communities.
270-272
 In the 
moist areas in and around glacial streams and lakes, cyanobacteria proliferate 
forming thick benthic mats.
273-275
 
 
Cyanobacteria which produce microcystins have been reported in almost every 
environment on Earth,
3
 including Antarctica.
276-278
 In 2008, we showed 
microcystin-producing cyanobacteria to be particularly prolific in the Dry Valleys, 
with each sample collected testing positive for at least low levels of 
microcystins.
279
 Previously, only [Asp
3
] MC-LR, MC-LR and nodularin had been 
reported in Antarctic cyanobacteria,
276-278
 but our 2008 study also identified 
[Asp
3
, Dha
7
] MC-LR, MC-FR and MC-RR (including the [Asp
3
] and 
[Asp
3
, Dha
7
] congeners of MC-RR).
279
 
 
During the course of this study,
279
 a discrepancy between the different methods of 
determining microcystin content was noted in several samples. Whilst a high level 
of microcystin was detected using an enzyme-linked immunosorbent assay and 
protein phosphatase inhibition assay, a low level was detected by liquid 
chromatography-mass spectrometry (LC-MS). Further investigation demonstrated 
that these samples contained several new microcystins which were not detected by 
the LC-MS multiple reaction monitoring method. This chapter details the partial 
characterisation of these new microcystins, as well as that of six novel linear 
peptides also present in the samples. 
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5.2 RESULTS 
5.2.1 Assessment of the Oligopeptide Diversity in the Miers Valley 
Cyanobacterial Mats 
Methanol extracts of two samples (MVAG1 and MVMG1) collected from Miers 
Valley, Antarctica were analysed by matrix-assisted laser desorption/ionisation-
time of flight (MALDI-TOF) MS. The positive ion mass spectrum (Figure 5.1) 
and post source decay experiments indicated the presence of two groups of 
oligopeptides; several linear peptides with masses between 800 and 844 Da, and 
eight microcystins between 966 and 1051 Da. 
 
 
Figure 5.1: Positive ion MALDI mass spectra of the two Miers Valley 
samples; MVAG1 (A) and MVMG1 (B). 
 
5.2.2 Structural Characterisation of Eight New Microcystins 
The Miers Valley samples were also analysed by LC-MS, which initially 
suggested that they contained four MC-LR congeners and four MC-RR congeners. 
The microcystins eluted from a reversed-phase C18 column within an appropriate 
retention region and possessed protonated ions which matched those of previously 
described microcystins (Appendix A). However, closer assessment of the 
retention times showed that most of the congeners eluted earlier than 
MC-LR/MC-RR or their demethylated analogues (Table 5.1). A combination of 
amino acid analysis, chemical derivatisation and MS confirmed that the eight 
microcystins were new and led to the putative structures for 179-186. 
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Table 5.1: Structures, molecular masses and retention times of the eight new 
Antarctic microcystins and two common congeners. 
 
Microcystin 
Mr 
a
 
(Da) 
RT b 
(min) 
X Z R1 R2 R3 R4 R5 
MC-LR (7) 994.5 7.40 L-Leu L-Arg -CH3 -H -CH3 -CH3 -CH3 
[Gly1, Asp3, Dhb7] MC-LR (179) 966.5 7.27 L-Leu Arg -H -CH3 -H -H -CH3 
[Gly1, Asp3, Dhb7] MC-LHar (180) 980.5 7.34 L-Leu Har -H -CH3 -H -H -CH3 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-LR (181) 994.5 7.29 L-Leu Arg -H -CH3 -H -H -COCH3 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-LHar (182) 1008.5 7.36 L-Leu Har -H -CH3 -H -H -COCH3 
MC-RR (85) 1023.6 6.48 L-Arg L-Arg -CH3 -H -CH3 -CH3 -CH3 
[Gly1, Asp3, Dhb7] MC-RR (183) 1009.6 6.29 Arg Arg -H -CH3 -H -H -CH3 
[Gly1, Asp3, Dhb7] MC-RHar (184) 1023.6 6.38 Arg Har -H -CH3 -H -H -CH3 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-RR (185) 1037.6 6.33 Arg Arg -H -CH3 -H -H -COCH3 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-RHar (186) 1051.6 6.42 Arg Har -H -CH3 -H -H -COCH3 
a Molecular weights are rounded to one decimal place. a RT = Retention time on a C18 column as per 
Table 9.3. 
 
On account of the small amount of material, fractionation of the Antarctic 
microcystins did not proceed beyond separating a mixture of the four -LR 
congeners and a mixture of the four -RR congeners from the other components in 
the extract. These two mixtures of four microcystins were individually hydrolysed 
and subjected to Advanced Marfey’s amino acid analysis204,205 to determine the 
amino acids present and their stereochemistry. 
 
Derivatisation of amino acids with L-FDLA allowed the separation of both 
stereoisomers by reversed-phase C18 high performance liquid chromatography 
(HPLC).
204,205
 LC-MS analysis of the L-FDLA derivatives of the hydrolysed -LR 
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Antarctic microcystin congeners, and comparison with standard amino acids, 
confirmed the presence of D-aspartic acid (Asp; m/z 426; 12.9 min; Figure 5.2), 
D-glutamic acid (Glu; m/z 440; 14.3 min), glycine (Gly; m/z 368; 15.2 min) and 
L-leucine (Leu; m/z 424; 21.0 min). Comparison with the L-FDLA derivatives of 
hydrolysed MC-LR (Appendix F.3) indicated the presence of 3(S)-Adda 
(3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid; m/z 592; 
32.9 min).
205
 
 
 
Figure 5.2: Advanced Marfey’s amino acid analysis of the -LR Antarctic 
microcystins. Extracted ion chromatograms for a hydrolysate of 
the -LR Antarctic microcystins derivatised with L-FDLA. 
 
Liquid chromatography-MS analysis of the L-FDLA derivatives of the 
hydrolysed -RR Antarctic microcystin congeners revealed similar results. The 
presence of D-Asp (m/z 426; 12.9 min; Figure 5.3), D-Glu (m/z 440; 14.3 min), 
Gly (m/z 368; 15.2 min) and 3(S)-Adda (m/z 592; 32.9 min) was confirmed by 
comparison with standard amino acids and hydrolysed MC-LR. 
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Figure 5.3: Advanced Marfey’s amino acid analysis of the -RR Antarctic 
microcystins. Extracted ion chromatograms for a hydrolysate of 
the -RR Antarctic microcystins derivatised with L-FDLA. 
 
N-Methylamine (m/z 324; 19.6 min) was not observed in the amino acid analysis 
of the Antarctic microcystin mixtures but is commonly observed during 
microcystin analysis,
205
 as it is the product of the hydrolytic breakdown of 
N-methyldehydroalanine (Mdha). A simple thiol derivatisation was used to 
verify the absence of Mdha in the Antarctic microcystins. A microcystin 
containing a terminal alkene, like that found in Mdha, will readily react with 
β-mercaptoethanol under alkaline conditions.41 Monitoring of the derivatisation 
by LC-MS showed that MC-LR, which contains Mdha, reacted quickly with 
β-mercaptoethanol (t½ = 4.8 min; Appendix D.1). A reaction rate approximately 
twice as fast was observed with a microcystin containing two arginine residues 
(MC-RR; t½ = 2.6 min). The -LR Antarctic microcystins reacted over two orders 
of magnitude slower than MC-LR (t½ = 1089 min; Appendix D.3). A similar 
difference in reaction rate was observed with the Antarctic -RR congeners when 
compared to MC-RR (t½  =  632 min). The slow reaction rate with 
β-mercaptoethanol, in combination with the absence of N-methylamine in the 
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amino acid analysis, suggested that the Antarctic microcystins contained a 
dehydrobutyrine (Dhb). 
 
The electrospray ionisation collision-induced dissociation (ESI CID) tandem MS 
(MS/MS) spectrum of 179 indicated that the compound contained Adda, as an 
intense m/z 135 fragment ion was present (Figure 5.4).
34,265
 The m/z 112, 129 and 
157 ions indicated that the microcystin contained an Arginine (Arg) residue.
181
 
The later retention time on reversed-phase C18 (7.27 min; Table 5.1) and the 
absence of a loss of 42 Da (CN2H2) in the MS/MS spectrum,
78
 suggested that it 
was not likely that there were two Arg residues present. The mass difference 
between the fragment ions indicated the position of the remaining amino acids in 
the compound (Table 5.2). 
 
 
 
 
Figure 5.4: Tandem mass spectrum of [Gly
1
, Asp
3
, Dhb
7
] MC-LR and 
fragments observed in the Adda-containing Antarctic 
microcystins. Fragmentation induced by electrospray ionisation 
collision-induced dissociation. 
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Table 5.2: Tandem mass spectrometry fragment ions for [Gly
1
, Asp
3
, 
Dhb
7
] MC-LR observed by electrospray ionisation collision-induced 
dissociation. 
m/z Fragment Assignment
 a
 m/z Fragment Assignment
 a
 
112 Arg fragment 129 Arg immonium 
135 Adda sidechain 141 Dhb-Gly + H 
157 Arg + H 163 Adda’ + H 
171 Gly-Leu + H 213 Glu-Dhb + H 
254 Dhb-Gly-Leu + H 270 Glu-Dhb-Gly + H 
272 Asp-Arg + H 292 Adda’-Glu + H 
375 Adda’-Glu-Dhb + H 385 Leu-Asp-Arg + H 
432 Adda’-Glu-Dhb-Gly + H 442 Gly-Leu-Asp-Arg + H 
525 Dhb-Gly-Leu-Asp-Arg + H 599 Arg-Adda-Glu + H 
682 Arg-Adda-Glu-Dhb + H 967 M + H 
a Fragments containing CO losses and NH4
+ adducts were not included; Adda’ = Adda minus NH2 and the sidechain 
fragment (C9H11O). 
 
The fragment ion series beginning with the Adda’ fragment (Adda minus NH2 and 
C9H11O; m/z 163) indicated that 179 contained Glu and Dhb in positions six and 
seven, respectively (Figure 5.5A). The m/z 432 ion extended this ion series to 
include a Gly in position one, yielding a sequence of Adda-Glu-Dhb-Gly. Another 
fragment ion series which began with Arg (m/z 157), extended to include Asp, 
Leu, Gly, Dhb and Glu (Figure 5.5B). This gave a sequence of Arg-Asp-Leu-Gly-
Dhb-Glu, the end of which overlapped with the previous sequence, resulting in a 
complete peptide sequence of Adda-Glu-Dhb-Gly-Leu-Asp-Arg. The m/z 599 ion 
(Arg-Adda-Glu) indicated that the Arg was joined to Adda and that the structure 
was cyclic (Figure 5.5C). 
 
 
Figure 5.5: Tandem mass spectrometry fragment ions indicating the amino 
acid sequence in [Gly
1
, Asp
3
, Dhb
7
] MC-LR. 
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The MS/MS spectrum for 180 again indicated that it contained Adda, because of 
the m/z 135 fragment ion (Figure 5.6). However, the m/z 126, 143 and 171 ions in 
this spectrum suggested that the microcystin contained a homoarginine (Har) 
residue. The later retention time on reversed-phase C18 (7.34 min; Table 5.1) and 
the absence of a 42 Da (CN2H2) loss in the MS/MS spectrum, suggested there 
were not two Har residues present. Comparison with the MS/MS spectrum for 179 
indicated that much of the structure was the same (Appendix J.1), apart from the 
position four amino acid which appeared to be Har. 
 
 
 
 
Figure 5.6: Tandem mass spectrum of [Gly
1
, Asp
3
, Dhb
7
] MC-LHar. 
Fragmentation induced by electrospray ionisation collision-
induced dissociation. 
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The MS/MS spectrum for 181 (Figure 5.7) did not contain the intense m/z 135 
fragment ion, which was observed in the previous microcystins. However, a loss 
of 60 Da (HOAc) was evident, which indicated that 181 contained an O-acetyl 
group. The m/z 265 ion suggested that this was due to an O-acetyl group on the 
Adda moiety (ADMAdda; Figure 5.7).
79
 As with 179, it was likely that a single 
Arg residue was present in this microcystin. Comparison with the MS/MS 
spectrum for 179 indicated that much of the structure for 181 was the same 
(Appendix J.1), apart from the inclusion of ADMAdda at position five. 
 
 
 
 
Figure 5.7: Tandem mass spectrum of [Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] 
MC-LR and fragments commonly observed in the ADMAdda-
containing microcystins. Fragmentation induced by electrospray 
ionisation collision-induced dissociation. 
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The MS/MS spectrum for 182 did not contain an intense m/z 135 fragment ion, 
but the presence of ADMAdda was suggested by the m/z 265 fragment and a loss 
of 60 Da (Figure 5.8). Comparison with the MS/MS spectrum for 181 indicated 
that much of the structure was the same (Appendix J.1), apart from the position 
four amino acid which was consistent with a Har. 
 
 
 
 
Figure 5.8: Tandem mass spectrum of [Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] 
MC-LHar. Fragmentation induced by electrospray ionisation 
collision-induced dissociation. 
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The MS/MS spectrum for 183 contained an intense m/z 135 fragment ion, 
suggesting the presence of Adda (Figure 5.9). The m/z 112, 129 and 157 ions in 
the spectrum indicated that 183 contained an Arg residue. However, the earlier 
retention time on C18 (6.29 min; Table 5.1) and loss of 42 Da (CN2H2) in the 
MS/MS spectrum, suggested that there were two Arg residues present. 
Comparison with the MS/MS spectrum for 179 indicated that much of the 
structure was the same (Appendix J.2) except that the Leu at position two had 
been replaced with Arg. 
 
 
 
 
Figure 5.9: Tandem mass spectrum of [Gly
1
, Asp
3
, Dhb
7
] MC-RR. 
Fragmentation induced by electrospray ionisation collision-
induced dissociation. 
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The MS/MS spectrum for 184 contained an intense m/z 135 fragment ion, 
suggesting the presence of Adda (Figure 5.10). The m/z 112, 129 and 157 ions in 
the spectrum indicated that 184 contained an Arg residue. However, the m/z 126, 
143 and 188 ions suggested that there was also a Har present. The presence of 
both a Har and an Arg residue in the compound was reinforced by the earlier 
retention time on C18 (6.38 min; Table 5.1) and the loss of 42 Da (CN2H2) in the 
MS/MS spectrum. Comparison with the MS/MS spectrum for 183 indicated that 
much of the structure was the same (Appendix J.2) except that the position four 
amino acid was Har. 
 
 
 
 
Figure 5.10: Tandem mass spectrum of [Gly
1
, Asp
3
, Dhb
7
] MC-RHar. 
Fragmentation induced by electrospray ionisation collision-
induced dissociation. 
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The MS/MS spectrum for 185 did not contain an intense m/z 135 fragment ion, 
but the presence of ADMAdda was suggested by the m/z 265 fragment and a loss 
of 60 Da (Figure 5.11). As with 183, the inclusion of two Arg residues was 
indicated by the m/z 112, 129 and 157 ions, and the earlier retention time on 
reversed-phase C18 (6.33 min; Table 5.1). Comparison with the MS/MS spectrum 
for 183 indicated that much of the structure for 185 was the same (Appendix J.2), 
apart from the inclusion of ADMAdda at position five. 
 
 
 
 
Figure 5.11: Tandem mass spectrum of [Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] 
MC-RR. Fragmentation induced by electrospray ionisation 
collision-induced dissociation. 
 
 
 
 
 
 
Chapter 5 
126 
 
The MS/MS spectrum for 186 did not contain an intense m/z 135 fragment ion, 
but the presence of ADMAdda was indicated by the m/z 265 fragment and a loss 
of 60 Da (Figure 5.12). As with 184, the inclusion of an Arg and Har residue was 
indicated by low mass fragments in the MS/MS spectrum (m/z 112, 129 and 157; 
m/z 126, 143 and 171) and the earlier retention time on reversed-phase C18 
(6.42 min; Table 5.1). Comparison with the MS/MS spectrum for 185 indicated 
that much of the structure for 186 was the same (Appendix J.2) except that Har 
was present at position five. 
 
 
 
 
Figure 5.12: Tandem mass spectrum of [Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] 
MC-RHar. Fragmentation induced by electrospray ionisation 
collision-induced dissociation. 
 
High resolution mass spectrometry (HRMS) analysis was conducted on semi-pure 
mixtures of the -LR and -RR Antarctic microcystins. Each mixture yielded 
mass-to-charge ratios consistent with the singly protonated ions of the structures 
179-186 and mass deviations of less than 4 ppm (Table 5.3). The accurate masses 
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for 181-182 and 185-186 indicated that the 28 Da mass increase observed in the 
position five amino acid of these compounds, was more likely due to an additional 
carbonyl (ADMAdda) than the addition of two methylations to the Adda moiety. 
 
Table 5.3: High resolution mass spectrometry analysis of the Antarctic 
microcystins. 
Microcystin 
Measured 
m/z 
Molecular 
Formula 
Calculated 
m/z 
Error 
(ppm) 
[Gly1, Asp3, Dhb7] MC-LR (179) 967.5285 C47H71N10O12 967.5247 + 3.86 
[Gly1, Asp3, Dhb7] MC-LHar (180) 981.5413 C48H73N10O12 967.5404 + 0.87 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-LR (181) 995.5206 C48H71N10O13 995.5197 − 0.94 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-LHar (182) 1009.5348 C49H73N10O13 1009.5353 + 0.47 
[Gly1, Asp3, Dhb7] MC-RR (183) 1010.5442 C47H72N13O12 1010.5418 − 2.44 
[Gly1, Asp3, Dhb7] MC-RHar (184) 1024.5569 C48H74N13O12 1024.5574 + 0.53 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-RR (185) 1038.5405 C48H72N13O13 1038.5367 − 3.82 
[Gly1, Asp3, ADMAdda5, Dhb7] MC-RHar (186) 1052.5541 C49H74N13O13 1052.5524 − 1.60 
 
 
Although every effort was made to garner as much structural information as 
possible on these new microcystins, the amount of material available was limited 
(< 50 µg of each congener), restricting purification of each individual congener 
and making nuclear magnetic resonance (NMR) studies unfeasible. 
 
A mixture of the four -LR congeners and a mixture of the four -RR Antarctic 
microcystin congeners were each subjected to Advanced Marfey’s amino acid 
analysis. This indicated that each microcystin contained Gly, D-Asp and D-Glu. 
The mixture of -LR congeners was shown to contain L-Leu, whilst this peak was 
absent in the -RR congeners. Comparison with the L-FDLA derivatives of 
hydrolysed MC-LR showed that each mixture of microcystins contained the 
amino acid Adda in the 3(S)-configuration. 
 
The N-methylamine signal commonly observed in microcystins was not observed 
in the amino acid analysis. This was further investigated using a thiol 
derivatisation, which verified that Mdha was not present in the Antarctic 
microcystins. The slow reaction rate observed, in combination with the MS/MS 
analysis, indicated that Dhb was very likely present in position seven. This 
substitution could be confirmed by analysis of the 2-ketobutyric acid produced 
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from the hydrolytic breakdown of Dhb,
250
 however there was only sufficient 
material to conduct amino acid analysis of the semi-purified microcystins. 
 
The MS/MS analysis indicated the presence of Arg in six of the microcystins and 
Har in four of the congeners. The amino acid analysis protocol used had poor 
sensitivity for arginine-like residues and with the small sample size available, 
these amino acids were not detected. The MS/MS analysis also suggested that 
four of the microcystins contained ADMAdda. Whilst there was no direct 
evidence of ADMAdda from the amino acid analysis, it is unclear how this moiety 
behaves during the acid hydrolysis and subsequent derivatisation. It is highly 
probable that ADMAdda would lose the O-acetyl group in the same manner that 
the O-methyl group of Adda is lost during acid hydrolysis;
54,205
 hence the two 
moieties would form the same product (Figure 5.13). 
 
 
Figure 5.13:Proposed system for the loss of the O-methyl group from Adda (A) 
and the O-acetyl group from ADMAdda (B) during acid 
hydrolysis. 
 
The MS/MS assignments laid out in Section 5.2.2 and Appendix J were consistent 
with previous analyses of low-energy, collision-activated spectra from similar 
microcystin variants.
80,280-282
  Whilst the Gly substitution in position one is novel, 
the fragment ion series observed were similar to those reported for other 
microcystin congeners containing a position one substitution.
72,111
 
 
In several of the spectra, possible contamination from MC-LR and MC-RR was 
observed, with m/z 155 (Mdha/Dhb-Ala) and m/z 135 (Adda sidechain fragment) 
ions present with the ADMAdda congeners. This is likely due to the high 
concentration of extract used to achieve these spectra and the ease with which 
those fragment ions form. However, the contaminant ions were present at much 
lower intensities than would be expected had the congener contained Adda or Ala. 
  Chapter 5 
129 
 
Furthermore, in each of the spectra containing these ions, the contaminant ion 
series do not continue further than these few easily formed, low-mass ions. 
 
5.2.3 Structural Characterisation of Six New Linear Peptides 
The MALDI MS analysis of the Miers Valley samples showed the presence of 
five compounds with molecular weights of 800, 814, 816, 830 and 844 Da 
(Figure 5.1). Additional analysis by LC-MS indicated the presence of a sixth 
compound which also possessed a mass of 830 Da.  Since the two 830 Da 
peptides have the same mass, they were not resolved by MALDI MS but were 
distinguished by their retention time on reversed-phase C18 (Table 5.4). MS/MS 
analysis suggested that each peptide contained an unusual 168 Da moiety at the 
N-terminus with the molecular formula C9H14NO2, isoleucine (Ile), two aromatic 
amino acids and a hydroxyphenyllactic acid (Hpla) C-terminus (187-192). Whilst 
a methyltyrosine (MeTyr) was consistently observed in position four, the position 
three amino acid varied between methylphenylalanine (MePhe), MeTyr and 
methoxy MeTyr (MeTyr(OMe)). 187-189 possessed an ester-linked Hpla at the 
carboxyl end, whilst 190-192 contained a methoxyphenyllactic acid (Mpla).  
 
Table 5.4: Structures, molecular masses and retention times of the six new 
Antarctic peptides. 
 
Compound 
Mr 
(Da) 
RT 
a 
(min) 
R1 R2 
Antarctic peptide 800 (187) 800.4 5.94 -H -H 
Antarctic peptide 816 (188) 816.4 5.45 -OH -H 
Antarctic peptide 830A (189) 830.4 5.96 -OCH3 -H 
Antarctic peptide 814 (190) 814.4 6.72 -H -CH3 
Antarctic peptide 830B (191) 830.4 6.36 -OH -CH3 
Antarctic peptide 844 (192) 844.4 6.77 -OCH3 -CH3 
a RT = Retention time on a C18 column as per Table 9.3.  
Chapter 5 
130 
 
The MALDI post-source decay (PSD) MS/MS spectrum of 187 (Figure 5.14) 
showed a strong fragment ion series beginning with a protonated 168 Da moiety 
(C9H14NO2; m/z 169) which extended to include Ile, MePhe, MeTyr and a 181 Da 
C-terminus. The mass of the C-terminus did not match with any generally 
observed amino acids, but could be Hpla incorporated through the 2-hydroxyl. 
Other less abundant ions included a fragment ion series beginning at the 
C-terminus and fragments of the amino acids (Table 5.5). 
 
 
 
 
Figure 5.14: Tandem mass spectrum of Antarctic peptide 800. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
Table 5.5: Tandem mass spectrometry fragment ions for Antarctic peptide 800 
observed by matrix-assisted laser desorption/ionisation post-source 
decay and electrospray ionisation collision-induced dissociation. 
m/z Fragment Assignment 
a 
m/z Fragment Assignment 
a
 
86 Ile immonium 91 MePhe sidechain 
107 MeTyr/Hpla sidechain 113 Fragment of C9H14NO2 
134 MePhe immonium 141 C9H14NO2 – CO + H 
151 C9H14NO2 – H2O + H 169 C9H14NO2 + H 
275 Ile-MePhe + H 282 C9H14NO2-Ile + H 
359 Hpla-MeTyr + H 443 C9H14NO2-Ile-MePhe + H 
520 Hpla-MeTyr-MePhe + H 620 C9H14NO2-Ile-MePhe-MeTyr + H 
801 M + H   
a C9H14NO2 is the unidentified 168 Da N-terminus 
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The MS/MS spectrum of 188 (Figure 5.15) also showed a strong fragment ion 
series, beginning with the protonated 168 Da moiety (m/z 169) and extending to 
include Ile, a 177 Da residue, MeTyr and an Hpla C-terminus. The 177 Da amino 
acid contained an additional 16 Da mass to the MePhe observed in 187. This mass 
increase could be due to a substitution of the MePhe in position three for MeTyr. 
This substitution was supported by a reduced retention time on reversed-phase C18 
(5.45 vs. 5.94 min; Table 5.5), as the additional hydroxyl group would increase 
the polarity of the compound. 
 
 
 
 
Figure 5.15: Tandem mass spectrum of Antarctic peptide 816. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
The MS/MS spectrum of 189 (Figure 5.16) showed the same fragment ion series 
observed in 187 and 188, but with a 191 Da residue in position three. The 191 Da 
amino acid contained an additional 14 Da mass to the MeTyr observed in 188. 
This mass increase could be due to an additional methylene in the sidechain arm 
or an O-methylation. Since the retention time of peptide 830A was very similar to 
that of peptide 800 (Table 5.5), the most likely modification would be an 
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O-methylation of the hydroxyl group of the MeTyr. The O-methylation would 
nullify the hydrophilic effect of the substitution observed in peptide 816. 
 
 
 
 
Figure 5.16: Tandem mass spectrum of Antarctic peptide 830A. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
The MS/MS spectrum of 190 (Figure 5.17) indicated that the compound was very 
similar to peptide 800. The fragment ion series extending from the protonated 
168 Da moiety (m/z 169) indicated that peptide 814 had the sequence; 
C9H14NO2-Ile-MePhe-MeTyr, except that the C-terminus contained an additional 
14 Da mass. This could be due to an additional methylene or an O-methylation. 
The increased retention time on reversed-phase C18 (6.72 vs. 5.94 min; Table 5.5) 
indicated this modification had disrupted a hydrophilic group on the residue. This 
suggested that the modification was a methylation of one of the hydroxyl groups 
present. 
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Figure 5.17: Tandem mass spectrum of Antarctic peptide 814. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
As peptide 830B (191) had the same mass as peptide 830A and was present in 
much lower quantities, the structure of 191 could not be deduced from the 
MALDI MS/MS, therefore, only the LC-MS/MS data was utilised. Whilst the 
fragment for the protonated 168 Da moiety (m/z 169) was too low to be observed 
in the LC-MS/MS spectrum presented (Figure 5.18), an MS
3
 experiment 
performed on the C9H14NO2-Ile fragment ion (m/z 282) confirmed that the same 
lower-mass fragments were present. The fragment ion series which extended from 
C9H14NO2-Ile included two MeTyr residues and the Mpla C-terminus present in 
190. As with peptides 800 vs. 816, peptide 830B had a reduced retention time on 
reversed-phase C18 compared to peptide 814 (6.36 vs. 6.72 min; Table 5.5), 
supporting the presence of an additional hydroxyl group. 
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Figure 5.18: Tandem mass spectrum of Antarctic peptide 830B. Fragmentation 
induced by electrospray ionisation collision-induced dissociation. 
 
The MS/MS spectrum of peptide 844 (192; Figure 5.19) showed great similarity 
to that of peptide 830A, except that the C-terminus possessed 14 Da extra mass. 
The fragment ion series indicated that 192 had an amino acid sequence of 
C9H14NO2-Ile-MeTyr(OMe)-MeTyr-Mpla. The later retention time on reversed-
phase C18 compared to peptide 830A indicated that the position five modification 
was most likely an O-methylation, and the later retention time compared to 
peptide 830B indicated that the position three modification was also most likely 
an O-methylation. 
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Figure 5.19: Tandem mass spectrum of Antarctic peptide 844. Fragmentation 
induced by matrix-assisted laser desorption/ionisation post-source 
decay. 
 
As discussed in Section 2.3, the amino acids Ile and Leu which possess the same 
mass, in some circumstances, can be distinguished by mass spectrometry.
242,243
 
This process involves performing MALDI MS/MS on the sample under PSD 
conditions and under conditions combining PSD and high-energy CID. As CID 
induces a harsher fragmentation, some of the amino acid sidechain dissociates and 
the two structural isomers can be distinguished (Figure 5.20). As the resulting 
sidechain fragment is produced at such low levels, the technique requires an 
intense parent fragment ion containing the Ile/Leu to be determined. 
 
 
Figure 5.20: Sidechain fragmentation of the amino acids isoleucine and 
leucine by high-energy collision-induced dissociation. 
 
This analysis was undertaken on the C9H14NO2-Ile/Leu fragment ion (m/z 282) of 
the two most abundant Antarctic peptides; 800 and 830A. When the PSD 
spectrum was compared with the PSD-CID spectrum, there was a small ion 
representing a loss of 28 Da (m/z 254) present in the PSD-CID spectrum which 
was not as prominent in the PSD spectrum (Figure 5.21). No loss of 
N
H
O
N
H
O
- 28 Da - 42 Da
Isoleucine Leucine
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42 Da (m/z 240) was observed in the PSD-CID spectrum, which indicated that the 
amino acid present in peptides 800 and 830A was likely to be Ile and not Leu. 
This analysis was not successful when undertaken on the other Antarctic peptides, 
most likely because they were present in lower quantities. In the putative 
structures 187-192, it has been assumed that of the peptides all contain Ile. 
 
 
Figure 5.21: Isoleucine/leucine determination performed on Antarctic 
peptide 830A. Fragmentation induced by MALDI PSD (A) and 
MALDI PSD-CID (B). 
 
The N-terminus of the Antarctic peptides was a 168 Da moiety which showed 
high ionisation efficiency by MALDI. Under MS
3
 conditions by ESI CID, a loss 
of water and carbon monoxide was evident, as well as a fragment at m/z 113. 
These pieces of evidence suggest that the 168 Da group contains at least one 
nitrogen atom in order to ionise readily by MALDI.
283
 The loss of water suggests 
that it contains an hydroxyl group
284
 and the loss of carbon monoxide, that it is 
linked to the next amino acid by the carbonyl of a peptide bond
285
 or that there is a 
hydroxyl group present on an aromatic ring.
286
 
 
Having determined the structure of the rest of each peptide, the accurate masses 
yielded from HRMS were used to generate potential molecular formulae for the 
remaining moiety. The already allocated molecular formula was set as the 
minimum value for the carbon, hydrogen, nitrogen and oxygen atoms, and a 
tolerance of ±5 ppm was utilised. Across the five different accurate masses, ten 
different molecular formulae were generated (Table 5.6). 
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Table 5.6: High resolution mass spectrometry analysis for the 
determination of the N-terminal moiety. 
# Potential Formula Calculated m/z Frequency Comments 
1 C9H14NO2 168.1025 5  
2 C7H12N4O 168.1011 3 Nitrogen Rule 
3 C6H16O5 168.0998 2 No Nitrogen 
4 C5H10N7 168.0998 2 No Oxygen 
5 C3H14N5O3 168.1097 2 Not Plausible 
6 C2H18NO7 168.1083 3 Not Plausible 
7 CH141N 168.1064 4 No Oxygen 
8 CH12N8O2 168.1083 3 Not Plausible 
9 CH121N 168.1064 1 No Oxygen 
10 H16N4O6 168.1070 5 Not Plausible 
 
 
Most of the potential formulae did not possess one of the structural attributes 
mentioned previously. Formulae 3, 4, 7 and 9 were ruled out as they did not 
contain an oxygen or a nitrogen (Table 5.6). Formulae 5, 6, 8 and 10 were also not 
plausible, as they contained too few carbon atoms. Formula 2 did not contain the 
correct valency to form the 168 Da substructure as it had four nitrogen atoms and 
twelve hydrogen atoms. This left only one viable molecular formula (Formula 1; 
C9H14NO2) for the N-terminus. 
 
The proportion of H:C/N/O in the resulting molecular formula indicated that the 
168 Da moiety contained three double bond equivalents. Assuming one of these 
was due to a carbonyl, the N-terminus could contain an alkyne, two alkenes, two 
rings or a combination of an alkene and a ring. Multiple structures can be 
designed using this formula, which could also account for the mass spectrometric 
observations (Figure 5.22). Therefore, the structure of the 168 Da N-terminal 
moiety in the Antarctic peptides remains undetermined. 
 
 
Figure 5.22: Potential structures for the N-terminal moiety of the Antarctic 
linear peptides. 2-carboxy-6-hydroxyoctahydroindole; Choi (A), 
3-amino-2-hydroxy-non-8-ynoic acid; Ahnya (B), tetrahydro-
tyrosine; (H4)Tyr (C). 
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High resolution MS of the Antarctic peptides yielded mass-to-charge ratios 
consistent with the singly protonated ions of the structures 187-190 and 192 and 
mass deviations of less than 4.5 ppm (Table 5.7). The accurate mass for peptide 
830B was not listed, as this minor component was not separated from the major 
component, peptide 830A, during the fractionation. 
 
Table 5.7: High resolution mass spectrometry analysis of the Antarctic 
linear peptides. 
Compound 
Measured 
m/z 
Molecular 
Formula 
Calculated 
m/z 
Error 
(ppm) 
Antarctic peptide 800 (187) 801.4082 C44H57N4O10 801.4069 − 1.54 
Antarctic peptide 816 (188) 817.4053 C44H57N4O11 817.4018 − 4.32 
Antarctic peptide 830A (189) 831.4183 C45H59N4O11 831.4175 − 0.95 
Antarctic peptide 814 (190) 815.4262 C45H59N4O10 815.4226 − 4.36 
Antarctic peptide 844 (192) 845.4359 C46H61N4O11 845.4331 − 3.32 
 
 
The putative structures of the Antarctic linear peptides (187-192) were assembled 
using a combination of MS/MS and HRMS. A strong fragment ion series 
indicated that each of the peptides contained a 168 Da N-terminus, Ile, two 
aromatic amino acids and an ester-linked Hpla. 
 
The position two amino acid was provisionally determined as Ile rather than Leu 
using high-energy MALDI-PSD/CID analysis. Further investigations using a 
LC-MS ion trap system and increasing collision energies could yield a more 
conclusive identification of this residue. The position three amino acid varied 
between MePhe, MeTyr and MeTyr(OMe). These assignments were made due to 
the retention time on reversed-phase C18. However, it was possible that these 
amino acids, and the position four MeTyr, could be the isometric homo-versions. 
The assignment of the N-methylated amino acids was made due to the structural 
similarities between these peptides and the microginins (see Section 1.2.5). In the 
microginins, N-methylated amino acids are frequently observed in positions three 
and four,
14
 whilst non-methylated versions are seen less frequently. In half of the 
peptides, the ester-linked Hpla C-terminus contained an O-methylation. This was 
assigned due to the different retention times observed on reversed-phase C18; 
however, it was not clear whether this was present on the C1 carboxylic acid or 
the C7 ring hydroxyl. 
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The structure of the N-terminus could not be assigned with the current data, but 
the analysis performed suggested that it possessed the molecular formula 
C9H14NO2. Due to the mass spectrometric characteristics it displayed, it was likely 
to contain a carbonyl, a hydroxyl and an amine. The H:C/N/O ratio indicated that 
it contained two additional unsaturations besides the carbonyl. As this could 
represent multiple structures, the moiety was left unassigned. 
 
 
5.3 DISCUSSION 
5.3.1 Discovery of Eight New Glycine-Containing Microcystins 
The identification of these new microcystins adds an additional eight congeners to 
the 111 microcystins already characterised (Appendix A). The eight different 
congeners all contain Gly in position one, D-Asp in position three, D-Glu in 
position six and what is highly likely to be Dhb in position seven. Variations of 
L-Leu/Arg, Arg/Har and Adda/ADMAdda in positions two, four and five, 
respectively, resulted in eight unique microcystin congeners (179-186). This work 
is the first report of glycine-containing microcystins and the first report of 
ADMAdda-containing microcystins from the Southern
 
Hemisphere.
279
 
 
Each of the new microcystins contained a D-Asp in position three, as has been 
frequently observed in multiple cyanobacterial genera including; Anabaena,
51
 
Microcystis,
34
 Nosotc,
55
 Oscillatoria
61
 and Plankothrix,
50
 as well as cyanobacteria 
from Antarctica.
278
 The position seven Dhb has been reported in nine other 
microcystins (Appendix A), three of which were ADMAdda-containing 
microcystins.
54
 However, the frequency of occurrence of Dhb-containing 
microcystins is potentially underestimated, as many microcystin congeners have 
been characterised solely by MS/MS. This does not allow for discrimination 
between the isometric Mdha and Dhb. The microscale thiol derivatisation
41,248
 
utilised in this work would be of great benefit to other researchers working with a 
small sample size, in order to easily confirm the presence of Mdha-containing 
microcystins. 
 
Substitution of Arg for Har is rare, with only four microcystin congeners 
containing this amino acid being characterised to date (Appendix A). Two further 
microcystins have been identified as containing Har, but a full structure was never 
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elucidated.
280
 Thirteen ADMAdda-containing microcystins have been reported 
(Appendix A), these were produced by Nostoc and Planktothrix species from 
across Europe. Although the cyanobacterial strain responsible for production of 
the new Antarctic microcystins was not isolated and cultured, molecular 
investigations identified the microcystin-producing cyanobacterium to be of the 
genus Nostoc.
279
 
 
The position one alanine in microcystins is highly conserved and although 
substitutions for Leu and serine have been reported,
68,72,111
 a substitution for Gly 
has not. Whilst the Gly substitution has not been observed, it is not an 
unreasonable proposition, as the adenylation domain responsible for incorporating 
the position one amino acid (McyA2; see Section 1.3.1) shows structural 
similarity to the saframycin synthetase Gly adenylation domain.
99,287
 
 
The small sample size available prevented purification of the Antarctic 
microcystins from proceeding beyond the separation of two mixtures containing 
the -LR and -RR congeners from the other components in the extract, therefore, 
no bioactivity screening was conducted. Other microcystins containing similar 
modifications to these new congeners have been shown to inhibit serine/threonine 
protein phosphatases 1 and 2A (Appendix A), so it is possible that these 
congeners would also exert the same effect. 
 
The Dry Valleys in Eastern Antarctica are a unique environment. The low 
temperatures are coupled with minimal precipitation, strong winds, high salinity, 
high ultraviolet light exposure during summer and extended periods of darkness 
during winter.
268,269
 These harsh conditions lead to simple ecosystems and 
predator-free environments for the cyanobacteria. There has been a lot of interest 
in the biological function of microcystins, with many researchers speculating that 
they may be produced as a defence mechanism against predators. The common 
occurrence of microcystins in this predator-free environment (as well as other 
investigations; see Section 1.3.3), suggest that microcystin production is not 
solely a predator-driven phenomenon. 
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5.3.2 Discovery of Six New Linear Peptides 
The discovery of six new linear peptides from the Antarctic hydroterrestrial mat 
samples was of significance, as the compounds do not identify directly with any 
class of known cyanobacterial oligopeptide. Each of the peptides contained a 
168 Da N-terminus, Ile, two aromatic amino acids and an ester-linked Hpla. 
Substitutions of the position three amino acid and methylation of the C-terminus 
resulted in six unique structures. 
 
The N-terminus of the Antarctic linear peptides did not match any previously 
observed N-terminal moieties from cyanobacterial oligopeptides. This 168 Da 
moiety could be the 2-carboxy-6-hydroxyoctahydroindole (Choi) observed in 
position three of the aeruginosins (see Section 1.2.1), although Choi has never 
been observed as the N-terminus of a peptide. Other possibilities for the moiety 
included 3-amino-2-hydroxy-non-8-ynoic acid, similar to the N-terminus of the 
microginins (see Section 1.2.5). Due to the small sample size available, the 
structure of the N-terminus could not be determined without more material or 
more sensitive characterisation techniques. 
 
An ester-linked Hpla has never been observed in aquatic cyanobacterial 
oligopeptides. Conceivably, this could be mediated by an ester-forming ligase 
acting upon the carboxylic acid of the position four amino acid and the 2-hydroxyl 
of Hpla (Figure 5.23). Supporting this theory is the presence of ester-linkages 
between amino acids in the cyanopeptolins and microviridins (see Section 1.2). 
The genes encoding the enzymes responsible for these reactions have been 
 
 
Figure 5.23: Potential pathway for the biosynthesis of the ester-linked 
hydroxyphenyllactic acid C-terminus. 
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identified for both oligopeptides.
29,30,288
 No investigations of the peptide 
synthetases and polyketide synthases responsible for the production of the 
Antarctic peptides were made. 
 
 
5.4 CONCLUSIONS 
A cyanobacterial mat sample from Miers Valley in Antarctica was investigated 
for the presence of new oligopeptides. The structures of eight new microcystins 
(179-186) containing a position one Gly were determined using a combination of 
amino acid analysis, chemical derivatisation and MS/MS. Amino acid analysis 
and a β-mercaptoethanol derivatisation indicated that the position seven amino 
acid was not the Mdha commonly observed in microcystins, but was highly likely 
to be Dhb. Tandem MS analysis indicated the presence of Har and ADMAdda 
residues. The combination of these two uncommon modifications, with the rare 
substitution of the position one amino acid is a significant observation. The 
addition of eight new microcystin congeners is also a significant increase to the 
111 structures presently characterised. 
 
Six new linear peptides (187-192) were also present in the Antarctic sample, 
which did not match any of the presently characterised cyanobacterial 
oligopeptides. The putative structures for the peptides were determined using a 
combination of MS/MS and HRMS. Each peptide contained a unique ester-linked 
Hpla C-terminus, two aromatic amino acids, Ile and an N-terminus with the 
molecular formula C9H14NO2. Although the structures could not be fully 
determined using the present sample, the information gathered points towards a 
novel class of cyanobacterial oligopeptides. 
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CHAPTER 6 
 
Enhanced Sample Preparation for Quantitation of Microcystins 
by Matrix-Assisted Laser Desorption/Ionisation-Time of Flight 
Mass Spectrometry 
 
 
6.1 INTRODUCTION 
On account of the health risk posed by microcystins (MCs), the World Health 
Organisation has recommended a ‘safe level’ for drinking waters of 1 µg/L of 
MC-LR.
152
 Microcystin concentrations in environmental water samples are 
generally analysed by enzyme-linked immunosorbent assay (ELISA), protein 
phosphatase inhibition assay (PPIA) or high performance liquid chromatography 
(HPLC).
153
  
 
ELISA and PPIA provide no information on the different microcystin congeners 
present in a sample, but the PPIA method gives an indication of the toxicity of the 
sample according to the strength of protein phosphatase inhibition observed.
157
 
HPLC coupled to a photo-diode array detector gives limited information on the 
congeners present, based upon their retention time on a C18 column and the 
ultraviolet spectrum of the eluting congener.
167
 Liquid chromatography in 
combination with mass spectrometry (LC-MS) is the most robust of current 
methods used for microcystin analysis as it gives definitive information on the 
congeners present according to their retention time on a C18 column and their 
mass-to-charge ratio (m/z).
166
 The major disadvantage with these methods of 
quantifying microcystins is the long duration of both sample handling and 
analytical procedures. Recent advances in small particle and monolithic silica 
columns have decreased run times significantly from those achieved using 
conventional HPLC.
173,174
 However, run times are still greater than the time it 
takes to obtain a matrix-assisted laser desorption/ionisation-time of flight 
(MALDI-TOF) spectrum (< 30 s). 
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As discussed in Section 1.4, MALDI MS gives comparable information to LC-MS, 
but analysis times are much shorter. MALDI MS is also well suited to automated 
high-throughput sample preparation and data acquisition,
177
 making it an ideal 
technology for analysing large numbers of microcystin-containing samples 
quickly. The technique has frequently been used for qualitative detection of 
microcystins in cyanobacterial samples,
44,176,178-182
 but has only recently been used 
as a quantitative tool.
184
 During quantitative MALDI analyses, an internal 
standard is commonly added to sample and standard solutions to improve the 
‘spot-to-spot’ and ‘shot-to-shot’ reproducibility.188-192 
 
Howard and Boyer found that of four internal standards tested for microcystin 
quantitation, nodularin gave the best results.
184
 Nodularin is a cyclic pentapeptide 
very similar to microcystins, but with a mass lower than any known microcystin. 
It is commercially available, but relatively expensive (> NZ$2,500/mg). Howard 
and Boyer’s work used a simple MALDI sample preparation technique which 
involved sonication of a mixture of microcystin and internal standard with matrix 
solution, followed by deposition onto a polished steel target. This technique 
provided good spot-to-spot reproducibility and sensitivity, but it is not well suited 
for automated sample preparation or for use in an instrument automatically 
acquiring data. 
 
Many manufacturers of MALDI mass spectrometers also produce targets 
modified with hydrophilic/hydrophobic regions to hold sample/matrix solutions in 
a certain location on the target whilst the solution dries. These targets generally 
yield a matrix/sample spot which is uniformly distributed at a designated 
location,
289
 an essential prerequisite for automated acquisitions. Such targets are 
also particularly useful for producing thin-layer preparations, where a layer of 
matrix crystals is formed on the target followed by sample deposition on top. This 
technique is amenable to automated sample preparation and generally gives better 
signal homogeneity than a dried droplet preparation.
290,291
 
 
In order for quantitative MALDI MS to reach its full potential as a 
high-throughput technique for microcystin analysis, different protocols are 
required to allow automated sample preparation and data acquisition. In the 
current study, angiotensin I was utilised as an internal standard in preference to 
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nodularin since it was a more cost effective option for analysis of large numbers 
of samples (ca. NZ$50/mg). The objective of this study was to establish a protocol 
compatible with automated sample preparation and data acquisition, whilst 
maintaining reproducibility and sensitivity. The performance of different MALDI 
sample preparation techniques was tested using a traditional polished steel target 
and a target modified with hydrophilic centres (Bruker Anchorchip).  
 
 
6.2 RESULTS 
6.2.1 Comparison of MALDI Sample Preparations 
Seven different MALDI sample preparations were tested for reproducibility and 
sensitivity. The sonicated dried droplet method was based on Howard and Boyer’s 
research.
184
 Traditionally, this sample preparation may have been performed by 
mixing the two solutions directly on the target with an auto-pipette (a dried 
droplet preparation). Three thin-layer preparations were also assessed. These were 
prepared on a Bruker anchorchip, on a polished steel target where the matrix was 
laid in a line, and also in a spot. Refer to Section 9.6.1 for more detail on on each 
of these sample preparations. 
 
Visually, the sonicated dried droplet and dried droplet preparations were very 
similar (Figure 6.1A-D). Those prepared on a polished steel target beaded during 
crystallisation, resulting in areas rich in matrix/sample and areas within the 
sample spot where no sample was present (Figure 6.1A & C). This irregular 
distribution makes these preparations unreliable for automated data acquisition on 
a mass spectrometer, due to the non-uniform distribution of matrix/sample on the 
target. The sonicated dried droplet and dried droplet preparations on an 
anchorchip showed a more uniform distribution of matrix/sample, as the droplet 
was held in place by the hydrophilic spot as it dried (Figure 6.1B & D). This 
would mean that matrix/sample would be present anywhere within this sample 
spot if automated data acquisition were undertaken. 
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Figure 6.1: Digital images of the sample preparations used in this study. 
Images acquired using the charged-coupled device camera 
installed in the mass spectrometer. 
 
The thin-layer preparation performed on an anchorchip was much smaller than the 
other preparations, as the matrix was restricted to the hydrophilic spot on the 
anchorchip (ca. 600 µm diameter; Figure 6.1E). The thin-layer-line preparation 
had small crystals of matrix on the surface of the polished steel target and a lighter 
circle where the sample had been laid and the matrix recrystallised (Figure 6.1F). 
The line through the centre was where the auto-pipette tip was dragged down the 
length of the target during preparation of the thin layer of matrix. The thin-layer-
  Chapter 6 
147 
 
spot preparation looked similar to the thin-layer-line preparation, in that it had 
small crystals of matrix on the surface of the target and a lighter circle where the 
sample was laid, but it lacked the line down the centre (Figure 6.1G). This was 
because each spot was formed individually from a drop of matrix dissolved in 
acetone, making the technique suitable for automated sample preparation. 
 
An assessment of the spot-to-spot reproducibility for each of the seven 
preparations was performed using the peak height ratio (PHR) of 
2.5 µM [Dha
7
] MC-LR/50 µM angiotensin I. The coefficients of variation (CVs) 
reported in Table 6.1 are the average of three separate analyses performed using 
fresh preparations on different days. High levels of reproducibility were not 
achieved using both the sonicated dried droplet and dried droplet preparations on 
either the polished steel or anchorchip targets, giving CVs of around 20%. During 
the analysis of the thin-layer preparation on an anchorchip, it was noted that both 
microcystin and angiotensin I signals were low in the centre of the sample spot 
and increased in intensity towards the outside edge. This preparation yielded a CV 
of 22.5%.  The two thin-layer preparations performed on a polished steel target 
gave good signal reproducibility, returning CVs of 11.9% for the line preparation 
and 9.5% for the spot preparation. The thicker line of matrix in the thin-layer-line 
preparation (Figure 6.1F) did not affect the signal compared with the rest of the 
sample spot. 
 
Table 6.1: Performance of seven MALDI sample preparations. 
Sample Preparation CV 
a 
(%) 
MDL 
b
 
(µM) 
Sonicated dried droplet: Polished Steel 18.7 0.100 
Sonicated dried droplet: Anchorchip 18.8 0.088 
Dried droplet: Polished Steel 18.1 0.086 
Dried droplet: Anchorchip 24.8 0.228 
Thin-layer: Anchorchip 22.5 0.073 
Thin-layer-line: Polished Steel 11.9 0.077 
Thin-layer-spot: Polished Steel 9.5 0.087 
Values are the average of triplicate analyses conducted over three days using fresh sample 
preparations. a CV = Coefficients of variation; determined using 2.5 µM [Dha7] MC-LR. 
b MDL = Method detection limit for [Dha7] MC-LR; as per Section 9.6.3. 
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The method detection limit (MDL) was used to assess the sensitivity of each 
preparation (Table 6.1; Refer to Section 9.6.3 for more details on how the MDL 
was determined). The sonicated dried droplet preparations had detection limits of 
0.1 µM [Dha
7
] MC-LR on polished steel and 0.088 µM on the anchorchip. The 
dried droplet preparation performed on polished steel displayed a similar 
sensitivity, with a detection limit of 0.086 µM, but only 0.228 µM when using the 
anchorchip. The thin-layer preparation performed on the anchorchip had a 
detection limit of 0.073 µM, but required a higher laser power than the other 
preparations, to ionise the microcystin/angiotensin I. The thin-layer preparations 
on polished steel performed well, with detection limits of 0.077 µM for the line 
preparation and 0.087 µM for the spot preparation. 
 
The performance of the thin-layer-spot preparation was also assessed using two 
other microcystin congeners; MC-RR and MC-YR. Both MC-RR and MC-YR 
yielded good CVs on the thin-layer-spot preparation (6.2% and 6.8%, respectively; 
Table 6.2). The MDLs were 0.031 µM for MC-RR and 0.056 µM for MC-YR. 
Both the reproducibility and sensitivity for these two congeners were better than 
that observed with [Dha
7
] MC-LR (CV 9.5%, MDL 0.087 µM).  
 
Table 6.2: Quantitative performance of the thin-layer-spot preparation 
performed on polished steel using three microcystin congeners. 
Microcystin 
CV 
a
 
(%) 
MDL 
b
 
(µM) 
Range 
c
 
(µM) 
Regression Equation R
2
 
[Dha
7
] MC-LR 9.5 0.087 0.279-10 y = 0.1288x + 0.0153 0.99 
MC-RR 6.2 0.031 0.116-10 y = 0.0752x + 0.0034 0.99 
MC-YR 6.8 0.056 0.180-10 y = 0.1705x + 0.0645 0.98 
a CV = Coefficients of variation; determined using 2.5 µM microcystin. b MDL = Method detection 
limit for each microcystin. c Quantitative ranges begin at the limit of quantitation. 
 
The quantitative performance of these three microcystin congeners was also tested 
using the thin-layer-spot preparation. Standard curves for each of the individual 
microcystins were constructed using microcystin concentrations in the range of 
0.1-10 µM. Each microcystin congener showed good linearity over this range, 
with R
2
 values between 0.98 and 0.99 (Table 6.2).  
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6.2.2 Laser Power Attenuation for Quantitative Analyses 
Assessment of the microcystin concentration, relative to that of the angiotensin I 
added to the sample, not only improves reproducibility
188-192
 but also allows the 
laser power to be attenuated to some degree. Use of an internal standard gave a 
limited range of laser powers where the PHR remained consistent (Figure 6.2). In 
this instance, the acceptable laser power fell in the range of 20 to 24%, 
corresponding to an intensity/shot ratio between 25 and 150 angiotensin I 
intensity/shot. At lower laser powers, the angiotensin I was ionised whilst the 
microcystin was not, resulting in a lower PHR. At laser powers higher than the 
optimal level, the angiotensin I signal saturated the detector whilst the microcystin 
signal continued to increase, resulting in a higher PHR. 
 
 
Figure 6.2: The effect of MALDI mass spectrometer laser power on the peak 
height ratio. 
 
 
6.3 DISCUSSION 
6.3.1 Enhanced Sample Preparation for Quantitative MALDI-TOF Mass 
Spectrometry Analysis of Microcystins 
Seven different MALDI sample preparation protocols were assessed for their 
effectiveness to quantify microcystins. The desired attributes were reproducibility 
(assessed using the CV) and sensitivity (assessed using the MDL) whilst using a 
cost-effective internal standard (angiotensin I), as well as compatibility with 
automated sample preparation and data acquisition systems. 
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The reproducibility achieved using the sonicated dried droplet preparations was 
higher than that reported previously using the same concentration of microcystin 
(CV 8%).
184
 In that instance, nodularin was used as the internal standard instead 
of the less expensive alternative used in this study (angiotensin I). Whilst the 
reproducibility could not be matched using the same sample preparation, the 
thin-layer preparations performed on polished steel did achieve CVs close to those 
reported using nodularin. The low reproducibility achieved using the thin-layer 
preparation on the anchorchip target was surprising, but could be due to the 
hydrophobic/hydrophilic regions present on the target. It was observed that both 
microcystin and angiotensin I signals were low in the centre of the sample spot 
and increased in intensity towards the outer edge. This would suggest a higher 
concentration of these slightly hydrophobic peptides at the edge of the sample 
spot, as they were repelled from the hydrophilic spot and attracted to the 
hydrophobic surface of the target. 
 
Excluding the dried droplet preparation performed on the anchorchip, the 
detection limits achieved were all lower than those reported elsewhere using 
angiotensin I as an internal standard.
184
 This was most likely due to the modern 
mass spectrometer used in the current study, since the enhanced sensitivity was 
observed across most of the preparations tested, including the sonicated dried 
droplet preparation used in the aforementioned study.
184
 The detection limits 
observed were not as low as those achieved by Howard and Boyer using nodularin 
as an internal standard (MDL of 0.015 µM). In studies where maximum 
sensitivity is desired and cost per sample is not restrictive, consideration should be 
given to using nodularin as an internal standard over the less expensive 
angiotensin I. The poor sensitivity achieved with the dried droplet preparation on 
the anchorchip was due to a lower PHR ratio than the other preparations, possibly 
resulting from deeper embedding of the microcystin in the matrix causing a lower 
microcystin signal within the 25-shot cycle. 
 
Each of the MALDI sample preparations used in this study, except the dried 
droplet preparation on an anchorchip, achieved reasonable sensitivities (MDLs of 
0.073-0.1 µM). However, most of the preparations did not show good 
reproducibility (CVs of 18.1-24.8%), except for the two thin-layer preparations 
performed on a traditional polished steel target (CVs of 11.9% and 9.5%). The 
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thin-layer-spot preparation was the only sample preparation which possessed all 
of the desired attributes of reproducibility (low CV), sensitivity (low MDL) and 
compatibility with automated high-throughput systems. Whilst not compatible 
with automated sample preparation, the thin-layer-line preparation yielded 
reproducibility and sensitivity rivalling the thin-layer-spot preparation, and it was 
less cumbersome to prepare manually. This sample preparation technique could 
be adopted when automated target-laying systems are not available. 
 
The quantitative performance achieved using the thin-layer-spot preparation was 
equal to that observed previously,
184
 with each microcystin congener showing R
2
 
values of at least 0.98. The present study also demonstrated that the linear range 
of quantitation can be extended up to 10 µM; the previous study had a linear range 
up to 5 µM.
184
 As noted by Howard and Boyer, the MALDI ionisation efficiency 
of different microcystin congeners varied,
184
 and hence, the regression equations 
observed in this study have different gradients. This demonstrates the necessity to 
construct a standard curve for each microcystin congener present in a sample, as 
opposed to using an MC-LR equivalent as is commonly used with other 
microcystin quantitation techniques. Howard and Boyer also recommended that a 
fresh standard curve be run with each set of samples analysed, as the slopes can 
vary from day to day.
184
 
 
On account of the potential for quantitative MALDI analysis to be used in studies 
with large sample numbers, a cost effective internal standard (angiotensin I) was 
utilised to provide a low cost per sample. We have shown that with modern 
instrumentation and different sample preparation techniques, reproducibility and 
sensitivity could be improved whilst using angiotensin I. Whilst the MDL for 
[Dha
7
] MC-LR could not be reduced to the levels obtained with the internal 
standard nodularin, those of MC-RR and MC-YR were very close to, or better 
than, those previously observed with the more expensive internal standard.
184
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6.3.2 Laser Power Attenuation during Quantitative MALDI-TOF Mass 
Spectrometry Analyses 
When operating without an internal standard, modulation of the laser power alters 
the analyte signal intensity, and hence affects the measurement of microcystin 
concentration. This would necessitate the use of a single laser power for an entire 
sample set or some sort of compensatory adjustment. Assessment of a 
microcystin/angiotensin I mixture over a range of laser powers indicated that there 
was a region where the PHR was consistent. The plateau in PHR means that the 
laser power can be attenuated to some degree when a sample gives a higher or 
lower response than the other samples present. Caution must be taken, however, 
to ensure the intensity/shot ratio stays within acceptable levels. 
 
6.3.3 Application of Quantitative MALDI-TOF Mass Spectrometry 
Analysis of Microcystins 
Although the detection limits achieved in the present study were within the range 
expected for quantitative MALDI analyses (ca. 100 nM), they were not near those 
required to detect microcystins directly from water samples used for regulatory 
requirements (1 nM; World Health Organisation advisory level).
152
 To achieve 
this level of sensitivity would necessitate concentrating the sample, a lengthy 
additional step in the sample handling protocol, which would negate the 
advantage of the rapid sample handling procedure possible with MALDI MS. 
Therefore, using this technique on water samples, while possible, would be 
cumbersome. 
 
However, if whole cells were being investigated, the concentration of the 
extracted microcystin could be controlled to some degree by reducing the 
extraction volume. This would allow analysis on, for example, surface 
cyanobacterial scum or benthic mat samples to determine the microcystin content 
present in the cyanobacterial biomass. A particularly promising application of 
quantitative MALDI MS is the quantification of the intracellular microcystin 
content of samples taken during culture experiments. Such samples are 
particularly amenable to analysis by this technique as there are usually large 
numbers of them and the microcystin congeners produced by the cyanobacterial 
species would likely be known. Thus the correct microcystin calibration standards 
could be on hand and the sample preparation could remain quick and simple. 
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6.4 CONCLUSIONS 
Most of the sample preparations tested during this study showed reasonable 
sensitivity, but poor reproducibility, apart from the two thin-layer preparations 
performed on polished steel. Both of these thin-layer preparations achieved low 
MDLs, low CVs, and the thin-layer-spot protocol was also compatible with 
high-throughput automated sample preparation. Assessment of the thin-layer-spot 
preparation using two other microcystin congeners also showed good sensitivity 
and reproducibility. Assessment of the quantitative performance yielded R
2
 values 
of at least 0.98 and a linear range which extended up to 10 µM. Furthermore, 
these results were achieved using a less expensive internal standard than was 
utilised in the previous work.
184
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CHAPTER 7 
 
A Preliminary Investigation into the Modulation of 
Microcystin Congener Abundance in 
Response to Nitrogen Supply 
 
 
7.1 INTRODUCTION 
Over the past 30 years, many studies have been conducted investigating the 
influence of environmental parameters on microcystin production 
(see Section 1.3.3).
292
 Most of these studies have focussed on the net production 
of microcystins and not on the levels of individual congeners. However, several 
studies have reported modulation of microcystin congener abundance under 
different environmental conditions. These studies examined responses to light 
intensity,
148,151
 temperature,
135,149
 growth phase
146
 and amino acid availability.
150
 
Previous investigations into the effect of nitrogen concentration on the abundance 
of microcystin congeners have observed no modulation over the time-course of 
the experiments.
146,150,151
 It was suggested that the lack of response could be due 
to the presence of phycocyanin pigments, which are utilised in times of nitrogen 
shortage, resulting in internal nitrogen stores not being fully depleted during the 
experimental period. 
 
Microcystins are produced by a hybrid polyketide synthase (PKS)/non-ribosomal 
peptide synthetase (NRPS) called microcystin synthase (see Section 1.3.1).
99-101
 
The occurrence of different microcystin congeners is due to differences in the 
coding of the microcystin synthase genes of different cyanobacterial strains which 
can affect the substrate specificity of the adenylation domains responsible for 
incorporating amino acids into the structure (see Section 1.3.2).
110
 When one of 
the adenylation domains has relaxed substrate specificity, a single strain of 
cyanobacteria can produce more than one microcystin congener.
110
 
 
A cyanobacterial strain will generally produce around four microcystin congeners, 
in most cases; MC-LR, MC-RR and desmethyl analogues of each congener 
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(Appendix C). Microcystis CYN06, which was isolated from Lake Hakanoa 
(Huntly, New Zealand),
246
, produces at least 27 microcystin congeners, however, 
this cyanobacterial strain could potentially produce 40 different congeners 
(see Section 3.3.1). In CYN06 this is due to relaxed substrate specificity at 
McyB1, McyB2 and McyC. As a result, five amino acids are incorporated at 
position two, four amino acids are incorporated at position four, and position three 
desmethyl analogues are also observed (see Section 3.2.1). Whilst cyanobacterial 
strains which produce at least 47 microcystin congeners have been reported,
245
 
CYN06 is unique as it has been shown to display relaxed substrate specificity at 
position four as well as at position two (see Section 3.3.1). As a result, CYN06 
produces microcystin congeners which contain no arginine residues (MC-XAs 
and MC-XLs), a single arginine residue (MC-XRs and MC-RZs) and two arginine 
residues (MC-RRs). 
 
As discussed in Section 1.3.2, structural variation of the microcystins can have a 
marked effect on the potency of the toxin. The most common microcystin; 
MC-LR, has a toxicity of 50 µg/kg,
115
 whilst another common congener; MC-RR, 
is an order of magnitude less toxic (500-600 µg/kg).
120
 Therefore, a change in 
microcystin congener levels in a cyanobacterial strain which produces multiple 
variants may lead to an increase or decrease in toxicity. The differing toxicities of 
microcystin congeners make it essential to acquire more knowledge about the 
environmental variables which regulate microcystin congener abundance. 
 
Previous investigations into the effect of nitrogen concentration on microcystin 
congener abundance have utilised cyanobacterial strains which only produced 
arginine-containing microcystin congeners.
146,150,151
 Use of a strain which also 
produces microcystins containing no arginine residues might allow new insights 
into the regulation of arginine incorporation in microcystins. In this study, the 
effect of nitrogen concentration on microcystin congener abundance was 
investigated by monitoring a batch culture of Microcystis CYN06 for 40 days 
until cells were nitrogen deplete. It is hypothesised that as the cells become 
starved of nitrogen, the abundance of the arginine-containing microcystins will 
decrease. 
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7.2 RESULTS 
Six batch cultures of Microcystis CYN06 were grown in 1 L Schott bottles for 
40 days (see Section 9.7.1 for more information). After this time, the cultures had 
changed colour from green to yellow (Figure 7.1), suggesting that the nitrogen 
stored in the phycocyanin pigments had been drawn upon.
293,294
 
 
 
Figure 7.1:  Images from a batch culture of Microcystis CYN06. Images 
recorded in a 1 L Schott bottle on day 8 (A), 15 (B), 22 (C), 
29 (D), 36 (E) and 40 (F). 
 
During the time course of the experiment, each batch culture was sampled once a 
week for dissolved nutrient concentrations, cell concentrations and microcystin 
content. Cell density of Microcystis CYN06 increased steadily to 
3.9×10
6
 cells/mL over 40 days (Figure 7.2A). Concentrations of nitrate in the 
media decreased from 1.8 mM to below the detection limit of the flow injection 
analysis (FIA) method used (< 0.005 mM). The concentration of dissolved 
reactive phosphorus remained relatively constant and never decreased below 
0.03 mM. Ammonium and nitrite were not detectable throughout the course of the 
experiment (≤ 0.005 mM). The total microcystin content increased from 2.5 to 
4.2 femtomoles/cell on day 8 and then decreased steadily to 0.6 femtomoles/cell 
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by day 40 (Figure 7.2B). The microcystin content for each congener followed the 
same general pattern (Figure 7.2C). 
 
 
Figure 7.2: The effect of nitrogen depletion on microcystin content during a 
40-day batch culture of Microcystis CYN06. Graphs depicting the 
cells, nitrate and dissolved reactive phosphorus concentrations (A), 
total microcystin concentration (B) and microcystin concentration 
of eleven individual congeners (C). 
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Linear regression of the relationship between log10 microcystin content and 
duration of incubation (days 8-36) revealed a strong correlation for each 
microcystin congener (R
2
 ≥ 0.87; Table 7.1), but with different slopes. The 
reduction in microcystin content of the congener containing two arginine residues 
(MC-RR) was more rapid than that of the congeners containing a single arginine 
residue (MC-XRs and MC-RZs), which in turn was more rapid than the congeners 
containing no arginine residues (MC-XAs and MC-XLs). In each case, the slope 
of decay for the tryptophan-containing congeners was less steep than the leucine- 
and phenylalanine-containing congeners (Table 7.1).  
 
Table 7.1: Linear regression of log10 microcystin content verses incubation 
time for days 8-36. 
Microcystin Regression Equation R
2
 
Average 
Gradient
 a
 
MC-RRs MC-RR y = −0.048x + 2.47 0.99 −0.048 (A) 
MC-XRs 
MC-LR y = −0.038x + 3.10 0.95 
−0.036 (B) MC-FR y = −0.037x + 2.95 0.96 
MC-WR y = −0.032x + 2.96 0.93 
MC-RZs 
MC-RA y = −0.032x + 2.26 0.97 
−0.033 (B) 
MC-RAba y = −0.034x + 1.62 0.96 
MC-XAs 
MC-LA y = −0.036x + 3.06 0.96 
−0.030 (B,C) MC-FA y = −0.029x + 2.91 0.97 
MC-WA y = −0.026x + 2.96 0.92 
MC-XLs 
MC-FL y = −0.029x + 1.41 0.94 
−0.026 (C) 
MC-WL y = −0.023x + 1.39 0.87 
a The letters in brackets indicate three groups that the gradients of the grouped congeners were 
divided into by a Student’s t-test (p < 0.05). 
 
The congener gradients were separated into three groups using a Student’s t-test 
(see Section 9.7.5 for more information). The gradient for MC-RR was 
significantly steeper than those of the other congeners (p ≤ 0.001). The gradients 
of the -XR, -RZ and -XA congeners were not significantly different from each 
other (p > 0.1). The third group encompassed the gradients of the -XA and -XL 
congeners, as they were not significantly different from each other (p > 0.05). 
However, the gradients of the lines representing the -XL congeners were 
significantly different from those of the -XR and -RZ congeners (p ≤ 0.05). 
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The result of these differing rates of decay was a change in the relative abundance 
of the microcystin congeners produced by Microcystis CYN06. As the 
microcystin content of the arginine-containing congeners decreased more quickly, 
the relative abundance of these microcystins decreased with time (Figure 7.3). As 
the microcystin content of the congeners containing no arginine residues 
decreased less quickly, the relative abundance of these congeners increased. This 
trend coincided with a decrease in the concentration of nitrate (Figure 7.2A). 
Graphs of the relative abundance for each individual microcystin congener are 
presented in Appendix K.1. 
 
 
Figure 7.3: Microcystin congener abundance during a 40-day batch culture of 
Microcystis CYN06. Graphs depicting the grouped relative 
abundance of the -XR and -XA microcystin congeners (A) and 
the grouped relative abundance of the -RR, -RZ and -XL 
microcystin congeners (B). Error bars indicate ±1 standard 
deviation; n = 6. 
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Over the 40-day incubation period, the abundance of MC-RR steadily decreased 
to less than one half of its initial value (from 3.6% to 1.5%; Figure 7.3B). 
Likewise, the -XR congeners (MC-LR, MC-FR and MC-WR) decreased in 
abundance from 51% to 41% (Figure 7.3A). In contrast, the -XA congeners 
(MC-LA, MC-FA and MC-WA) increased in abundance from 40% to 52%. 
The -XL congeners (MC-FL and MC-WL) showed a very slight increase in 
abundance from 1% to 1.4% (Figure 7.3B). The -RZ congeners (MC-RA and 
MC-RAba) did not change significantly (p > 0.05) during the 40-day incubation 
period. 
 
Apart from the -RZ congeners, a statistically significant change in relative 
abundance was observed for each of the groups of microcystins between day 1 
and day 36 (Figure 7.4). The -XA and -XR congeners displayed a significant 
change in abundance within 7 days (Day 8; p ≤ 0.05). A significant decrease in 
MC-RR abundance was evident by day 22 (p ≤ 0.01), whilst the -XL congeners 
did not show a significant increase in abundance until day 29 (p > 0.05). 
Correlation matrices for each group of congeners are presented in Appendix K.2. 
 
Day 1 8 15 22 29 36 
1  * * ** ** ** ** ** *** ** ** * *** *** *** *** 
8 * *   * ** * * ** *** *** *** *** 
15 ** **   * * * ** * ** ** *** 
22 ** ** ** * *  ** ** ** ** *** 
29 *** *** ** * *** *** * ** * * ** ** **   
36 *** *** *** *** *** *** *** *** * ** ** *** ** ** ***   
Figure 7.4: Correlation matrix indicating the statistically significant 
differences in the relative abundance of the grouped microcystin 
congeners. No shading indicates that there was no significant 
difference in microcystin abundance between those two sampling 
points (p > 0.05). Coloured shading indicates that a significant 
difference in microcystin abundance was observed between those 
two sampling points. The colour of the shading indicates the 
microcystin congeners where the significant difference was 
observed; Green = MC-RR, Red = MC-XRs, Blue = MC-XAs 
and Orange = MC-XLs. No significant differences were observed 
for the MC-RZs (p > 0.05). The level of significance observed is 
indicated by the number of asterisks; * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001. 
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Scatter-plots for log10 microcystin content against nitrate concentration (days 8-36; 
Figure 7.5A) revealed a linear relationship between the two parameters. However, 
for the low nitrate concentrations there was spread in the microcystin content 
which lowered the observed correlation coefficients. When log10 microcystin 
content of the time-points with nitrate concentrations less than 
 
 
Figure 7.5: Scatter-plots depicting the relationship between log10 microcystin 
content and nitrate concentration (A). The dashed circles in (A) 
indicate the time-points with low nitrate concentrations and these 
values were plotted against incubation time (B). 
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0.005 mM was plotted against the incubation time, modulation of the microcystin 
content of the cells was still observed (Figure 7.5B). These changes may have 
been due to the utilisation of internal cell quotas of nitrogen, as nitrate 
concentrations in the media were negligible by this time. An attempt at modelling 
the internal nitrogen content was made, but due to a lack of data for the total 
nitrogen content, this has thus far proven unsuccessful. Scatter-plots for each 
individual congener can be found in Appendix K.3 and K.4. 
 
Comparison of the gradients produced from linear regression of the relationship 
between log10 microcystin content and nitrate concentration revealed different 
slopes related to the number of arginine residues present in the microcystin 
(Table 7.2). The gradient for the nitrate dependence of MC-RR was steeper than 
that of the congeners containing a single arginine residue (MC-XRs and MC-RZs), 
which had a steeper gradient than the -XA and -XL congeners. Again, the slopes 
for the tryptophan-containing microcystin congeners were less than those of the 
leucine- and phenylalanine-containing counterparts.  
 
Table 7.2: Linear regression of log10 microcystin content verses nitrate 
concentration for days 8-36. 
Microcystin Regression Equation R
2
 
Average 
Gradient
 a
 
MC-RRs MC-RR y = 0.610x + 1.00 0.82 0.610 (A) 
MC-XRs 
MC-LR y = 0.455x + 2.05 0.66 
0.433 (B) MC-FR y = 0.436x + 2.02 0.64 
MC-WR y = 0.407x + 2.02 0.70 
MC-RZs 
MC-RA y = 0.398x + 1.32 0.62 
0.415 (B) 
MC-RAba y = 0.431x + 0.61 0.72 
MC-XAs 
MC-LA y = 0.434x + 2.00 0.59 
0.370 (B,C) MC-FA y = 0.350x + 2.05 0.56 
MC-WA y = 0.326x + 2.21 0.58 
MC-XLs 
MC-FL y = 0.355x + 0.57 0.59 
0.325 (C) 
MC-WL y = 0.295x + 0.73 0.55 
a The letters in brackets indicate three groups that the gradients of the grouped congeners were 
divided into by a Student’s t-test (p < 0.05). 
 
Student’s t-test was used to divide the congener gradients for nitrate dependence 
into three significantly different groups. The slope from MC-RR was again 
significantly higher than those of the other congeners (p ≤ 0.001). The second 
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group consisted of the gradients from the -XR, -RZ and -XA congeners, which 
were not significantly different from each other (p > 0.05). The final group 
encompassed the gradients of the -XA and -XL congeners, as they were not 
significantly different from each other (p > 0.05). However, the gradients of 
the -XL congeners were significantly different from those of the -XR and -RZ 
congeners (p ≤ 0.05).  
 
Following the 40-day incubation of six replicate CYN06 batch cultures where 
nitrate was progressively depleted, triplicate cultures were supplemented with 
1.5 mM nitrate and 0.1 mM phosphate, then monitored for a further 16 days. 
Triplicate control cultures received 0.1 mM phosphate but did not receive any 
nitrate. Two days post-supplementation, the cultures which had received 1.5 mM 
nitrate had regained their green colour whereas the cultures which did not receive 
nitrate remained a yellow colour. However, there was a large degree of variability 
between the individual cultures during this portion of the experiment and as a 
result, no significant changes in congener abundance were observed. The 
variability in congener abundance may have been related to differences in the 
level of nitrogen depletion between the replicates, which caused the individual 
cultures to react to the supplementary nitrogen at different rates. 
 
 
7.3 DISCUSSION 
Previous research has shown that microcystin production is regulated in response 
to environmental factors that influence cell growth.
129,144,292
 Factors which yield 
increased cell growth, such as increased nutrient concentrations, result in 
increased microcystin concentrations. During the present experiment the total 
microcystin content of Microcystis CYN06 increased within the first seven days, 
before steadily decreasing. This response coincided with changes in the nitrate 
concentration of the medium, which was in accordance with previous research 
investigating microcystin production in relation to nitrogen supply.
134,136
  
 
Microcystins are synthesised by a hybrid PKS/NRPS which incorporates amino 
acids into a cyclic peptide (see Section 1.3.1).
99-101
 The amino acid arginine is 
nitrogen-rich compared to other amino acids; arginine contains four nitrogen 
atoms, tryptophan contains two nitrogen atoms, whilst phenylalanine, leucine, 
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alanine and 2-aminobutanoic acid contain only one nitrogen atom. During this 
experiment, the abundance of arginine-containing microcystins decreased as 
nitrate was depleted. This response might be expected as nitrogen-rich amino 
acids would be less abundant when cells become starved for nitrogen. 
 
Linear regression of log10 microcystin content and nitrate (Table 7.2) revealed 
slopes which differed based on the number of arginine residues present in the 
microcystin. However, the correlation coefficients were reduced by a spread in 
microcystin contents at low nitrate concentrations. This bias was most likely due 
to the cells utilising internal nitrogen stores,
295
 as cell replication still occurred 
despite no nitrate being detected in the filtered media, and the microcystin content 
continued to decrease in the pattern observed over the previous fourteen days. 
 
The abundance of the microcystin congeners which contained a single arginine 
residue at position two (MC-RZs) did not change significantly throughout the 
nitrogen depletion period. During this same period, the abundance of MC-RR and 
the -XR congeners did show a significant decrease in abundance. As these 
congeners both contain a position four arginine, this observation suggests that 
there could be an element of selectivity in regards to which arginine in the 
structure is modulated.  
 
Three studies have investigated the effects of nitrogen concentration on the 
abundance of microcystin congeners.
146,150,151
 One of these studies used a 
chemostat culture set-up where media with 6 mM nitrate was provided to one set 
of cultures and media with 0.2 mM nitrate was provided to another set, however, 
no modulation in congener abundance was observed during the experiment.
150
 As 
the cultures were continuously supplied with nitrogen, albeit at a lower level, it is 
unlikely that the cells were strongly depleted of nitrogen. The second study used a 
similar set-up but with different concentrations of nitrate, which yielded similar 
results.
151
 The third study used a batch culture set-up with a starting nitrate 
concentration of 0.016 mM and observed no change in congener abundance.
146
 As 
this study was conducted over a 36 hour period, it is unlikely that any modulation 
would be observed over such a short period. Furthermore, each of these 
experiments
146,150,151
 utilised cyanobacterial strains which produced only -RR and 
-XR microcystin congeners. If selectivity between the position two and four 
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arginine occurred during these studies, then no modulation in congener abundance 
would be observed in a cyanobacterial strain that produces microcystins which 
only contain arginine at position four. 
 
Whether the change in microcystin congener abundance observed during this 
experiment would cause a change in toxicity is hard to gauge as there is no 
toxicity data available for three of the major microcystin congeners present in 
Microcystis CYN06 (MC-LA, MC-FA and MC-WA). However, the seven-fold 
reduction in microcystin content observed with lower nitrate concentrations would 
have a definite effect on the toxicity of the strain. 
 
Whilst the results from this study indicate nitrogen supply may play a role in 
regulating the abundance of arginine-containing microcystin congeners, a nitrogen 
supplementation experiment did not yield statistically significant results (data not 
shown). This was likely due to variability in level of depletion of nitrogen 
between the culture replicates. As a result, the microcystin congener abundance 
varied and the cultures reacted to the supplementary nitrogen at different rates. 
Future work in this area is required to confirm the causative factor of the changes 
in microcystin congener abundance observed. 
 
 
7.4 CONCLUSIONS 
Modulation of the abundance of microcystin congeners in response to nitrogen 
supply was investigated during a 40-day batch culture of Microcystis CYN06. A 
decrease in the abundance of the arginine-containing microcystin congeners 
coincided with a decrease in the concentration of nitrate. Linear regression of 
log10 microcystin content and nitrate revealed slopes which were dependent upon 
the number of arginine residues present in the microcystin congener. The 
abundance of the congeners which contained a single arginine at the position two 
did not change significantly throughout the experiment. However, the abundance 
of the congeners containing a position four arginine did vary, which suggests an 
element of selectivity to which arginine in the microcystin is modulated. This 
study is the first to correlate changes in microcystin congener abundance with 
nitrogen supply. 
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CHAPTER 8 
 
Future Directions 
 
 
During this study, several new microcystin congeners were purified in sufficient 
quantities to conduct toxicology examinations (MC-FA, MC-WA and MC-NfkA). 
However, the purity of the samples was not adequate to proceed and there was 
insufficient time to undertake further purification. The other new microcystins 
characterised were not present in sufficient quantities to undertake toxicology 
studies. Fractionation of more material could yield sufficient amounts of 
compound to determine the toxicity of these microcystins. Toxicity data for these 
congeners would be of great benefit to the microcystin research community and 
allow further interpretation of the results of the culturing experiment conducted in 
Chapter 7.  
 
It was not possible to fully characterise the structures of the Antarctic 
microcystins and linear peptides with the small sample size available. Continued 
monitoring of the region where the original sample was collected could yield a 
larger sample or a cyanobacterial specimen which could be cultured. This would 
enable further purification of the microcystins and nuclear magnetic resonance 
spectroscopy could be used to confirm the presence of homoarginine, 
dehydrobutyrine and ADMAdda. Amino acid analysis could also be conducted to 
determine the stereochemistry of the arginine and homoarginine residues. With 
the Antarctic peptides, it would allow characterisation of the 168 Da N-terminus 
and confirmation of other amino acids, including deduction of their 
stereochemistry. 
 
During this study, it was noted that tryptophan residues in microcystins could 
become oxidised. Further investigations into the rate of oxidation under different 
storage conditions would be very beneficial, as this has the potential to impact 
research where tryptophan-containing microcystins are being quantified. 
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The sample preparations designed for use during quantitative analysis of 
microcystins by matrix-assisted laser desorption/ionisation-time of flight mass 
spectrometry were tested using a simple mixture of microcystin standards. Further 
assessment of this sample preparation technique could be undertaken using 
complex cyanobacterial extracts and a standardised method for quantifying a 
sample could be developed. 
 
The culturing experiment performed using CYN06 suggested that nitrogen supply 
was the main factor responsible for the modulation of microcystin congener 
abundance. An experiment to determine if nitrogen supply was the causative 
factor did not yield statistically significant results, as the replicate cultures reacted 
to supplementary nitrogen at different rates. Supplementing the cultures before 
complete nitrogen starvation might yield a more consistent result. Collecting 
additional samples to assess the quantity of intracellular nitrogen throughout the 
culturing experiment might also allow the relationship between microcystin 
content and nitrogen concentration to be more accurately modelled. Performing 
experiments utilising a chemostat culturing setup would allow the nitrogen 
concentration to be manipulated more easily. If modulation of microcystin 
congener abundance was also observed using a chemostat setup, it would 
demonstrate that previous research on the effect of nitrogen concentration on 
microcystin congener abundance
146,150,151
 was due to the use of a cyanobacterial 
strain which only produced microcystins that contained a position four arginine. 
Toxicology data for MC-LA, MC-FA and/or MC-WA would allow for an 
estimation of the toxicity of CYN06 at different nitrate concentrations. 
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CHAPTER 9 
 
Experimental 
 
 
9.1 GENERAL EXPERIMENTAL 
9.1.1  Materials 
Deionised water (> 18 MΩ∙cm resistivity) purified on an E-pure still (Barnstead) 
was used for all solutions. Ethanol (EtOH), methanol (MeOH) and 
dichloromethane (DCM) were drum-grade solvents which were distilled prior to 
use, unless otherwise stated. Unless stated, all other chemicals were analytical 
grade (Table 9.1). 
 
Table 9.1: Chemicals used and their suppliers 
Chemical Source 
Trifluoroacetic acid (TFA) Acros Organics 
[Dha
7
] MC-LR standard AgResearch Ruakura 
Acetone; Anhydrous magnesium sulphate; Ammonia (28%; NH3); 
Ammonium dihydrogen phosphate; Boric acid; Calcium chloride 
dehydrate; Copper (II) sulphate pentahydrate; Formic acid (88%; 
FA); HPLC-grade methanol; Hydrochloric acid (HCl); 
Hydrogen peroxide (30%); Magnessium sulphate heptahydrate; 
Manganese (II) chloride tetrahydrate; 2-Propanol (IPA); Potassium 
carbonate; Sodium bicarbonate; Sodium hydroxide 
Ajax Chemicals 
D-Leucinamide; L-Leucinamide  Bachem 
L-Alanine (Ala); 2-Aminoisobutanoic acid (Aib); Ammonium 
chloride; L-Aspartic acid (Asp); 1,5-Difluoro-2,4-dinitrobenzene 
(FFDNB); L-Glutamic acid (Glu); Glycine (Gly); Iodine; Iron (III) 
chloride hexahysrate; L-Ornithine (Orn); Potassium iodide; Sodium 
nitrate 
BDH Chemicals 
α-Cyano-4-hydroxycinnamic acid (CHCA); Peptide calibration 
standard 
Bruker Daltonics 
2-Aminobutanoic acid (Aba); L-Arginine (Arg); L-Isoleucine (Ile); 
L-Leucine (Leu); L-Lysine (Lys); L-Phenylalanine (Phe) 
Calbiochem 
MC-LR standard; MC-RR standard; MC-YR standard DHI Lab Products 
Glacial acetic acid Fisher Scientific 
HPLC-grade acetonitrile (ACN) Honeywell International 
Cobalt (II) chloride hexahydrate; Sodium nitrite Hopkins and Williams 
Chapter 9 
170 
 
Dipotassium phosphate; Sodium formate; Sodium molybdate 
dihydrate; 
May and Baker 
Ammonium acetate; Selenous acid Riedel-de Haën 
HPLC-grade ethanol; Sodium ethylenediaminetetraacetic acid 
(EDTA); Zinc sulphate heptahydrate 
Scharlau 
Angiotensin I; β-Mercaptoethanol; Biotin; Methanol-d3 (CD3OH); 
Methanol-d4 (CD3OD); Thiamine·HCl; Vitamin B12 
Sigma-Aldrich 
 
 
9.1.2 Common Solutions 
The compositions of the solutions commonly used during this study are listed in 
Table 9.2. 
 
Table 9.2: Commonly used solutions. 
Solution Composition 
10% Formic acid 11.4 mL of 88% formic acid (10%; v/v) 
- Make up to 100 mL with H2O and filter (0.45 µm) 
LC-MS Solvent A 10 mL of 10% formic acid (0.1%; v/v) 
20 mL of HPLC-grade acetonitrile (2%; v/v) 
- Make up to 1 L with H2O 
LC-MS Solvent B 10 mL of 10% formic acid (0.1%; v/v) 
10 mL of H2O (2%; v/v) 
- Make up to 1 L with HPLC-grade acetonitrile 
L-FDLA 10 mg L-FDLA (1%; w/v) 
- Dissolve in 1 mL acetone 
DL-FDLA 10 mg of L-FDLA (1%; w/v) 
10 mg of D-FDLA (1%; w/v) 
- Dissolve in 1 mL of acetone 
MALDI matrix solution 500 µL of MeOH (50%; v/v) 
250 µL of acetonitrile (25%; v/v) 
250 µL of 0.1% (v/v) TFA (0.025%; v/v) 
- Discard after one week 
MALDI wash solution 100 µL of 1% (v/v) TFA (0.1%; v/v) 
900 µL of 11.1 mM NH4H2PO4 (10 mM) 
- Store at 4 °C and discard after one month 
Ammonium acetate stock 7.71 g of ammonium acetate (200 mM) 
- Make up to 500 mL with H2O and filter (0.45 µm) 
Ammonium acetate solution 50 mL of ammonium acetate stock (10 mM) 
- Make up to 1 L with H2O 
MLA
296
 vitamin stock 10 mg of thiamine·HCL (332 µM) 
50 µL of 409 µM biotin (205 nM) 
50 µL of 73 µM vitamin B12 (37 nM) 
- Make up to 100 mL with H2O and store at 4 °C 
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MLA
296
 micronutrient stock 4.36 g of Na2EDTA·2H2O (11.7 mM) 
- Add 800 mL H2O and stir over a low heat to dissolve 
1.58 g of FeCl3·6H2O (5.8 mM) 
0.60 g of NaHCO3 (3.5 mM) 
0.36 g of MnCl2·4H2O (1.8 mM) 
10 mL of 4 mM CuSO4·5H2O (40 µM) 
10 mL of 7.7 mM ZnSO4·7H2O (77 µM) 
10 mL of 4.2 mM CoCl2·6H2O (42 µM) 
10 mL of 2.5 mM Na2MoO4·2H2O (25 µM) 
- Make up to 1 L with H2O and store at 4 °C 
40× MLA
296
 stock 10 mL of 200 mM MgSO4·7H2O (8 mM) 
20 mL of 1 M NaNO3 (80 mM) 
50 mL of 40 mM K2HPO4 (8 mM) 
10 mL of 40 mM H3BO3 (1.6 mM) 
10 mL of 10 µM H2SeO3 (400 nM) 
10 mL of vitamin stock 
10 mL of micronutrient stock 
- Make up to 250 mL with H2O, filter sterilise (0.2 µm) and 
store at 4 °C 
MLA
296
 sodium bicarbonate 
stock 
4.23 g of NaHCO3 (200 mM) 
- Make up to 250 mL with H2O, autoclave and store at 4 °C 
MLA
296
 calcium chloride 
stock 
0.29 g of CaCl2·2H2O (200 mM) 
- Make up to 100 mL with H2O, autoclave and store at 4 °C 
MLA
296
 culturing medium 25 mL of 40× MLA Stock 
10 mL of sodium bicarbonate stock (2 mM) 
1 mL of calcium chloride stock (200 µM) 
- Make up to 1 L with autoclaved H2O and store at 4 °C 
Lugol’s solution 10 g of potassium iodide (602 mM) 
- Dissolve in 70 mL H2O 
5 g of iodine (394 mM) 
10 mL of acetic acid (10%; v/v) 
- Make up to 100 mL with H2O and store in the dark 
 
 
9.1.3 Commonly Used Laboratory Techniques 
Freeze-Drying 
Lyophilisation of samples was conducted using a FreeZone6 freeze-drier 
(Labconco). 
 
Centrifugation 
Centrifugation was undertaken on one of three centrifuges; a Labnet Z150A 
centrifuge (samples greater than 1.5 mL), an Eppendorf MiniSpin Plus centrifuge 
(samples less than 1.5 mL) or an Eppendorf 5810 centrifuge (when temperature 
control was required). 
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Sonication 
Samples and solvents were sonicated at ambient temperature in an ultrasonic bath 
(Aquawave, Barnstead International). 
 
Microscopy 
Microscopy was conducted using an inverted microscope (Olympus CK40). 
 
Nutrient Analysis 
Dissolved nutrient concentrations were determined by flow injection analysis 
(Lachat Quickchem FIA+ 8000; Zellweger Analytics). Stored nutrient samples 
were thawed and allowed to come to room temperature. The concentration of the 
total oxidised nitrogen species (NOx) was determined by passing the sample 
through a copperised cadmium column to reduce nitrate to nitrite. This was 
performed using Lachat QuickChem Method 10-107-04-1-A (MDL = 5 µM). 
Nitrite concentrations were determined using Lachat QuickChem Method 
10-107-05-1-A (MDL = 5 µM). As nitrite levels were below the detection limit, 
nitrate concentrations were determined directly from the NOx measurements. 
Lachat QuickChem Method 10-107-06-2-L was used to determine ammonia 
concentrations (MDL = 5 µM). Dissolved reactive phosphorus concentrations 
were determined using Lachat QuickChem Method 10-115-01-1-A 
(MDL = 0.6 µM).  
 
The concentration of each nutrient was determined by comparing the response 
from a sample with a standard curve constructed using KH2PO4, NH4Cl and 
KNO3 or NaNO2 at known concentrations (0.16-32 µM for phosphorous and 
7-140 µM for the nitrogen-containing standards). Quality control checks were 
conducted every fifteen samples using a mid range calibration standard. 
 
9.1.4 Commonly Used Fractionation Techniques 
All fractions were collected in conical flasks and concentrated under vacuum 
using a rotary evaporator (Büchi). Fractions were then transferred to a glass vial 
and dried at 35 °C under a stream of nitrogen. As microcystins are a harmful 
substance, precautions for personal protection were taken. Cultures were labelled 
as hazardous, gloves and safety galsses were worn and a facemask was used when 
floculant material was being handled. 
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Reversed-Phase C18 Chromatography 
Reversed-phase column chromatography was conducted using C18 material 
(YMC-gel ODS-A, YMC). Samples were prepared for chromatography by 
dissolution in one part MeOH, which was diluted with six parts H2O and 
lyophilised in a glass vial. The resulting solid was scraped into a powder with a 
stainless steel spatula before being loaded onto the top of the column. The sample 
vial was rinsed with DCM (0.5 mL) then MeOH (0.5 mL), and eluted using a 
stepped gradient under the pressure of nitrogen gas. 
 
Size Exclusion Chromatography 
Size exclusion column chromatography was conducted using LH-20 material 
(Sephadex LH-20, Pharmacia Fine Chemicals). The samples were dissolved in 
minimal MeOH, applied to the top of the column and eluted with MeOH. 
 
Gradient High Performance Liquid Chromatography 
Gradient high performance liquid chromatography (HPLC) was performed using 
two HPLC pumps (Waters 515) controlled by Empower Pro (Waters). Eluting 
compounds were detected by a photo-diode array detector (PDA; 200-400 nm; 
Waters 2996). Samples were dissolved in HPLC-grade MeOH (1.2 mL) and 
syringe filtered (0.2 µm). Repeated injections (100 µL) were fractionated on a C18 
HPLC column (Luna C18, 150 × 4.6 mm, 5-µ; Phenomenex) using the 
H2O→ACN gradient (1 mL/min) specified in each section. 
 
Isocratic High Performance Liquid Chromatography 
Isocratic HPLC was performed using two HPLC pumps (Waters 515) set to 
deliver different volumes of solvent. Eluting compounds were detected by a PDA 
detector (200-400 nm; Waters 2996). Samples were dissolved in HPLC-grade 
MeOH (1.25 mL) and syringe filtered (0.2 µm). Repeated injections (100 µL) 
were fractionated on a C18 HPLC column (Econosil C18, 250 × 10 mm, 10-µ; 
Alltech) using a mixture of ACN and 10 mM ammonium acetate (5 mL/min).  
 
Solid-Phase C18 Cleanup 
Solid-phase cleanup was performed using a glass Pasteur pipette lightly plugged 
with cotton wool and filled with C18 material (200 mg; YMC-gel ODS-A; YMC). 
The solid-phase cleanup column was primed with MeOH (2 × 0.6 mL) then 
Chapter 9 
174 
 
equilibrated with 15% MeOH (3 × 0.6 mL; v/v). Lyophilised samples were 
resuspended in MeOH (0.3 mL) and diluted with H2O (1.8 mL). The sample was 
loaded onto the solid-phase cleanup column and allowed to flow through. The 
column was washed with 15% MeOH (5 × 0.6 mL; v/v) before the microcystin 
was eluted using 80% MeOH (3 × 0.6 mL; v/v). 
 
9.1.5 Commonly Used Characterisation Techniques 
Matrix-Assisted Laser Desorption/Ionisation-Time of Flight Mass Spectrometry 
Samples were analysed using an AutoFlex II matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) mass spectrometer (Bruker 
Daltonics) operated with FlexControl (Bruker Daltonics). Samples were prepared 
for MALDI-TOF analysis as described in each section. Mass calibration was 
performed using a peptide calibration standard which was prepared in the same 
manner as the samples. Spectra were acquired over various m/z ranges, with an 
acceleration voltage of 19 kV and a reflector voltage of 20 kV. Pulsed ion 
extraction of 60 ns was used to build up the concentration of ions in the ion source 
and ions below 500 m/z were suppressed to avoid detector saturation from matrix 
ions. Mono-isotopic peaks were manually annotated using FlexAnalysis (Bruker 
Daltonics). 
 
Tandem mass spectrometry (MS/MS) data was acquired using the same 
instrument. Fragmentation was induced by post-source decay (PSD) or a 
combination of PSD and collision-induced dissociation (CID). Because of the 
“LIFT” capabilities of this particular MALDI-TOF mass spectrometer, the 
resulting fragment ions could be resolved in a single spectrum. The spectra were 
annotated in FlexAnalysis, where each spectrum was smoothed (Savitzky Golay 
algorithm) and the baseline subtracted (Median algorithm), before the 
mono-isotopic peaks were automatically selected (SNAP algorithm). 
 
Liquid Chromatography-Mass Spectrometry 
Samples were separated using an HPLC system (UltiMate 3000; Dionex) which 
was directly coupled to an electrospray ionisation (ESI)-ion trap mass 
spectrometer (AmaZon X; Bruker Daltonics). HyStar (Bruker Daltonics) was used 
to control the duel systems. Samples (20 µL) were separated on a C18 column 
(Ascentis Express C18, 100 × 2.1 mm, 2.7-µ; Supleco Analytical) using the 
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H2O→ACN gradient outlined in Table 9.3 (200 µL/min; 40 °C). The m/z of the 
eluting compounds was assessed using a capillary voltage of 3.5 kV for negative 
ions and 4.5 kV for positive ions and a nebuliser pressure of 1.5 bar. Desolvation 
was accomplished with a nitrogen flow of 8 L/min at 225 °C. 
 
Table 9.3: HPLC gradient for general LC-MS analysis.
 a
 
Time 
(min) 
%A 
(98:2 H2O/ACN 
+ 0.1% Formic Acid) 
%B 
(2:98 H2O/ACN 
+ 0.1% Formic Acid) 
0 90 10 
1 90 10 
13 0 100 
15 0 100 
16 90 10 
20 90 10 
a Flow rate = 200 µL/min; Column temperature = 40 °C. 
 
Tandem mass spectra were gathered using the protonated ion of a compound and 
CID to induce fragmentation of the parent ion (collision amplitude of 1.0). In 
some cases MS
3
 spectra were acquired; where the parent ion was fragmented, one 
of the resulting fragment ions was isolated then fragmented, and the m/z of those 
fragment ions were recorded. 
 
Chromatograms and spectra were annotated in DataAnalysis (Bruker Daltonics), 
where each chromatogram was smoothed (Gauss algorithm; 0.2 s; 1 cycle). Mass 
spectra were smoothed (Gauss algorithm; 0.2 m/z; 1 cycle) and the peaks were 
automatically selected (Apex algorithm). 
 
High Resolution Mass Spectrometry 
Semi-pure and purified compounds were analysed using an ESI-TOF mass 
spectrometer (MicrOTOF; Bruker Daltonics) operated with MicrOTOF Control 
(Bruker Daltonics). Samples were resuspended at a concentration of ≤ 0.1 mg/mL 
in HPLC-grade MeOH + 0.1% formic acid (v/v) and introduced into the mass 
spectrometer using a syringe pump (3 µL/min). Positive ions were assessed, using 
a capillary voltage of 4.5 kV and a nebuliser pressure of 0.5 bar. Desolvation was 
accomplished with a nitrogen flow of 4 L/min at 180 °C. The instrument was 
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calibrated before each sample was analysed using a solution of sodium formate 
(2 mM), the cluster ions of which spanned the mass range assessed.  
 
Spectra were annotated in DataAnalysis, where each spectrum was smoothed 
(Gauss algorithm; 0.2 m/z; 1 cycle) and the peaks were automatically selected 
(Sum Peak algorithm). Molecular formulae were generated using the accurate 
mass obtained and the Generate Molecular Formula tool. 
 
Amino Acid Analysis 
Semi-pure and purified microcystins were subjected to amino acid analysis 
according to the Advanced Marfey’s method.202-205 1-Fluoro-2,4-dinitrophenyl-5-
leucine (FDLA) was synthesised according to the method of Marfey,
201
 but using 
leucinamide instead of alaninamide. Both the D- and L- forms of the reagent were 
synthesised from the respective stereoisomers of leucinamide. The resulting 
product was characterised by visual appearance, melting point and ESI MS 
(yellow crystals; m.p.: 168-170 °C; m/z 315 [M+H]
+
, 337 [M+Na]
+
, 353 [M+K]
+
, 
270 [M−NO2+2H]
+
).
202
 
 
Samples were dried at 35 °C under a stream of nitrogen in a glass reaction vial, 
resuspended in 6 N HCl (0.5 mL) and incubated at 110 °C for 16 h. The HCl was 
removed at 35 °C under a stream of nitrogen. Hydrolysates were resuspended in 
H2O (105 µL) and aliquoted into two microcentrifuge tubes (50 µL each), to 
which 1 M NaHCO3 (20 µL) and 1% L- or DL-FDLA (100 µL; w/v) were added. 
The tubes were vortexed and incubated at 40 °C for 1 h, before being quenched 
with 1 N HCl (20 µL). The derivatised hydrolysates were diluted with 
HPLC-grade MeOH (810 µL), centrifuged (14,000 rcf, 5 min) and the supernatant 
(950 µL) transferred to a septum-capped LC vial. 
 
The resulting derivatives were analysed by LC-MS using the instrumentation 
described above. The derivatised sample (20 µL) was separated on a C18 column 
(Econosil C18, 250 × 3.2 mm, 5-µ; Alltech) using the H2O→ACN gradient 
outlined in Table 9.4 (600 µL/min; 40 °C). Eluting derivatives were detected by 
ultraviolet (UV) absorption (250-500 nm) and ESI MS (m/z 300-1,100). Negative 
ions were assessed using a capillary voltage of 3.5 kV and a nebuliser pressure of 
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1.5 bar. Desolvation was accomplished with a nitrogen flow of 10 L/min at 
220 °C. 
 
Table 9.4: HPLC gradient for Advanced Marfey’s amino acid analysis. a 
Time 
(min) 
%A 
(98:2 H2O/ACN 
+ 0.1% Formic Acid) 
%B 
(2:98 H2O/ACN 
+ 0.1% Formic Acid) 
0 75 25 
1 75 25 
31 35 65 
33 0 100 
35 0 100 
38 75 25 
45 75 25 
a Flow rate = 600 µL/min; Column temperature = 40 °C. 
 
The resulting chromatograms and spectra were annotated in DataAnalysis, where 
extracted ion chromatograms were generated and smoothed (Gauss algorithm; 
0.643 s; 2 cycles). 
 
β-mercaptoethanol Derivatisation 
Standards, extracts and semi-pure mixtures of microcystins (1,420 µL) were 
mixed with 200 mM NaHCO3 (pH 9.7; 360 µL) in a septum-capped vial and left 
to equilibrate to 30 °C.
41
 Following an LC-MS injection (as described previously) 
β-mercaptoethanol (20 µL) was added and the tube inverted to mix. The reaction 
was maintained at 30 °C in the sample tray of the LC-MS and injections were 
performed periodically over an 8 h period when Mdha/Dha was suspected to be 
present and over a 90 h period when Dhb was suspected to be present. 
 
400 MHz Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance (NMR) spectra for 163 and 165 were recorded on a 
Bruker AVIII-400 NMR spectrometer. Chemical shifts were determined at 300 K 
and are reported relative to the solvent signal (CD3OD; 
1
H 3.31 ppm, 
13
C 49.15 ppm). Standard pulse sequences were used for HSQC, HMBC, COSY, 
TOCSY and ROESY experiments. TOCSY experiments were conducted with 
mixing times optimised for the detection of short, medium and long range 
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couplings. HMBC spectra were acquired using parameter sets optimised for 
2-3
J 1H-
13
C correlations. 
 
600 MHz Nuclear Magnetic Resonance Spectroscopy 
Nuclear magnetic resonance spectra for 175 were recorded by Dr. Chris Miles 
(Norwegian Veterinary Institute, Oslo, Norway) on a Bruker AVII-600 NMR 
spectrometer equipped with a TCI cryoprobe and Z-gradient coils. Chemical shifts 
were determined at 298 K and are reported relative to the solvent signal (CD3OH; 
1
H 3.31 ppm, 
13
C 49.0 ppm). Spectra (
1
H, HSQC, COSY, TOCSY, and ROESY) 
were obtained with continuous wave presaturation and/or excitation sculpturing of 
either or both of the residual OH/H2O and CHD2OH signals. TOCSY experiments 
were conducted with mixing times optimised for the detection of short, medium 
and long range couplings. HMBC spectra were acquired using parameter sets 
optimised for 
2
J 1H-
13
C correlations. 
 
Ultraviolet Absorption Spectrophotometry 
The UV absorption of the purified microcystins was determined using an 
UV-visible spectrophotometer (Cary 100 Scan; Varian). Microcystins dissolved in 
HPLC-grade MeOH were assessed over a wavelength range of 200-800 nm. 
 
Optical Rotation 
Optical rotation of the purified microcystins was determined using a polarimeter 
(AUTOPOL IV; Rudolph Research Analytical). Microcystins were dissolved in 
HPLC-grade MeOH at concentrations of ≤ 0.6 mg/mL. 
 
 
9.2 WORK DESCRIBED IN CHAPTER TWO 
9.2.1 Sample Preparation 
An environmental bloom sample containing several Microcystis species was 
collected from Lake Wiritoa (Manawatu, New Zealand; Voucher LW20403 is 
stored in the University of Waikato Chemistry Department). The sample was 
extracted in MeOH (100 µL) overnight. Extract (0.5 µL) was mixed 1:1 with a 
saturated solution of α-cyano-4-hydroxycinnamic acid (CHCA) dissolved in 
MALDI matrix solution (2:1:1 MeOH/ACN/0.1% TFA), directly on a 600 μm 
anchorchip (Bruker Daltonics). The dried spot was washed by pipetting MALDI 
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wash solution (5 µL; 0.1% TFA in 10 mM NH4H2PO4) onto the spot for 5 s, then 
withdrawing the liquid. 
 
9.2.2 MALDI-TOF Mass Spectrometry 
The sample was analysed as described in Section 9.1.5. Positive ion MS spectra 
were acquired over a 600-2,000 m/z range by summing 500 shots. MS/MS data 
was acquired using the same sample preparation. Fragmentation was induced by 
PSD for structural characterisation and by a combination of PSD and CID for 
leucine/isoleucine determination. 
 
 
9.3 WORK DESCRIBED IN CHAPTER THREE 
9.3.1 Culturing of CYN06 
The Microcystis species CYN06 (Micro-algae culture collection, Cawthron 
Institute, Nelson, New Zealand) was grown in 20 × 20 L plastic carboys, each 
containing 16 L of MLA
296
 media. Cultures were grown at 18 °C under a 12:12 h 
light/dark cycle with a photon-flux of 100 μEin∙m–2∙s–1. After 40 days, the cultures 
were harvested using plankton net (11 µm mesh diameter). The concentrated cell 
material was lyophilised and stored at −20 °C until extracted. 
 
9.3.2 Extraction of CYN06 Material 
Freeze-dried CYN06 (76.9 g) was extracted in 70% EtOH (5 × 800 mL; v/v). This 
involved; homogenisation of the cells in a Waring blender followed by vacuum 
filtration (#1 filter paper). The remaining cell pellet was then re-homogenised and 
filtered four more times. The resulting extract was gravity filtered, concentrated 
under vacuum, and dried at 35 °C under a stream of nitrogen to yield 5.6 g. In 
addition, the cell pellet which remained after the initial extraction was re-extracted 
in 100% MeOH (5 × 250 mL), in the same manner as the initial extraction. This 
yielded 0.45 g of extract. A voucher of the lyophilised material is retained in the 
University of Waikato Chemistry Department, Hamilton, New Zealand (24.5 mg; 
JP2-033-05). 
 
9.3.3 Assessment of the Fraction Composition 
The composition of the CYN06 fractions was assessed by LC-MS using the 
instrumentation and protocols outlined in Section 9.1.5. Fractions were 
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resuspended in HPLC-grade MeOH (500 µL), an aliquot (5 µL) was syringe 
filtered (0.2 µm) into a septum-capped LC vial. The filter and syringe were then 
washed with 50% HPLC-grade MeOH (995 µL; v/v). Negative ions were assessed 
over a 100-2,000 m/z range and the resulting ion-chromatograms were integrated 
using QuantAnalysis (Bruker Daltonics). 
 
9.3.4 Isolation of the -XA Microcystins 
The two CYN06 extracts (5.6 and 0.45 g) were individually separated on a 
reversed-phase C18 column (50 g), where the extract components were eluted with 
a steep stepped gradient from H2O→MeOH→DCM. The fractions between 7:3 
and 1:1 H2O/MeOH contained the -XA microcystins. 
 
The fractions which contained the -XA microcystins (331.8 mg) were combined 
and loaded onto a reversed-phase C18 column (20 g) which had been equilibrated 
with H2O + 0.1% formic acid (FA; v/v). The sample components were eluted with 
increasing concentrations of H2O + FA→MeOH + FA→MeOH→DCM. The 
fractions at 3:7 H2O/MeOH + 0.1% FA (v/v) contained the -XA microcystins. 
 
The fractions which contained the -XA microcystins (127.5 mg) were combined 
and dried. The sample was resuspended in MeOH, K2CO3 (40 mg) was added and 
the sample was left for 1 min. The solution was then transferred to a new vial and 
prepared for C18 chromatography. The sample was loaded onto a reversed-phase 
C18 column (20 g) and the sample components eluted with more refined 
increments of H2O→MeOH. The fractions at 3:1 H2O/MeOH contained the -XA 
microcystins. 
 
The fractions which contained the -XA microcystins (34.2 mg) were combined, 
loaded onto a LH-20 column (35 g) and eluted with MeOH. MC-LA eluted after 
90 mL of MeOH had passed through the column, MC-FA and several oxidised 
tryptophan congeners after 100 mL, and MC-WA after 110 mL. This yielded three 
mixtures with varying proportions of the different microcystins. 
 
The three mixtures (4.9 mg, 6.7 mg and 10.2 mg) were individually prepared for 
and fractionated by isocratic HPLC using 27:73 ACN/10 mM ammonium acetate. 
The dried samples were lyophilised before the residual ammonium acetate was 
 Chapter 9 
181 
 
removed by solid-phase cleanup. This yielded a mixture of MC-LA and the 
oxidised -XA tryptophan congeners (6 min), MC-FA (9 min), MC-WA (10 min) 
and a mixture of MC-FAba, MC-WAba with other contaminants (14-20 min). 
 
MC-FA (163): White amorphous solid (2.3 mg, 2.99×10
-3 %); [α]20D −173° 
(c 0.06 g/100 mL, MeOH); UV (MeOH) λmax (log ɛ) 207 (4.20), 238 (4.13) nm; 
1
H NMR data at 400 MHz, 
13
C NMR data at 101 MHz (CD3OD) see Table 3.3; 
HRESIMS m/z 966.4550 (calculated for C49H65N7O12Na, 966.4583, Δ −3.41 ppm). 
 
MC-WA (165): White amorphous solid (0.8 mg, 1.04×10
-3 %); [α]20D −40° 
(c 0.04 g/100 mL, MeOH); UV (MeOH) λmax (log ɛ) 207 (4.19), 224 (4.25), 238 
(4.13) nm; 
1
H NMR data at 400 MHz, 
13
C NMR data at 101 MHz (CD3OD) see 
Table 3.5; HRESIMS m/z 1005.4650 (calculated for C51H66N8O12Na, 1005.4692, 
Δ −4.25 ppm). 
 
9.3.5 Isolation of the -RZ Microcystins 
The two CYN06 extracts (5.6 and 0.45 g) were individually separated on a 
reversed-phase C18 column (50 g), where the extract components were eluted with 
increasing concentrations of H2O→MeOH→DCM. The fractions between 7:3 and 
1:1 H2O/MeOH contained the -RZ microcystins. 
 
The fractions which contained the -RZ microcystins (130 mg) were combined and 
loaded onto a reversed-phase C18 column (20 g) which had been equilibrated with 
H2O + 0.1% FA (v/v). The sample components were eluted with increasing 
concentrations of H2O + FA→MeOH + FA→MeOH→DCM. The fractions at 
7:13 H2O/MeOH + 0.1% FA (v/v) contained the -RZ microcystins. 
 
The fractions which contained the -RZ microcystins (36.2 mg) were combined, 
loaded onto a LH-20 column (35 g) and eluted with MeOH. The -RZ microcystins 
eluted after 95 mL of MeOH had passed through the column. 
 
The sample (12.5 mg) was fractionated by isocratic HPLC using 
13:37 ACN/10 mM ammonium acetate. The dried samples were lyophilised 
before the residual ammonium acetate was removed by solid-phase cleanup. This 
yielded MC-RA (12 min) and MC-RAba (20 min). 
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MC-RA (16): White amorphous solid (0.2 mg, 2.60×10
-4 
%); [α]20D −100° 
(c 0.02 g/100 mL, MeOH); UV (MeOH) λmax (log ɛ) 205 (4.26), 238 (4.26) nm; 
HRESIMS m/z 953.5122 (calculated for C46H69N10O12, 953.5091, Δ +3.28 ppm). 
 
MC-RAba (19): White amorphous solid (0.1 mg, 1.30×10
-4 
%); [α]20D −60° 
(c 0.013 g/100 mL, MeOH); UV (MeOH) λmax (log ɛ) 207 (4.29), 238 (4.18) nm; 
HRESIMS m/z 967.5259 (calculated for C47H71N10O12, 967.5247, Δ +1.15 ppm). 
 
9.3.6 LC-MS/MS Analysis of the CYN06 Microcystins 
Analysis of the CYN06 microcystins by LC-MS/MS was undertaken with 
semi-pure fractions using the instrumentation and protocols outlined in 
Section 9.1.5. 
 
9.3.7 MALDI-TOF MS/MS Analysis of the CYN06 Microcystins 
Tandem MS spectra for the arginine-containing microcystins were obtained using 
semi-pure fractions and MALDI PSD. The sample was resuspended in MeOH 
(0.6 mL) and an aliquot (0.5 µL) was mixed 1:1 with a saturated solution of 
CHCA in MALDI matrix solution (2:1:1 MeOH/ACN/0.1% TFA), directly on a 
600 μm anchorchip. The dried spot was washed by pipetting MALDI wash 
solution (5 µL; 0.1% TFA in 10 mM NH4H2PO4) onto the spot for 5 s, then 
withdrawing the liquid. The sample was analysed using the instrumentation and 
protocols described in Section 9.1.5. 
 
9.3.8 High Resolution Mass Spectrometry of the CYN06 Microcystins 
Accurate masses for the CYN06 microcystins were determined with semi-pure 
fractions using the instrumentation and protocols described in Section 9.1.5. 
 
9.3.9 Amino Acid Analysis of the CYN06 Microcystins 
The identity and stereochemistry of the amino acids in several of the CYN06 
microcystins were determined using the protocols described in Section 9.1.5 and 
purified samples of MC-FA, MC-WA, MC-RA and MC-RAba (100 µg each). 
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9.4 WORK DESCRIBED IN CHAPTER FOUR 
The isolation of the oxidised tryptophan-containing microcystins from CYN06 
utilised the same extract described in Section 9.3.2. The composition of the 
fractions was assessed by LC-MS as described in Section 9.3.3. 
 
9.4.1 Isolation of the -XA Oxidised Tryptophan Congeners 
Isolation of the -XA oxidised tryptophan congeners continued from the desalted 
6 min isocratic HPLC fraction containing MC-LA and the oxidised tryptophan 
congeners (Section 9.3.4). The fraction (1.9 mg) was loaded onto a LH-20 column 
(35 g) and eluted with MeOH. MC-LA eluted after 90 mL of MeOH had passed 
through the column, MC-NfkA eluted after 100 mL, MC-OiaA after 105 mL, and 
MC-KynA after 110 mL. This yielded fractions with varying proportions of the 
different microcystins. 
 
The fractions which contained a high proportion of MC-NfkA (1.5 mg) were 
combined and re-fractionated on a LH-20 column (35 g) three more times. This 
yielded a fraction which contained the MC-NfkA and MC-OiaA, but with low 
levels of MC-LA. 
 
The fraction (0.6 mg) was fractionated by isocratic HPLC using 
27:73 ACN/10 mM ammonium acetate. The residual ammonium acetate in the 
dried fractions was removed by solid-phase cleanup. This yielded MC-NfkA 
(5.8 min) and MC-OiaA (6.3-7.3 min). 
 
MC-NfkA (175): White amorphous solid (0.4 mg, 5.20×10
-4 
%); 
1
H NMR data at 
600 MHz, 
13
C NMR data at 151 MHz (CD3OH) see Table 4.3; HRESIMS 
m/z 1037.4598 (calculated for C51H66N8O14Na, 1037.4591, Δ −0.75 ppm). UV 
data and optical rotation measurements for this compound remain to be 
determined. 
 
9.4.2 Isolation of the -XR Oxidised Tryptophan Congeners 
The two CYN06 extracts (5.6 and 0.45 g) were individually separated on a 
reversed-phase C18 column (50 g), where the extract components were eluted with 
increasing concentrations of H2O→MeOH→DCM. The fractions between 7:3 and 
1:1 H2O/MeOH contained the -XR oxidised tryptophan microcystins. 
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The fractions which contained the -XR oxidised tryptophan microcystins 
(331.8 mg) were combined and loaded onto a reversed-phase C18 column (20 g) 
which had been equilibrated with H2O + 0.1%  FA (v/v). The sample components 
were eluted with increasing concentrations of H2O + FA→MeOH + FA→MeOH 
→DCM. The fractions at 2:3 H2O/MeOH + 0.1% FA (v/v) contained the -XR 
oxidised tryptophan microcystins. 
 
The fractions which contained the -XR oxidised tryptophan microcystins (81.7 mg) 
were combined and dried. The sample was resuspended in MeOH, K2CO3 (40 mg) 
was added and the sample was left for 1 min. The solution was then transferred to 
a new vial and prepared for C18 chromatography. The sample was loaded onto a 
reversed-phase C18 column (20 g) and the sample components eluted with more 
refined increments of H2O→MeOH. The fractions at 7:3 H2O/MeOH contained 
the -XR oxidised tryptophan microcystins. 
 
The fractions which contained the -XR oxidised tryptophan microcystins (9.8 mg) 
were combined, loaded onto a LH-20 column (35 g) and eluted with MeOH. 
The -XR oxidised tryptophan microcystins eluted with MC-LR after 95 mL of 
MeOH had passed through the column. 
 
The sample (0.6 mg) was fractionated by isocratic HPLC using 1:3 ACN/10 mM 
ammonium acetate. Following lyophilisation, residual ammonium acetate was 
removed by solid-phase cleanup. This yielded MC-OiaR (7.2 min), a mixture of 
MC-LR and MC-NfkR (9 min), and MC-KynR (11.6 min). 
 
9.4.3 LC-MS/MS Analysis of the Oxidised Tryptophan Microcystins 
Analysis of the oxidised tryptophan microcystins by LC-MS/MS was undertaken 
with semi-pure fractions using the instrumentation and protocols outlined in 
Section 9.1.5. 
 
9.4.4 MALDI-TOF MS/MS Analysis of the Oxidised Tryptophan 
Microcystins 
Tandem MS spectra for the arginine-containing oxidised tryptophan microcystins 
were also obtained as described in Section 9.3.7 using semi-pure fractions. 
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9.4.5 High Resolution Mass Spectrometry of the Oxidised Tryptophan 
Microcystins 
Accurate masses for the oxidised tryptophan microcystins were determined as 
described in Section 9.1.5 using semi-pure fractions. 
 
9.4.7 Oxidation of Tryptophan-Containing Microcystins 
A healthy culture of Microcystis CYN06 (150 mL) grown at 20 °C 12:12 h 
light/dark with no perturbation was harvested on nylon net (100 µm mesh). The 
concentrated cells were washed with MLA
296
 (3 × 50 mL; at ambient temperature) 
then sonicated (35 W, 30 min) in 70 % MeOH (25 mL; v/v; previously degassed 
by sonication). The resulting extract was filtered through nylon net (100 µm mesh) 
to remove large cellular debris. An aliquot (0.5 mL) was transferred to a 
microcentrifuge tube, diluted with H2O (0.5 mL) and centrifuged (14,000 rcf, 
5 min). The supernatant (0.9 mL) was transferred to a septum-capped LC vial and 
analysed by LC-MS according to the protocol laid out in Section 9.1.5. This 
process was completed in 50 min. 
 
Three aliquots of the remaining CYN06 extract (7 mL each) were transferred to 
Falcon tubes and centrifuged (2,850 rcf, 10 min). The supernatant (5 mL) was 
transferred to a beaker, two of the aliquots were diluted with H2O (5 mL each; 
degassed by sonication) or 10% hydrogen peroxide (5 mL; degassed by 
sonication). An aliquot (1 mL) was transferred to a microcentrifuge tube and 
centrifuged (14,000 rcf, 5 min). The supernatant (0.9 mL) was transferred to a 
septum-capped LC vial and analysed by LC-MS according to the protocol laid out 
in Section 9.1.5. As this process took ca. 10 min to complete, no zero time-point 
was recorded. Each of the extracts were shielded from light using tin foil, lightly 
covered and left at ambient temperature. One of the aliquots diluted with H2O was 
stirred (250 rpm) whilst the other had no further treatment. The extract diluted 
with hydrogen peroxide was not stirred. Samples (1 mL) were removed at 1, 2, 6, 
26, 52 and 124 h, prepared for and analysed by LC-MS as described above. 
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9.5 WORK DESCRIBED IN CHAPTER FIVE 
9.5.1 Sample Collection 
In December 2006, two hydro-terrestrial cyanobacterial mat samples were 
collected from Miers Valley in the McMurdo Dry Valleys, Antarctica. These 
samples were obtained from the moist areas in front of Adams Glacier (MVAG1; 
78°6'36''S, 163°54'20''E; Figure 9.1) and Miers Glacier (MVMG1; 78°5'42''S, 
163°55'38''E). Microbial mat material was collected with a stainless steel spatula 
(swabbed with EtOH between samples) and placed in sterile 50 mL Falcon tubes. 
Whilst in the field, samples were stored in the dark and below 0 °C, and at −80 °C 
in the laboratory until analysed. Vouchers of MVAG1 and MVMG1 are retained 
at the Cawthron Institute (Nelson, New Zealand). 
 
 
Figure 9.1: Location of the McMurdo Dry Valleys and sampling locations 
within Miers Valley. 
 
9.5.2 Initial Mass Spectrometric Characterisation 
The frozen samples were lyophilised and the freeze-dried material stored at 
−18 °C. Freeze-dried material (0.2 g) was placed in 50 mL Falcon tubes with 
70% MeOH (15 mL; v/v) and sonicated for 60 min, vortexed and centrifuged 
(20,000 rcf, 10 min, 4 °C). After removing the supernatant, the extraction was 
repeated and the combined supernatants were dried at 35 °C under a flow of 
nitrogen. The dried extract was resuspended in 20% MeOH (2 mL; v/v) and 
filtered (0.45 µm). 
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The extract (0.5 µL) was mixed 1:1 with a saturated solution of CHCA in MALDI 
matrix solution (2:1:1 MeOH/ACN/0.1% TFA), directly on a 600 μm Anchorchip. 
The dried spot was washed by pipetting MALDI wash solution (5 µL; 0.1% TFA 
in 10 mM NH4H2PO4) onto the spot for 5 s, then withdrawing the liquid. The 
sample was analysed as described in Section 9.1.5. Positive ion mass spectra were 
acquired over a 600-2,000 m/z range by accumulating 500 shots. 
 
The Antarctic microcystins were analysed by LC-MS/MS at the Cawthron 
Institute (Nelson, New Zealand). The extract (10 µL) was separated by HPLC 
(Alliance 2695; Waters) using a C18 column (Luna C18, 150 × 2 mm, 5-µ; 
Phenomenex) and the H2O→ACN gradient outlined in Table 9.5 (200 µL/min; 
30 °C). At the end of the gradient the column was washed with 1:39 MeOH/IPA 
and re-equilibrated in the starting solvent. A Quattro Ultima TSQ triple-
quadrupole mass spectrometer (Waters-Micromass) was operated using ESI in 
positive ion mode. Tandem mass spectra for the protonated ions were gathered for 
each microcystin using a collision energy of 52 eV. 
 
Table 9.5: HPLC gradient for LC-MS/MS of the Antarctic microcystins.
 a
 
Time 
(min) 
%A 
(1:9 H2O/ACN) 
%B 
(9:1 H2O/ACN) 
%C 
(200 mM Formic Acid 
+ 33 mM NH3) 
0 77 18 5 
7 35 60 5 
9 0 95 5 
18 0 95 5 
a Flow rate = 200 µL/min; Column temperature = 30 °C. 
 
The Antarctic linear peptides were analysed by LC-MS/MS at the University of 
Waikato. The extract was analysed using the instrumentation and protocols 
outlined in Section 9.1.5. 
 
9.5.3 Extraction of the Antarctic Cyanobacterial Material 
After all other analyses were completed on the MVAG1 and MVMG1 samples,
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the remaining material was fractionated in order to undertake HRMS and amino 
acid analysis. MVAG1 (21 g) and MVMG1 (1 g) were extracted in 70% MeOH 
(5 × 300 mL; v/v). This involved disrupting the cells by sonication (35 W, 
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30 min), followed by vacuum filtration (#1 filter paper). The remaining cell 
material was then re-extracted and filtered four more times. The resulting extract 
was gravity filtered, concentrated under vacuum and dried at 35 °C under a flow 
of nitrogen to yield 51.2 mg of extract. 
 
9.5.4 Assessment of the Fraction Composition 
The composition of the Antarctic oligopeptide fractions was assessed by 
MALDI-TOF MS using a double dried-droplet sample preparation technique. 
Fractions were resuspended in MeOH (0.6 mL), loaded onto a 600 μm anchorchip 
(0.5 µL) and allowed to dry. The dried sample was resuspended, directly on the 
target, by pipetting up and down with a saturated solution of CHCA in MALDI 
matrix solution (0.5 µL; 2:1:1 MeOH/ACN/0.1% TFA). The resulting mixture 
was left on the target to dry at ambient temperature. The sample/matrix spot was 
washed by pipetting MALDI wash solution (5 µL; 0.1% TFA in 10 mM 
NH4H2PO4) onto the spot for 5 s, then withdrawing the liquid. Samples were 
analysed using the instrumentation and protocols described in Section 9.1.5. 
 
9.5.5 Isolation of the Antarctic Microcystins 
The Antarctic mat extract (51.2 mg) was loaded onto a reversed-phase C18 column 
(20 g) and extract components eluted with increasing concentrations of 
H2O→MeOH→DCM. The fractions between 3:7 and 1:9 H2O/MeOH contained 
the Antarctic microcystins. 
 
The fractions which contained the microcystins (4.1 mg) were combined and 
loaded onto a reversed-phase C18 column (20 g) and the extract components eluted 
with more refined increments of H2O→MeOH. The -LR microcystin congeners 
eluted from the column with 1:1 H2O/MeOH and the -RR congeners eluted from 
the column with 4:6 H2O/MeOH. 
 
The fractions containing the -RR congeners (1.2 mg) were combined and 
subjected to gradient HPLC using the H2O→ACN gradient outlined in Table 9.6 
(1 mL/min, ambient temperature). The -RR congeners eluted as a single peak at 
17 min. 
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Table 9.6: HPLC gradient for fractionation of the -RR Antarctic microcystins.
a
 
Time 
(min) 
%A 
(H2O + 0.05% TFA) 
%B 
(ACN + 0.05% TFA) 
0 90 10 
4 90 10 
20 45 55 
22 0 100 
24 0 100 
26 90 10 
30 90 10 
a Flow rate = 1 mL/min; At ambient temperature. 
 
The fractions containing the -LR congeners (2 mg) were combined and subjected 
to gradient HPLC using the H2O→ACN gradient outlined in Table 9.7 (1 mL/min, 
ambient temperature). The -LR congeners eluted as a single peak at 16 min. 
 
Table 9.7: HPLC gradient for fractionation of the -LR Antarctic microcystins.
a
 
Time 
(min) 
%A 
(H2O + 0.05% TFA) 
%B 
(ACN + 0.05% TFA) 
0 90 10 
4 90 10 
7 70 30 
20 40 60 
22 0 100 
24 0 100 
26 90 10 
30 90 10 
a Flow rate = 1 mL/min; At ambient temperature. 
 
9.5.6 Isolation of the Antarctic Linear Peptides 
The Antarctic mat extract (51.2 mg) was loaded onto a reversed-phase C18 column 
(20 g) and extract components eluted with increasing concentrations of 
H2O→MeOH→DCM. The fractions between 7:3 and 1:9 H2O/MeOH contained 
the Antarctic linear peptides. 
 
The fractions which contained the linear peptides (13.1 mg) were combined, 
loaded onto a LH-20 column (35 g) and eluted with MeOH. The linear peptides 
eluted after 80 mL of MeOH had passed through the column. 
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The fractions containing the linear peptides (7.3 mg) were combined and 
subjected to gradient HPLC using the H2O→ACN gradient outlined in Table 9.8 
(1 mL/min, ambient temperature). Peptide 816 eluted at 20.5 min, Peptides 800 
and 830A eluted at 21.5 min, and Peptides 814, 830B and 844 eluted between 
23-24 min. 
 
Table 9.8: HPLC gradient for fractionation of the Antarctic linear peptides.
a
 
Time 
(min) 
%A 
(H2O + 0.05% TFA) 
%B 
(ACN + 0.05% TFA) 
0 90 10 
5 90 10 
8 75 25 
19 60 40 
21 0 100 
23 0 100 
25 90 10 
30 90 10 
a Flow rate = 1 mL/min; At ambient temperature. 
 
9.5.7 High Resolution Mass Spectrometry of the Antarctic Oligopeptides 
Accurate masses for the Antarctic oligopeptides were determined with semi-pure 
fractions using the instrumentation and protocols described in Section 9.1.5. 
 
9.5.8 Amino Acid Analysis of the Antarctic Microcystins 
The identity and stereochemistry of the amino acids in the Antarctic microcystins 
were determined using the protocols described in Section 9.1.5 and a semi-pure 
mixture of the -LR and the -RR microcystin congeners (200 µg each). 
 
 
9.6 WORK DESCRIBED IN CHAPTER SIX 
9.6.1 Sample Preparation 
Seven different sample preparations were utilised during this study. All 
preparations used CHCA as a matrix and either a 384-spot polished steel MALDI 
target (Bruker Daltonics) or a 600 µm anchorchip. Angiotensin I was utilised as 
an internal standard to enhance reproducibility and zinc sulfate heptahydrate was 
added to eliminate sodium and potassium adducts.
297
 Microcystin (MC) standards 
([Dha
7
] MC-LR, MC-YR or MC-RR) were dissolved in 40% MeOH (v/v) and on 
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the day of the analyses were mixed 9:1 with 500 µM angiotensin I/50 mM Zn
2+
 
(IS), to yield final concentrations of 50 µM and 5 mM, respectively. Coefficients 
of variation (CVs) were measured using 2.5 µM microcystin. Method detection 
limits (MDLs) were determined using 40% MeOH (v/v) as a blank and 0.1 µM 
microcystin. CVs and MDLs were conducted on three separate days; the average 
of these three results is reported. 
 
The sonicated dried droplet preparation
184
 used a saturated solution of CHCA in 
EtOH/ACN/H2O (15:9:1), mixed 1:1 with the MC/IS solution and sonicated 
(35 W, 5 min). This MC/IS/CHCA solution (1 µL) was deposited onto either a 
polished steel or an anchorchip target, and allowed to dry at ambient temperature. 
The dried droplet preparation used CHCA saturated in EtOH/ACN/H2O (15:9:1; 
0.5 µL) mixed with the MC/IS solution (0.5 µL) directly on a polished steel or an 
anchorchip target. These preparations were allowed to dry at ambient temperature. 
 
The three thin-layer preparations were produced using a saturated solution of 
CHCA in acetone. The anchorchip thin-layer preparation was prepared by 
dragging a drop of matrix solution (5 µL) over the hydrophilic spots on the target 
using an auto-pipette tip and allowing the acetone to evaporate. MC/IS solution 
(0.5 µL) was then applied on top of the matrix crystals and allowed to dry at 
ambient temperature. 
 
The polished steel thin-layer-line preparation was made by dragging an auto-
pipette tip containing matrix solution (5 µL) along the length of the target and 
allowing the acetone to evaporate. MC/IS solution (0.5 µL) was then applied to 
the centre of this line of matrix crystals and allowed to dry at ambient temperature. 
The polished steel thin-layer-spot preparation was prepared by depositing a drop 
of matrix solution (0.2 µL) onto the centre of each sample spot and allowing the 
acetone to evaporate. MC/IS solution (0.5 µL) was then applied to the centre of 
the spot of matrix crystals and allowed to dry at ambient temperature. Prior to 
each use, the polished steel target was cleaned with a free-rinsing detergent, 
washed with water, sonicated in 50% MeOH (v/v), rinsed with water and dried 
with acetone. 
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All seven sample preparation techniques were assessed for CV and MDL using 
only [Dha
7
] MC-LR. The thin-layer-spot preparation performed on polished steel 
was also assessed for CV and MDL using MC-RR and MC-YR. 
 
Standard curves for [Dha
7
] MC-LR, MC-RR and MC-YR were constructed 
individually using 0.1-10 µM solutions diluted in 40% MeOH (v/v). These 
solutions were mixed 9:1 with IS to yield a final concentration of 50 µM 
angiotensin I and 5 mM Zn
2+
. This MC/IS solution (0.5 µL) was applied in 
quadruplicate to a thin-layer-spot preparation performed on polished steel and 
allowed to dry at ambient temperature. Each standard curve was constructed using 
the average of these four analyses. 
 
The laser power attenuation and varied volume experiments were both conducted 
using a 2.5 µM [Dha
7
] MC-LR solution which was mixed 9:1 with IS on the day 
of the analyses. The laser attenuation experiment used 0.5 µL of MC/IS solution 
on a thin-layer-spot preparation performed on polished steel. 
 
9.6.2 MALDI-TOF Mass Spectrometry 
Analyses were performed on the instrumentation described in Section 9.1.5. 
Spectra were obtained in positive ion reflectron mode with matrix suppression set 
at 400 Da and pulsed ion extraction of 90 ns. Spectra were accumulated from ten 
separate 25-shot acquisitions at different locations on each sample spot (250 shots 
total). Values expressed in this study were based on the [M+H]
+
 monoisotopic 
peak and did not include any adduct peaks. Only the peak height was utilised in 
accordance with the findings of previous studies.
297,298
 The peak height ratio (PHR) 
was found by dividing the microcystin signal by that of the internal standard. 
 
9.6.3 Statistical Treatments 
The MDL was determined by analysing seven replicates of the blank (x0) and a 
sample (xs) near the estimated detection limit (0.1 µM).
184
 The following equation 
was then used: 
 
MDL = 
 
m
bs 14.3
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where s is the standard deviation of the xs replicates, b and m are the intercept and 
the slope of a regression in the region of x0 to xs, and 3.14 is the one-tailed t-test 
value at the 99% confidence level. The limit of quantitation (LOQ) was calculated 
using a multiplier of 10 instead of 3.14. 
 
 
9.7 WORK DESCRIBED IN CHAPTER SEVEN 
9.7.1 Culture and Sampling Conditions 
Six autoclaved 1 L Schott bottles containing MLA medium
296
 (800 mL) were 
inoculated with Microcystis CYN06 (4 mL at 8×10
6
 cells/mL). Cultures were 
grown at 20 °C with a photon-flux of 54 μEin∙m-2∙s-1 (12:12 h light/dark) whilst 
being continuously aerated with sterile filtered air (300 mL/min). 
 
Each culture was grown for 36 days and sampled once a week, 2 h after the light 
phase had begun. The pH was measured using litmus paper. A sample for nutrient 
analysis (15 mL) was filtered (0.45 µm) and stored at −20 °C. A sample for cell 
enumeration (1 to 5 mL) was preserved immediately with Lugol’s solution (20 µL) 
and stored in the dark. A sample for microcystin analysis (5 mL) was taken and 
concentrated as follows. The sample was pressurised in a blocked syringe to break 
gas vesicles in the cells and allow them to be pelleted by centrifugation (2,850 rcf, 
15 min). The supernatent was removed and the pellet transferred to a 
microcentrifuge tube and centrifuged (14,000 rcf, 5 min). The remaining 
supernatant was removed before the sample was lyophilised and stored at −20 C 
until extracted for microcystin analysis. 
 
On day 40, the cultures were sampled for nutrient analysis and supplemented with 
additional nutrients. At this point, 550 mL of culture remained. Additional 
phosphorous (0.1 mM; 137.5 µL of 400 mM K2HPO4) was added to each culture. 
Additional nitrate (≈ 2 mM; 275 µL of 2 M NaNO3) was added to three randomly 
selected cultures, however, the subsequent nutrient analysis showed this to only 
be 1.5 mM of additional nitrate. Water (275 µL) was added to the remaining three 
cultures (negative control). Samples for nutrient analysis, cell enumeration and 
microcystin analysis were acquired immediately following the manipulation. For 
the following 16 days, samples for cell enumeration and microcystin analysis 
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were taken every second day and a sample for nutrient analysis was taken every 
fourth day. 
 
9.7.2 LC-MS/MS Quantitation of Microcystins in CYN06 
The lyophilised cells were sonicated (35 W, 30 min) in HPLC-grade MeOH 
(0.3-0.7 mL) and clarified by centrifugation (14,000 rcf, 5 min). The supernatant 
(180 µL) was then diluted 1:9 in 50% HPLC-grade MeOH (1,620 µL; v/v) 
directly in a septum-capped LC vial. 
 
The microcystin concentration of the resulting extracts was determined by 
LC-MS/MS using the instrumentation described in Section 9.1.5. The extract 
(20 µL) was separated on a C18 column (Ascentis Express C18, 100 × 2.1 mm, 
2.7-µ; Supleco Analytical) using the H2O→ACN gradient outlined in Table 9.9 
(200 µL/min, 40 °C). 
 
Table 9.9: HPLC gradient for microcystin quantitation by LC-MS/MS. 
a
 
Time 
(min) 
%A 
(98:2 H2O/ACN 
+ 0.1% Formic Acid) 
%B 
(2:98 H2O/ACN 
+ 0.1% Formic Acid) 
0 80 20 
1 80 20 
2 70 30 
12 40 60 
13 0 100 
15 0 100 
16 80 20 
20 80 20 
a Flow rate = 200 µL/min; Column temperature = 40 °C. 
 
Microcystins were detected by negative ion ESI MS, using a capillary voltage of 
3.5 kV and a nebuliser pressure of 3.0 bar. Desolvation was accomplished with a 
nitrogen flow of 8 L/min at 250 °C. The parent ions were fragmented by CID 
using helium as the collision gas and a collision amplitude of 0.85. 
 
Microcystis CYN06 produces at least 27 different microcystin congeners, 
however many of these are produced at very low levels. Only those microcystins 
produced at moderate to high levels (MC-RR, MC-YR, [Asp
3
] MC-LR, MC-LR, 
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MC-FR, MC-WR, MC-RA, MC-RAba, MC-LA, MC-FA, MC-WA, MC-FL and 
MC-WL) were assessed in the current study. 
 
A multiple reaction monitoring (MRM) method was used to determine the 
abundance of each of the microcystin congeners. The [M−H]− ion was collected, 
fragmented by CID and the resulting [M−H2O−H]
−
 ion was used to determine the 
quantity of microcystin present in the sample. To increase the scan rate, the MRM 
method was split into eight segments corresponding to the retention time of the 
microcystin congener being monitored and a maximum of two ions were assessed 
at any given time. The ions acquired in each segment of the MRM method are 
listed in Table 9.10. 
 
Table 9.10: Multiple reaction monitoring method for microcystin 
quantification by LC-MS/MS. 
Time (min) Microcystin [M−H]− [M−H2O−H]
−
 
0.00-5.50 MC-RR 1036.5 1018.5 
5.50-6.00 MC-YR 1022.5 1004.5 
6.00-6.45 
 
[Asp
3
] MC-LR 
MC-LR 
979.5 
993.5 
961.5 
975.5 
6.45-7.00 
 
MC-FR 
MC-WR 
1027.5 
1068.5 
1009.5 
1048.5 
7.00-9.50 
 
MC-RA 
MC-RAba 
951.5 
965.5 
933.5 
947.5 
9.50-10.25 
 
MC-LA 
MC-FA 
908.5 
942.5 
890.5 
924.5 
10.25-12.00 
 
MC-FA 
MC-WA 
942.5 
981.5 
924.5 
963.5 
12.00-20.00 
 
MC-FL 
MC-WL 
984.5 
1023.5 
966.5 
1005.5 
 
 
The concentration of microcystin present was determined by comparing the 
abundance of the [M−H2O−H]
−
 ion with a standard curve constructed using a 
mixture of three microcystin standards (MC-LR, 0.5-1,000 nM; MC-RR and 
MC-YR, 0.25-500 nM). For those microcystin congeners not present in the 
standard, the concentration was calculated in comparison with the MC-LR 
standard curve. Quality control checks were conducted every eighteen injections 
using calibration standards (1 or 10 nM). 
 
Chapter 9 
196 
 
9.7.3 Cell Enumeration 
Microcystis colonies were disrupted using a Potter-Elvehjem mortar and pestle. 
Cell concentrations were determined using a Whipple grid and an Utermöhl 
settling chamber.
299
 
 
9.7.4 Dissolved Nutrient Analysis 
Samples of filtered medium were analysed for dissolved nutrient concentrations 
(nitrite, total oxidised nitrogen species, ammonia and dissolved reactive 
phosphorus). Assessment of the samples collected on days 1, 36 and 56 indicated 
that ammonia concentrations were below the detection limit, therefore the other 
samples were not analysed for ammonia concentration. 
 
9.7.5 Statistical Treatments 
All statistical analyses were performed using Minitab 15, where p-values ≤ 0.05 
were considered significant. 
 
Data Transformation 
Two variables were assessed during the experiment (intracellular microcystin 
content and microcystin congener abundance). Intracellular microcystin content 
was determined by dividing the microcystin concentration (MC/mL) by the cell 
concentration (cells/mL). Microcystin congener abundance was expressed as the 
percentage of the concentration of an individual microcystin congener compared 
to the total microcystin concentration. At times, the grouped microcystin congener 
abundance was utilised, which was the sum of the abundance for each individual 
congener present in the group. 
 
Regression Analysis 
Relationships between the intracellular microcystin content and incubation time or 
between intracellular microcystin content and nitrate concentration were 
determined using linear regression analysis. Linear regression of the data for each 
culture replicate was used to produce gradients which were compared for 
statistically significant differences. 
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Analysis of Variance 
One-way analysis of variance (ANOVA) was used to determine if there were 
significant differences within a dataset. When a significant difference was 
detected, multiple Student’s t-tests were used to determine where the significant 
difference lay. 
 
Student’s t-test 
Multiple two-sample Student’s t-tests were used to determine p-values for the 
differences observed between the gradients produced from linear regression and 
for each grouped microcystin congener abundance over time. These p-values were 
collated in correlation matrices (Appendix K.2, K.5 and K.6) and used to 
determine where significant differences between the two parameters were located. 
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Appendix A: Structures, molecular masses and bioactivity data for the known microcystins.
 
 
Microcystin Mr
a
 
(Da) 
X Z A B R1 R2 R3 R4 
PPIA
b
 
(IC50; nM) 
Toxicity
c 
(LD50; µg/kg) 
Ref.
d
 
[Asp
3
] MC-LA (8) 895.5 Leu Ala Ala Dha CH3 H CH3 H     34 
MC-LA (9) 909.5 Leu Ala Ala Dha CH3 H CH3 CH3     32 
[Asp
3
, Glu(OMe)
6
] MC-LAba (10) 923.5 Leu Aba Ala Dha CH3 CH3 CH3 H     35 
MC-LAba (11) 923.5 Leu Aba Ala Dha CH3 H CH3 CH3     36,249 
[Asp
3
] MC-FA (162) 929.5 Phe Ala Ala Dha CH3 H CH3 H   This Study 
MC-LV (12) 937.5 Leu Val Ala Dha CH3 H CH3 CH3     37 
[Asp
3
] MC-LL (13) 937.5 Leu Leu Ala Dha CH3 H CH3 H     34 
NH
O
Z
H
N
H
N X
HN
N
B NH
HN
AO
O
O
O O
O
O
HO O
R3
R1
OO
R4
R2
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[Asp
3
] MC-RA (160) 938.5 Arg Ala Ala Dha CH3 H CH3 H   This Study 
MC-FA (163) 943.5 Phe Ala Ala Dha CH3 H CH3 CH3     This Study 
MC-LL (14) 951.5 Leu Leu Ala Dha CH3 H CH3 CH3     37 
MC-AR (15) 952.5 Ala Arg Ala Dha CH3 H CH3 CH3   250 38 
MC-RA (16) 952.5 Arg Ala Ala Dha CH3 H CH3 CH3     39 
[Asp
3
] MC-RAba (161) 952.5 Arg Aba Ala Dha CH3 H CH3 H   This Study 
MC-FAba (166) 957.5 Phe Aba Ala Dha CH3 H CH3 CH3   This Study 
MC-YA (17) 959.5 Tyr Ala Ala Dha CH3 H CH3 CH3     31 
MC-AHar (18) 966.5 Ala Har Ala Dha CH3 H CH3 CH3   40 
MC-RAba (19) 966.5 Arg Aba Ala Dha CH3 H CH3 CH3   41 
[Gly
1
, Asp
3
, Dhb
7
] MC-LR (179) 966.5 Leu Arg Gly Dha CH3 H CH3 H     This Study 
[Asp
3
, Dha
7
] MC-LR (20) 966.5 Leu Arg Ala Dha H H CH3 H     42 
[Asp
3
] MC-WA (164) 968.5 Trp Ala Ala Dha CH3 H CH3 H   This Study 
[Asp
3
, Dha
7
] MC-EE(OMe) (21) 969.4 Glu Glu(OMe) Ala Dha H H CH3 H     43 
MC-LM (22) 969.5 Leu Met Ala Dha CH3 H CH3 CH3     37 
[Asp
3
] MC-LF (23) 971.5 Leu Phe Ala Dha CH3 H CH3 H     
 
44 
MC-VF (24) 971.5 Val Phe Ala Dha CH3 H CH3 CH3     45 
[Asp
3
, Dha
7
] MC-LY (25) 973.5 Leu Tyr Ala Dha H H CH3 H     41 
MC-YAba (26) 974.5 Tyr Aba Ala Dha CH3 H CH3 CH3   41 
MC-VR (27) 980.5 Val Arg Ala Dha CH3 H CH3 CH3     46 
MC-RV (28) 980.5 Arg Val Ala Dha CH3 H CH3 CH3   41 
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Microcystin Mr
a
 
(Da) 
X Z A B R1 R2 R3 R4 
PPIA
b
 
(IC50; nM) 
Toxicity
c 
(LD50; µg/kg) 
Ref.
d
 
MC-RApa (29) 980.5 Arg Apa Ala Dha CH3 H CH3 CH3   41 
[Gly
1
, Asp
3
, Dhb
7
] MC-LHar (180) 980.5 Leu Har Gly Dha CH3 H CH3 H     This Study 
[Asp
3
] MC-LR (30) 980.5 Leu Arg Ala Dha CH3 H CH3 H   160-300 47,74 
[Asp
3
, Dhb
7
] MC-LR (31) 980.5 Leu Arg Ala Dhb H H CH3 H   70 48,61 
[DMAdda
5
] MC-LR (32) 980.5 Leu Arg Ala Dha CH3 H H CH3 1.5 90-100 38,82 
[Dha
7
] MC-LR (33) 980.5 Leu Arg Ala Dha H H CH3 CH3 5 250 38,42,82 
MC-AW (34) 982.5 Ala Trp Ala Dha CH3 H CH3 CH3     49 
MC-WA (165) 982.5 Trp Ala Ala Dha CH3 H CH3 CH3     This Study 
[Dha
7
] MC-EE(OMe) (35) 983.4 Glu Glu(OMe) Ala Dha H H CH3 CH3     43 
[Asp
3
, Dha
7
] MC-E(OMe)E(OMe) (36) 983.4 Glu(OMe) Glu(OMe) Ala Dha H H CH3 H     43 
MC-LF (37) 985.5 Leu Phe Ala Dha CH3 H CH3 CH3     37 
MC-FL (168) 985.5 Phe Leu Ala Dha CH3 H CH3 CH3   This Study 
[Asp
3
] MC-LY (38) 987.5 Leu Tyr Ala Dha CH3 H CH3 H   41 
[Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] MC-LR (181) 994.5 Leu Arg Gly Dha CH3 H COCH3 H     This Study 
[Asp
3
, Dhb
7
] MC-HilR (39) 994.5 Hil Arg Ala Dhb H H CH3 H     50 
[Asp
3
, Glu(OMe)
6
] MC-LR (40) 994.5 Leu Arg Ala Dha CH3 CH3 CH3 H     51 
MC-LR (7) 994.5 Leu Arg Ala Dha CH3 H CH3 CH3 0.3 50 31,82,115 
MC-RL (41) 994.5 Arg Leu Ala Dha CH3 H CH3 CH3   41 
[(6Z)Adda
5
] MC-LR (42) 994.5 Leu Arg Ala Dha CH3 H CH3 CH3   > 1,200 52,82,121 
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MC-WAba (167) 996.5 Trp Aba Ala Dha CH3 H CH3 CH3   This Study 
[Dha
7
] MC-E(OMe)E(OMe) (43) 997.5 Glu(OMe) Glu(OMe) Ala Dha H H CH3 CH3     43 
[Ser
7
] MC-LR (44) 998.5 Leu Arg Ala Ser H H CH3 CH3     53 
[Asp
3
] MC-HilY (45) 1001.5 Hil Tyr Ala Dha CH3 H CH3 H    41 
[Asp
3
, Ser
7
] MC-E(OMe)E(OMe) (46) 1001.5 Glu(OMe) Glu(OMe) Ala Ser H H CH3 H     43 
[Ser
7
] MC-EE(OMe) (47) 1001.5 Glu Glu(OMe) Ala Ser H H CH3 CH3     43 
MC-LY (48) 1001.5 Leu Tyr Ala Dha CH3 H CH3 CH3     45 
MC-YL (49) 1001.5 Tyr Leu Ala Dha CH3 H CH3 CH3     35 
[Asp
3
, MeSer
7
] MC-LY (50) 1005.5 Leu Tyr Ala Ser CH3 H CH3 H    41 
[Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] MC-LHar (182) 1008.5 Leu Har Gly Dha CH3 H COCH3 H     This Study 
[Asp
3
, ADMAdda
5
, Dhb
7
] MC-LR (51) 1008.5 Leu Arg Ala Dhb H H COCH3 H     54 
[Asp
3
, ADMAdda
5
] MC-LR (52) 1008.5 Leu Arg Ala Dha CH3 H COCH3 H ≈ 1 160 55,56,80 
[Glu(OMe)
6
] MC-LR (53) 1008.5 Leu Arg Ala Dha CH3 CH3 CH3 CH3 > 100 > 1,000 33,51,82 
[Mdhb
7
] MC-LR (54) 1008.5 Leu Arg Ala Dhb CH3 H CH3 CH3     
 
56 
MC-HilR (55) 1008.5 Hil Arg Ala Dha CH3 H CH3 CH3   100 57 
[Gly
1
, Asp
3
, Dhb
7
] MC-RR (183) 1009.5 Arg Arg Gly Dha CH3 H CH3 H     This Study 
[Asp
3
, Dha
7
] MC-RR (56) 1009.5 Arg Arg Ala Dha H H CH3 H     47 
[Asp
3
] MC-LW (57) 1010.5 Leu Trp Ala Dha CH3 H CH3 H     44 
[MeSer
7
] MC-LR (58) 1012.6 Leu Arg Ala Ser CH3 H CH3 CH3    150 38,57 
[Asp
3
] MC-FR (59) 1014.5 Phe Arg Ala Dha CH3 H CH3 H     58 
[Dha
7
] MC-FR (60) 1014.5 Phe Arg Ala Dha H H CH3 CH3     59 
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Microcystin Mr
a
 
(Da) 
X Z A B R1 R2 R3 R4 
PPIA
b
 
(IC50; nM) 
Toxicity
c 
(LD50; µg/kg) 
Ref.
d
 
[Asp
3
] MC-RF (61) 1014.5 Arg Phe Ala Dha CH3 H CH3 H   41 
[Ser
7
] MC-E(OMe)E(OMe) (62) 1015.5 Glu(OMe) Glu(OMe) Ala Ser H H CH3 CH3     43 
[Asp
3
, Dha
7
] MC-RY (63) 1016.5 Arg Tyr Ala Dha H H CH3 H    41 
MC-YM (64) 1019.5 Tyr Met Ala Dha CH3 H CH3 CH3     35 
[Asp
3
, ADMAdda
5
] MC-LHar (65) 1022.5 Leu Har Ala Dha CH3 H COCH3 H     56,72 
[ADMAdda
5
] MC-LR (66) 1022.5 Leu Arg Ala Dha CH3 H COCH3 CH3   ≈ 60 55,56 
[Gly
1
, Asp
3
, Dhb
7
] MC-RHar (184) 1023.6 Arg Har Gly Dha CH3 H CH3 H     This Study 
[Asp
3
] MC-RR (67) 1023.6 Arg Arg Ala Dha CH3 H CH3 H  250 60 
[Asp
3
, Dhb
7
] MC-RR (68) 1023.6 Arg Arg Ala Dhb H H CH3 H   250 61 
[Dha
7
] MC-RR (69) 1023.6 Arg Arg Ala Dha H H CH3 CH3   180 62 
MC-LW (70) 1024.5 Leu Trp Ala Dha CH3 H CH3 CH3     45 
MC-WL (169) 1024.5 Trp Leu Ala Dha CH3 H CH3 CH3   This Study 
MC-M(O)R (71) 1028.5 Met(O) Arg Ala Dha CH3 H CH3 CH3   700-800 38 
MC-FR (72) 1028.5 Phe Arg Ala Dha CH3 H CH3 CH3   250 38 
MC-RF (73) 1028.5 Arg Phe Ala Dha CH3 H CH3 CH3   41 
[Dha
7
] MC-HphR (74) 1028.5 Hph Arg Ala Dha H H CH3 CH3    63 
[Asp
3
] MC-YR (75) 1030.5 Tyr Arg Ala Dha CH3 H CH3 H     64 
[Dha
7
] MC-YR (76) 1030.5 Tyr Arg Ala Dha H H CH3 CH3     65 
[Asp
3
, Dha
7
] MC-HtyR (77) 1030.5 Hty Arg Ala Dha H H CH3 H     63 
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[Asp
3
] MC-RY (78) 1030.5 Arg Tyr Ala Dha CH3 H CH3 H     66 
[Dha
7
] MC-RY (79) 1030.5 Arg Tyr Ala Dha H H CH3 CH3   41 
MC-LY(OMe) (80) 1031.5 Leu Tyr(OMe) Ala Dha CH3 H CH3 CH3   41 
MC-YM(O) (81) 1035.5 Tyr Met(O) Ala Dha CH3 H CH3 CH3   56 67 
[Leu
1
] MC-LR (82) 1036.6 Leu Arg Leu Dha CH3 H CH3 CH3 0.3-4.43 100 68,111 
[ADMAdda
5
] MC-HilR (83) 1036.6 Hil Arg Ala Dha CH3 H COCH3 CH3    69 
[ADMAdda
5
] MC-LHar (84) 1036.6 Leu Har Ala Dha CH3 H COCH3 CH3   ≈ 60 55,56 
MC-RR (85) 1037.6 Arg Arg Ala Dha CH3 H CH3 CH3   500-600 70,119,120 
[Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] MC-RR (185) 1037.5 Arg Arg Gly Dha CH3 H COCH3 H     This Study 
[Asp
3
] MC-YY (86) 1053.5 Tyr Tyr Ala Dha CH3 H CH3 H     41 
[Asp
3
, Glu(OMe)
6
] MC-RR (87) 1037.6 Arg Arg Ala Dha CH3 CH3 CH3 H     71 
[(6Z)Adda
5
] MC-RR (88) 1037.6 Arg Arg Ala Dha CH3 H CH3 CH3   > 1,200 
 
52,121 
[Ser
1
, ADMAdda
5
] MC-LR (89) 1038.5 Leu Arg Ser Dha CH3 H COCH3 CH3     72 
[ADMAdda
5
, MeSer
7
] MC-LR (90) 1040.6 Leu Arg Ala Ser CH3 H COCH3 CH3     72 
[Asp
3
, MeSer
7
] MC-RR (91) 1041.6 Arg Arg Ala Ser CH3 H CH3 H     73 
[Ser
7
] MC-RR (92) 1041.6 Arg Arg Ala Ser H H CH3 CH3     53 
[Asp
3
, Dhb
7
] MC-HtyR (93) 1044.5 Hty Arg Ala Dhb H H CH3 H    70 48,61 
[Dha
7
] MC-HtyR (94) 1044.5 Hty Arg Ala Dha H H CH3 CH3     63 
[Asp
3
] MC-HtyR (95) 1044.5 Hty Arg Ala Dha CH3 H CH3 H   160-300 74 
MC-YR (96) 1044.5 Tyr Arg Ala Dha CH3 H CH3 CH3   68 31,120 
MC-RY (97) 1044.5 Arg Tyr Ala Dha CH3 H CH3 CH3     66 
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Microcystin Mr
a
 
(Da) 
X Z A B R1 R2 R3 R4 
PPIA
b
 
(IC50; nM) 
Toxicity
c 
(LD50; µg/kg) 
Ref.
d
 
[Asp
3
, MeSer
7
] MC-RY (98) 1048.5 Arg Tyr Ala Ser CH3 H CH3 H   41 
[Ser
7
] MC-YR (99) 1048.5 Tyr Arg Ala Ser H H CH3 CH3   75 
MC-(H4)YR (100) 1048.6 (H4)Tyr Arg Ala Dha CH3 H CH3 CH3     57 
[Gly
1
, Asp
3
, ADMAdda
5
, Dhb
7
] MC-RHar (186) 1051.5 Arg Har Gly Dha CH3 H COCH3 H     This Study 
[Asp
3
, Dhb
7
] MC-HtyY (101) 1051.5 Hty Tyr Ala Dhb H H CH3 H     76 
[Asp
3
, ADMAdda
5
, Dhb
7
] MC-RR (102) 1051.5 Arg Arg Ala Dhb H H COCH3 H    200 54 
[Glu(OC3H6OH)
6
] MC-LR (103) 1052.6 Leu Arg Ala Dha CH3 C3H6OH CH3 CH3    > 1,000 38,57 
[Asp
3
] MC-WR (104) 1053.5 Trp Arg Ala Dha CH3 H CH3 H     58 
MC-HtyR (105) 1058.5 Hty Arg Ala Dha CH3 H CH3 CH3   80-100 
 
74 
[Ser
7
] MC-HtyR (106) 1062.5 Hty Arg Ala Ser H H CH3 CH3     63 
[MeSer
7
] MC-YR (107) 1062.5 Tyr Arg Ala Ser CH3 H CH3 CH3   77 
[MeSer
7
] MC-RY (108) 1062.5 Arg Tyr Ala Ser CH3 H CH3 CH3   41 
MC-HarHar (109) 1065.6 Har Har Ala Dha CH3 H CH3 CH3     78 
[Asp
3
, Dhb
7
] MC-HtyHty (110) 1065.5 Hty Hty Ala Dhb H H CH3 H     76 
[ADMAdda
5
] MC-RR (111) 1065.6 Arg Arg Ala Dha CH3 H COCH3 CH3     79 
MC-WR (112) 1067.5 Trp Arg Ala Dha CH3 H CH3 CH3   150-200  38 
[Asp
3
, ADMAdda
5
] MC-HtyR (113) 1072.5 Hty Arg Ala Dha CH3 H COCH3 H ≈ 1.29   80 
[Asp
3
, ADMAdda
5
, Dhb
7
] MC-HtyR (114) 1072.5 Hty Arg Ala Dhb H H COCH3 H   100 54 
MC-RY(OMe) (115) 1074.5 Arg Tyr(OMe) Ala Dha CH3 H CH3 CH3   41 
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[ADMAdda
5
] MC-(H4)YR (116) 1076.6 (H4)Tyr Arg Ala Dha CH3 H COCH3 CH3     69 
[MeLan
7
] MC-LR (117) 1115.6 Leu Arg Ala Lan CH3 H CH3 CH3   1000 57 
Also reported was a linear form of a microcystin: seco[Asp
3
] MC-RR (119).
71
 
a
 Molecular weights are rounded to one decimal place. 
b
 PPIA = Protein phosphatase inhibition assay. 
c
 Performed using the mouse bioassay.
153
 
d
 Ref = Reference(s). 
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Appendix B: Studies on microcystin (MC) concentration in response to environmental factors. 
a
 
Parameter Organism Analysis Method 
b
 
Change in MC 
Concentration/Toxicity 
Information Yielded References 
Temperature (C)  
10-28 
Anabaena species 
Continuous cultures 
HPLC
 
3-10 Lowest at 10 C; Highest at 25 C 130 
10, 25, 34 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 5 Lowest toxicity at 10 C; Highest at 25 C 131 
15-35 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 
HPLC 
4 
Highest toxicity at 20 C; Different levels of 
microcystin congeners at different temperatures 
132,133 
18, 25, 35 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 1.4 Lowest toxicity at 32 C; Highest at 18 C 134 
20, 28 
Microcystis aeruginosa, 
Semi-continuous cultures 
HPLC NC 
Different levels of microcystin congeners at 
different temperatures 
135 
15-30 
Oscillatoria agardhii 
Batch cultures 
HPLC 7 Strain dependent; Lowest at 30 C 136 
Light (µEin·m
-2
·s
-1
)  
2-100; continuous 
Anabaena species 
Batch cultures 
HPLC 3 Highest at 25 µEin·m
-2
·s
-1
 137 
7, 19, 42; continuous 
Anabaena species 
Continuous cultures 
HPLC 2.5-15 Lowest at 10 µEin·m
-2
·s
-1
; Highest at 25 µEin·m
-2
·s
-1
 130 
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5-50; continuous 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 2.4 Highest toxicity at 20 µEin·m
-2
·s
-1
 131 
20-75; continuous 
Microcystis aeruginosa 
Continuous cultures 
HPLC 2.5 Highest at 40 µEin·m
-2
·s
-1
 138 
21-205; continuous 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 1.2 
Lowest toxicity at 21 µEin·m
-2
·s
-1
; Highest at 
142 µEin·m
-2
·s
-1
 
132 
7.5, 30, 75; continuous 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 3.8 
Lowest toxicity at 7.5 µEin·m
-2
·s
-1
; Highest at 
30 µEin·m
-2
·s
-1
 
134 
12-95; continuous 
Oscillatoria agardhii 
Batch cultures 
HPLC 2.5 Highest at 12-44 µEin·m
-2
·s
-1
 136 
6-112; 12 h/12 h 
Planktothrix agardhii 
Batch cultures 
HPLC 
ELISA
 10 
Lowest at 6 µEin·m
-2
·s
-1
; Highest at 60 µEin·m
-2
·s
-1
; 
Different levels of microcystin congeners at different 
photon irradiations 
148 
Phosphorous (mg/L)  
0.05-5.5 
Anabaena species 
Batch cultures 
HPLC 5 Lowest at 0.05 mg/L; Highest at 5.5 mg/L 137 
BG-11 medium; 
with and without phosphorous 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 1.7 
Higher toxicity with the medium without 
phosphorous 
131 
0.0025, 0.025 
Microcystis aeruginosa 
Continuous cultures 
HPLC 2.3 Higher at 0.025 mg/L 139 
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Parameter Organism Analysis Method 
b
 
Change in MC 
Concentration/Toxicity 
Information Yielded References 
Phosphorous (mg/L) continued  
MA medium; 
diluted 1/10 and 1/20 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay <1 Highest toxicity with the undiluted medium 134 
0.1-5.5 
Oscillatoria agardhii 
Batch cultures 
HPLC 1.7-2.5 Lowest at 0.1 mg/L 136 
Nitrogen (mg/L)  
BG-11 medium; 
with and without nitrogen 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 5 Higher toxicity with the medium containing nitrogen 131 
0.05-1.0 
Microcystis aeruginosa 
Continuous cultures 
HPLC 3 Higher with high nitrogen 139 
MA medium; 
diluted 1/10 and 1/20 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 2.5 Highest toxicity with the undiluted medium 134 
Z8 medium; 
plus 4.3 mg/L of NH4NO3 
Microcystis aeruginosa 
Semi-continuous cultures 
HPLC 0.5 Lower with added NH4NO3 135 
0.42-0.84 
Oscillatoria agardhii 
Batch cultures 
HPLC 5 Lowest with low nitrogen; Higher with high nitrogen 136 
Micronutrients  
Al, Cd, Cr, Cu, Fe, Mn, Ni, Sn, 
Zn; at various concentrations 
Microcystis aeruginosa 
Batch cultures 
HPLC 1.7 
Higher with lower Fe concentrations; Zn required 
for toxin production 
140 
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0.1-3.4 µg/L of Fe 
Microcystis aeruginosa 
Continuous cultures 
HPLC 1.5 Higher with higher Fe concentrations 139 
0.03-1.2 µg/L of Fe 
Microcystis aeruginosa 
Continuous cultures 
HPLC 0-3 Higher with lower Fe concentrations 141 
56, 560 µg/L of Fe 
Microcystis aeruginosa 
Semi-continuous cultures 
HPLC 2 Higher with higher Fe concentrations 135 
Carbon Dioxide  
BG-11 medium; 
with and without CO2 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 6 Higher toxicity with the medium containing CO2 131 
pH  
1-14 
Microcystis aeruginosa 
Batch cultures 
Mouse bioassay 1.8 Toxicity highest at low and high pH 300 
Cell Density (cells/mL)  
500,000-7,000,000 
Microcystis assemblage 
Lake mesocosms 
ELISA 13.8 
After cell density reached a threshold; Microcystin 
content increased with higher cell density 
301 
a
 Adapted from Table 3.8 of Reference 12. 
b
 HPLC = High pressure liquid chromatography; ELISA = Enzyme-linked immunosorbent assay. 
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Appendix C: Microcystin (MC) congeners produced by reported cyanobacterial strains.
a
 
Cyanobacterial Strain Microcystins Identified 
Number 
of MCs 
b
 
Position 
Two 
c 
Position 
Four 
d
 
Other 
Modifications 
Potential 
MCs 
e
 
Ref. 
f
 
Anabaena 18B6 [Dha
7
] MC-RR; [Asp
3
, Dha
7
] MC-RR; Unidentified MCs × 2 
4 Arg Arg 
Pos. 3 × 2 
Pos. 7 × 1 
- 245 
Anabaena 60 MC-LR; [Asp
3
] MC-LR; MC-RR; [Asp
3
] MC-RR 
4 
Leu 
Arg 
Arg Pos. 3 × 2 4 302 
Anabaena 66 [Dha
7
] MC-HphR; [Dha
7
] MC-HtyR; [Ser
7
] MC-HtyR; 
[Asp
3
, Dha
7
] MC-HtyR 
4 
Hph 
Hty 
Arg 
Pos. 3 × 2 
Pos. 7 × 2 
8 
63, 
302 
Anabaena 66A [Dha
7
] MC-LR; [Ser
7
] MC-LR; [Asp
3
, Ser
7
] MC-LR; 
[Asp
3
, Dha
7
] MC-LR; [Dha
7
] MC-FR; [Asp
3
, Dha
7
] MC-FR; 
[Dha
7
] MC-HphR; [Asp
3
, Dha
7
] MC-HphR; MC-HtyR; 
[Dha
7
] MC-HtyR; [Ser
7
] MC-HtyR; [Asp
3
, Dha
7
] MC-HtyR; 
[Asp
3
, Ser
7
] MC-HtyR; Unidentified MCs × 20 
33 
Leu 
Phe 
Hph 
Hty 
Arg 
Pos. 3 × 2 
Pos. 7 × 3 
- 245 
Anabaena 90 MC-LR; [Asp
3
] MC-LR; [DMAdda
5
] MC-LR; 
[Dha
7
] MC-LR; [MeSer
7
] MC-LR; [Asp
3
, MeSer
7
] MC-LR; 
MC-HilR; [Asp
3
] MC-HilR; MC-RR; [Asp
3
] MC-RR; 
[Dha
7
] MC-RR 
11 
Leu 
Hil 
Arg 
Arg 
Pos. 3 × 2 
Pos. 5 × 2 
Pos. 7 × 3 
36 
112,130, 
245,302 
Anabaena 141 MC-LR; [Asp
3
] MC-LR; MC-RR; [Asp
3
] MC-RR 
4 
Leu 
Arg 
Arg Pos. 3 × 2 4 302 
Anabaena 186 [Dha
7
] MC-E(OMe)E(OMe); [Ser
7
] MC-E(OMe)E(OMe); 
[Asp
3
, Dha
7
] MC-E(OMe)E(OMe); 
[Asp
3
, Ser
7
] MC-E(OMe)E(OMe); [Dha
7
] MC-EE(OMe); 
[Ser
7
] MC-EE(OMe); [Asp
3
, Dha
7
] MC-EE(OMe) 
7 
Glu 
Glu(OMe) 
Glu(OMe) 
Pos. 3 × 2 
Pos. 7 × 2 
8 43 
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Anabaena 202 A1 [Dha
7
] MC-LR; [Asp
3
, Dha
7
] MC-LR; [Ser
7
] MC-LR; 
[Asp
3
, Ser
7
] MC-HilR; [Dha
7
] MC-RR; 
[Asp
3
, Dha
7
] MC-RR; [Ser
7
] MC-RR 
7 
Leu 
Hil 
Arg 
Arg 
Pos. 3 × 2 
Pos. 7 × 2 
12 53, 
302 
Anabaena 202 A2 [Dha
7
] MC-LR; [Asp
3
, Dha
7
] MC-LR; [Ser
7
] MC-LR; 
[Dha
7
] MC-RR; [Asp
3
, Dha
7
] MC-RR; [Ser
7
] MC-RR 
6 
Leu 
Arg 
Arg 
Pos. 3 × 2 
Pos. 7 × 2 
8 53,112, 
302 
Anabaena flos-aquae CYA83/1 MC-LR; [Asp
3
] MC-LR; MC-RR; [Asp
3
] MC-RR; 
[Glu(OMe)
6
] MC-LR; [Asp
3
, Glu(OMe)
6
] MC-LR 
6 
Leu 
Arg 
Arg 
Pos. 3 × 2 
Pos. 6 × 2 
8 51 
Anabaena flos-aquae NRC 525-17 MC-LR; [Asp
3
] MC-LR; MC-HtyR; [Asp
3
] MC-HtyR 
4 
Leu 
Hty 
Arg Pos. 3 × 2 4 74 
Fischerella CENA161 MC-LR 1 Leu Arg  1 93 
Hapalosiphon hibernicus BZ-3-1 MC-VA; [Asp
3
] MC-VA; MC-LA; [Asp
3
] MC-LA; 
[Dha
7
] MC-LA; [Asp
3
, DMAdda
5
] MC-LA; MC-LV; 
MC-LL; MC-RA; [Asp
3
] MC-RA 
10 
Val 
Leu 
Arg 
Ala 
Val 
Leu 
Pos. 3 × 2 
Pos. 5 × 2 
Pos. 7 × 2 
72 245 
Microcystis CYN06 MC-LA; [Asp
3
] MC-LA; MC-FA; [Asp
3
] MC-FA; MC-YA; 
MC-WA; [Asp
3
] MC-WA; MC-RA; [Asp
3
] MC-RA; 
MC-RAba; [Asp
3
] MC-RAba; MC-RL; MC-LAba; MC-FAba; 
MC-WAba; MC-LL; MC-FL; MC-WL; MC-LR; 
[Asp
3
] MC-LR; MC-FR; [Asp
3
] MC-FR; MC-YR; MC-WR; 
[Asp
3
] MC-WR; MC-RR; [Asp
3
] MC-RR 
27 
Leu 
Phe 
Tyr 
Trp 
Arg 
Ala 
Aba 
Leu 
Arg 
Pos. 3 × 2 40 
This 
Study 
Microcystis HUB 5-2-4 MC-LR; dmMC-LR; MC-RR; dmMC-RR; MC-YR 
5 
Leu 
Tyr 
Arg 
Arg DM × 2 6 
 
 
180 
Microcystis MB-K MC-LR; dmMC-LR; MC-YR; dmMC-YR 
4 
Leu 
Tyr 
Arg DM × 2 4 220 
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Cyanobacterial Strain Microcystins Identified 
Number 
of MCs 
b
 
Position 
Two 
c 
Position 
Four 
d
 
Other 
Modifications 
Potential 
MCs 
e
 
Ref. 
f
 
Microcystis MG-K MC-RR; dmMC-RR; MC-WR 
3 
Arg 
Trp 
Arg DM × 2 4 220 
Microcystis PCC7806 MC-LR; [Asp
3
] MC-LR; [Dha
7
] MC-LR; [MeSer
7
] MC-LR; 
[Asp
3
, Dha
7
] MC-LR; [Asp
3
, MeSer
7
] MC-LR; 
Unidentified MCs × 5 
11 Leu Arg 
Pos. 3 × 2 
Pos. 7 × 3 
- 
127, 
245 
Microcystis PCC7813 MC-LR; [Asp
3
] MC-LR 2 Leu Arg Pos. 3 × 2 2 180 
Microcystis aeruginosa MC-LR 1 Leu Arg  1 303 
Microcystis aeruginosa B2666 MC-LA; [Asp
3
] MC-LA; MC-LAba; [Asp
3
] MC-LAba; 
MC-LL; MC-LF; MC-LR; [MeSer
7
] MC-LR 
8 Leu 
Ala 
Aba 
Leu 
Phe 
Arg 
Pos. 3 × 2 
Pos. 7 × 2 
20 34 
Microcystis aeruginosa CALU972 [Dha
7
] MC-LR; [Asp
3
, Dha
7
] MC-LR; [Dha
7
] MC-RR; 
[Asp
3
, Dha
7
] MC-RR; [Dha
7
] MC-YR 5 
Leu 
Tyr 
Arg 
Arg 
Pos. 3 × 2 
Pos. 7 × 1 
6 65 
Microcystis aeruginosa K-139 [Dha
7
] MC-LR; [Asp
3
, Dha
7
] MC-LR 
2 Leu Arg 
Pos. 3 × 2 
Pos. 7 × 1 
2 112 
Microcystis aeruginosa MK10.10 MC-VR; MC-LR; MC-HilR 
3 
Val 
Leu 
Hil 
Arg  3 46 
 A
p
p
en
d
ix
 C
 
  
2
1
3
 
Microcystis aeruginosa NIES90 MC-LR; MC-YR; MC-RR 
3 
Leu 
Tyr 
Arg 
Arg  3 182 
Microcystis aeruginosa PCC7820 MC-LR; dmMC-LR; [Glu(OMe)
6
] MC-LR; MC-LF; 
dmMC-LF; MC-LW; dmMC-LW; MC-LL; MC-LM; 
MC-LY 
10 Leu 
Arg 
Phe 
Leu 
Met 
Trp 
Tyr 
DM × 2 
Pos. 6 × 2 
24 44 
Microcystis aeruginosa TN-2 MC-LR; MC-FR; [Asp
3
] MC-FR; MC-WR; [Asp
3
] MC-WR; 
MC-RR; MC-RA 
7 
Leu 
Phe 
Trp 
Arg 
Arg 
Ala 
Pos. 3 × 2 16 58 
Microcystis aeruginosa UAM1303 MC-LR; [Asp
3
] MC-LR; [MeSer
7
] MC-LR; MC-HilR; 
MC LY; MC-LF; MC-LW 
7 
Leu 
Hil 
Arg 
Tyr 
Phe 
Trp 
Pos. 3 × 2 
Pos. 7 × 2 
32 35 
Microcystis aeruginosa UTEX2666 MC-LA; [Asp
3
] MC-LA; MC-LAba; 
[Asp
3
, Glu(OMe)
6
] MC-LAba; MC-LR; 
[Asp
3
] MC-LR; didmMC-LR 
7 Leu 
Ala 
Aba 
Arg 
Pos. 3 × 2 
Pos. 6 × 2 
24 35 
Microcystis aeruginosa UTEX2670 MC-YA; MC-YL; MC-YM; MC-YM(O); Unidentified MC 
5 Tyr 
Ala 
Leu 
Met 
Met(O) 
 - 
 
 
 
35 
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Cyanobacterial Strain Microcystins Identified 
Number 
of MCs 
b
 
Position 
Two 
c 
Position 
Four 
d
 
Other 
Modifications 
Potential 
MCs 
e
 
Ref. 
f
 
Microcystis aeruginosa UV-006 MC-LA; MC-LAba; MC-LV; MC-LL; MC-LR; 
[Asp
3
] MC-LR; Unidentified MCs × 2 
8 Leu 
Ala 
Aba 
Val 
Leu 
Arg 
Pos. 3 × 2 ≥ 10 252 
Microcystis novacekii UAM250 MC-LR; MC-YR; MC-RR 
3 
Leu 
Tyr 
Arg 
Arg  3 304 
Microcystis viridis NIES102 [Asp
3
] MC-LR; [Dha
7
] MC-LR; [Ser
1
, Asp
3
, Dha
7
] MC-LR; 
MC-HilR; MC-FR; MC-YR; [Asp
3
] MC-YR; MC-HtyR; 
MC-WR; [Asp
3
] MC WR; MC-RR; [Asp
3
] MC-RR; 
Unidentified MCs × 35 47 
Leu 
Hil 
Phe 
Tyr 
Hty 
Trp 
Arg 
Arg 
Pos. 1 × 2 
Pos. 3 × 2 
Pos. 7 × 2 
- 245 
Nostoc 152 [Asp
3
, ADMAdda
5
] MC-VR; [DMAdda
5
] MC-LR; 
[ADMAdda
5
] MC-LR; [Mdhb
7
] MC-LR; [Ser
1
, ADMAdda
5
] 
MC-LR; [Ser
1
, Asp
3
, ADMAdda
5
] MC LR; [Asp
3
, DMAdda
5
] 
MC-LR; [ADMAdda
5
, MeSer
7
] MC-LR; [ADMAdda
5
, Dha
7
] 
MC-LR; [Asp
3
, ADMAdda
5
, Dha
7
] MC-LR; [ADMAdda
5
] 
MC-LHar; [DMAdda
5
] MC-LHar; [Asp
3
, ADMAdda
5
] 
MC-LHar; [ADMAdda
5
] MC-HilR; [ADMAdda
5
] 
MC-HilHar; [Asp
3
, ADMAdda
5
] MC-HilR; 
Unidentified MCs × 9 
25 
Val 
Leu 
Hil 
Arg 
Har 
Pos. 1 × 2 
Pos. 3 × 2 
Pos. 5 × 3 
Pos. 7 × 3 
≥ 216 55,56, 
72,245 
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Nostoc IO-102-I [ADMAdda
5
] MC-LR; [DMAdda
5
] MC-LR; 
[Asp
3
, ADMAdda
5
] MC LR; [DMAdda
5
] MC-HilR; 
[ADMAdda
5
] MC-YR; Unidentified MCs × 15 
20 
Leu 
Hil 
Tyr 
Arg 
Pos. 3 × 2 
Pos. 5 × 2 
- 
245, 
280 
Nostoc species [Asp
3
, ADMAdda
5
, Dhb
7
] MC-LR; 
[Asp
3
, ADMAdda
5
, Dhb
7
] MC HtyR; 
[Asp
3
, ADMAdda
5
, Dhb
7
] MC-RR 
3 
Leu 
Hty 
Arg 
Arg 
Pos. 3 × 1 
Pos. 5 × 1 
Pos. 7 × 1 
3 54 
Planktothrix Max06 [Asp
3
, DMAdda
5
] MC-HtyR; [Asp
3
] MC-YR; 
[Asp
3
, MeSer
7
] MC-HtyR; [Asp
3
, MeSer
7
] MC-LR; 
[Asp
3
] MC-HtyR; [Asp
3
] MC-LR; [Asp
3
, Dha
7
] MC-LR; 
[Asp
3
] MC-HilR; [Asp
3
, Glu(OMe)
6
] MC-HtyR; [Asp
3
] 
MC-HphR; [Asp
3
, Glu(OMe)
6
] MC-LR 
11 
Leu 
Hil 
Tyr 
Hty 
Hph 
Arg 
Pos. 3 × 1 
Pos. 5 × 2 
Pos. 6 × 2 
Pos. 7 × 3 
60 305 
Planktothrix agardhii [Asp
3
] MC-LR; [Asp
3
] MC-RR 
2 
Leu 
Arg 
Arg Pos. 3 × 1 2 148 
Planktothrix agardhii 213 [Asp
3
] MC-LR; [Asp
3
, Dha
7
] MC-LR; [Asp
3
] MC-RR 
3 
Leu 
Arg 
Arg 
Pos. 3 × 1 
Pos. 7 × 2 
4 245 
Planktothrix agardhii NIVA 126/8 [Asp
3
] MC-LR; [Asp
3
] MC-RR; Unidentified MC 
3 
Leu 
Arg 
Arg Pos. 3 × 1 - 245 
Planktothrix agardhii PH-123 [Asp
3
] MC-LR; [Asp
3
, ADMAdda
5
] MC-LR; 
[Asp
3
] MC-HtyR; [Asp
3
, ADMAdda
5
] MC-HtyR 
4 
Leu 
Hty 
Arg 
Pos. 3 × 1 
Pos. 5 × 2 
4 80 
Planktothrix rubescens No80 [Asp
3
, Dhb
7
] MC-HtyY; [Asp
3
, Dhb
7
] MC-HtyHty 
2 Hty 
Tyr 
Hty 
Pos. 3 × 1 
Pos. 7 × 1 
2 76 
a An assessment of the microcystin diversity of 42 microcystin-producing strains reported in scientific journals. b Number of microcystins observed, including unidentified microcystins which the 
researchers noted during the studies. c Amino acids incorporated into position two of the microcystins reported to be produced by the cyanobacterial strain. d Amino acids incorporated into position 
four of the microcystins reported to be produced by the cyanobacterial strain. e Potential number of microcystins which could be produced by the cyanobacterial strain according to the information 
collected; In some cases this is omitted as the presence of unidentified microcystins makes this value difficult to estimate.  f Ref = Reference(s). 
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Appendix D.1: β-Mercaptoethanol derivatisation of standard microcystins. 
 
 
MC-LR (7) Half-life = 4.8 min 
   
 
[Dha
7
] MC-LR (33) Half-life = 5.4 min 
   
 
MC-YR (96) Half-life = 3.8 min 
   
 
MC-RR (85) Half-life = 2.6 min 
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Appendix D.2: β-Mercaptoethanol derivatisation of the CYN06 microcystins. 
 
 
 
[Asp
3
] MC-RR (67) Half-life = 2.6 min 
   
 
MC-RR (85) Half-life = 3.2 min 
   
 
MC-YR (96) Half-life = 6.8 min 
   
 
[Asp
3
] MC-LR (30) Half-life = 3.5 min 
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MC-LR (7) Half-life = 5.2 min 
   
 
[Asp
3
] MC-FR (59) Half-life = 5.0 min 
   
 
MC-FR (72) Half-life = 4.5 min 
   
 
[Asp
3
] MC-WR (104) Half-life = 3.4 min 
   
 
MC-WR (112) Half-life = 4.1 min 
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[Asp
3
] MC-RA (160) Half-life = 3.5 min 
   
 
MC-RA (16) Half-life = 5.1 min 
   
 
[Asp
3
] MC-RAba (161) Half-life = 1.5 min 
   
 
MC-RAba (19) Half-life = 6.0 min 
   
 
MC-RL (41) Half-life = 3.6 min 
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MC-YA (17) Half-life = 6.5 min 
   
 
[Asp
3
] MC-LA (8) Half-life = 5.8 min 
   
 
MC-LA (9) Half-life = 4.0 min 
   
 
[Asp
3
] MC-FA (162) Half-life = 6.2 min 
   
 
MC-FA (163) Half-life = 5.6 min 
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[Asp
3
] MC-WA (164) Half-life = 6.9 min 
   
 
MC-WA (165) Half-life = 5.5 min 
   
 
MC-LAba (11) Half-life = 7.4 min 
   
 
MC-FAba (166) Half-life = 3.9 min 
   
 
MC-WAba (167) Half-life = 2.2 min 
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MC-LL (14) Half-life = 18.4 min 
   
 
MC-FL (168) Half-life = 8.4 min 
   
 
MC-WL (169) Half-life = 8.2 min 
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Appendix D.3: β-Mercaptoethanol derivatisation of the Antarctic microcystins. 
 
 
Antarctic -LR congeners Half-life = 1089.3 min 
   
 
Antarctic -RR congeners Half-life = 632.3 min 
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Appendix E.1: Tandem mass spectrometry fragment assignments for the CYN06 -RR 
microcystin congeners observed by ESI CID. 
Fragment Assignment 
a MC-RR
 
[Asp
3
] MC-RR 
[M+2H]
2+
 [M+H]
+
 [M+2H]
2+
 [M+H]
+
 
M 519.8 1038.6 512.8 1024.6 
M – H2O 510.7 1020.4
b
 503.7 1006.4
b
 
M – Mdha – H2O 469.2 937.4
b
 462.2 923.4
b
 
M – Adda sidechain 452.8 904.4 445.7 890.3 
M – Adda sidechain – H2O 443.7 886.4 436.6 872.3 
M – Adda 363.2 725.3 356.1 711.3 
M – Adda – H2O 354.2 707.3 347.1 693.3 
Arg-Adda-Glu – NH3  582.2  582.2 
Arg-Adda – NH3+ H  453.2  453.2 
Arg-Adda-Glu – CO  571.3  571.2 
(Me)Asp-Arg-Adda-Glu  728.3  714.2 
(Me)Asp-Arg-Adda  599.3  585.2 
Arg-Adda-Glu  599.3  599.2 
Mdha-Ala-Arg-(Me)Asp-Arg 298.2 596.3 291.2 582.2 
Mdha-Ala-Arg-(Me)Asp  440.2  426.1 
Mdha-Ala-Arg  311.2  311.1 
Mdha-Ala  155.1  155.0 
Adda’-Glu-Mdha  375.2  375.1 
Adda’  163.1  163.0 
(Me)Asp-Arg  286.2  272.1 
Arg  157.1  157.1 
a Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
b [M+H]+ ion was deconvoluted from the [M+2H]2+ ion. 
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Appendix E.2: Tandem mass spectrometry fragment assignments for the CYN06 -XR microcystin congeners observed by MALDI PSD 
and ESI CID. 
Fragment Assignment 
a MC-LR 
X = 113 Da
 
[Asp
3
] MC-LR 
X = 113 Da 
MC-FR 
X = 147 Da 
[Asp
3
] MC-FR 
X = 147 Da 
MC-YR 
X = 163 Da 
MC-WR 
X = 186 Da 
[Asp
3
] MC-WR 
X = 186 Da 
M + H 995 981 1029 1015 1045 1068 1054 
M – Ala + H 924 910 958 944 974 997  
M – CH2NHCN2H3 + H 923 909 957 943 973 996  
M – (Me)Asp + H 866 866 900 900 916 939 939 
M – Glu + H 866 852 900 886 916 939 925 
M – Adda sidechain + H 861 847 895 881 911 934 920 
(Me)Asp-Arg-Adda-Glu + H 728 714 728 714 728 728 714 
(Me)Asp-Arg-Adda + H 599 585 599 585 599 599 585 
Arg-Adda-Glu + H 599 599 599 599 599 599 599 
Arg-Adda + H 470 470 470 470 470 470 470 
Mdha-Ala-X-(Me)Asp-Arg + NH4 570 556 604 590 620 643 629 
Ala-X-(Me)Asp-Arg + NH4 487 473 521 507 537 560 546 
Mdha-Ala-X-(Me)Asp-Arg + H 553 539 587 573 603 626 612 
Ala-X-(Me)Asp-Arg + H 470 456 504 490 520 543 529 
X-(Me)Asp-Arg + H 399  433 419 449   
Mdha-Ala-X-(Me)Asp + H 397 383 431  447 470 456 
Mdha-Ala-X + H 268 268 302 302 318 341 341 
Mdha-Ala + H 155 155 155 155 155 155 155 
Adda’-Glu-Mdha-Ala + H 446 446 446 446 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 375 375 375 375 
Adda’ + H 163 163 163 163 163 163 163 
Glu-Mdha + H 213 213 213 213 213 213 213 
Adda sidechain 135 135 135 135 135 135 135 
Arg related ions 70/84/112/174 70/84/112/174 70/84/112/174 70/84/112/174 70/84/112/174 70/84/112/174 70/84/112/174 
X immonium 86 86 120 120 136 159 159 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O); CH2NHCN2H3 is a fragment of the Arg sidechain; Fragment ions containing NH3 and CO losses have been omitted. 
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Appendix E.3: Tandem mass spectrometry fragment assignments for the CYN06 -RZ microcystin congeners observed by MALDI PSD 
and ESI CID. 
Fragment Assignment 
a MC-RA 
Z = 71 Da
 
[Asp
3
] MC-RA 
Z = 71 Da 
MC-RAba 
Z = 85 Da 
[Asp
3
] MC-RAba 
Z = 85 Da 
MC-RL 
Z = 113 Da 
M + H 953 939 967 953 995 
M – H2O + H 935 921 949 935 977 
M – COOH + H 908 894 922 908 950 
M – Z + H 882 868 882 868 882 
M – CH2NHCN2H3 + H 881 867 895 881 923 
M – Glu + H 824 810 838 824 866 
M – (Me)Asp + H 824 824 838 838 866 
M – Adda sidechain + H 819 787 833 819 861 
Mdha-Ala-Arg-(Me)Asp-Z + NH4 528 514 542 528 570 
Mdha-Ala-Arg-(Me)Asp-Z – H2O + NH4 510 496 524 510 552 
Mdha-Ala-Arg-(Me)Asp-Z + H 511 497 525 511 553 
Mdha-Ala-Arg-(Me)Asp – CH2NHCN2H3 + H 368 354 368 354 368 
Mdha-Ala-Arg-(Me)Asp + H 440 426 440 426 440 
Mdha-Ala-Arg + H 311 311 311 311 311 
Mdha-Ala + H 155 155 155   
Arg-(Me)Asp-Z + H 357 343  357  
Glu-Mdha-Ala-Arg – COOH + H 395 395 395 395 395 
Glu-Mdha-Ala-Arg – CH2NHCN2H3 + H 368 368 368 368 368 
Glu-Mdha-Ala-Arg + H 440 440 440 440 440 
Glu-Mdha + H 213  213   
Adda’-Glu-Mdha + H 375 375 375 375 375 
Adda’ + H 163 163 163   
a Z = Position four amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O); CH2NHCN2H3 is a fragment of the Arg sidechain. 
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Appendix E.4: Tandem mass spectrometry fragment assignments for the CYN06 -XA microcystin congeners observed by ESI CID. 
Fragment Assignment 
a MC-LA 
X = 113 Da
 
[Asp
3
] MC-LA 
X = 113 Da 
MC-FA 
X = 147 Da 
[Asp
3
] MC-FA 
X = 147 Da 
MC-YA 
X = 163 Da 
MC-WA 
X = 186 Da 
[Asp
3
] MC-WA 
X = 186 Da 
M + H 910 896 944 930 960 983 969 
M – H2O + H 892 878 926 912 942 965 951 
M – Mdha – H2O + H 809 795 843 829  882 868 
M – Adda sidechain + H 776 762 810 796 826 849 835 
M – Adda sidechain – H2O + H 758 744 792 778 808 831 817 
M – Adda + H 597 583 631 617 647 670 656 
M – Adda – H2O + H 579 565 613 599 629 652  
Adda-Glu-Mdha-Ala-X-(Me)Asp – NH3 + H 822 808 856 842 872 895 881 
Adda-Glu-Mdha-Ala-X – NH3 + H 693 693 727 727 743 766 766 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 580 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 509 509 509 509 
Adda’-Glu-Mdha-Ala-X + H 559 559 593 593 609 632 632 
Adda’-Glu-Mdha-Ala + H 446 446 446 446 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 375 375 375 375 
Mdha-Ala-X-(Me)Asp-Ala + NH4 485 471 519 505 535 558  
Ala-X-(Me)Asp-Ala + NH4 402 388 436 422 452 475 461 
X-(Me)Asp-Ala + NH4 331 317 365 351 381 404 390 
Mdha-Ala-X-(Me)Asp-Ala + H 468 454 502 334 518 541 527 
Ala-X-(Me)Asp-Ala + H 385 371 419 405 435 458 444 
X-(Me)Asp-Ala + H 314 300 348 488 364 387 373 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
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Appendix E.5: Tandem mass spectrometry fragment assignments for the CYN06 -XAba microcystin congeners observed by ESI CID. 
Fragment Assignment 
a MC-LAba 
X = 113 Da
 
MC-FAba 
X = 147 Da 
MC-WAba 
X = 186 Da 
M + H 924 958 997 
M – H2O + H 906 940 979 
M – Mdha – H2O + H 823  896 
M – Glu or Masp – H2O + H 777   
M – Adda sidechain + H 790 824 863 
M – Adda sidechain – H2O + H 772 806 845 
M – Adda + H 611 645 684 
M – Adda – H2O + H 593 627 666 
Adda-Glu-Mdha-Ala-X-Masp – NH3 + H   895 
Adda-Glu-Mdha-Ala-X – NH3 + H 693 727 766 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Adda’-Glu-Mdha-Ala-X + H 559 593 632 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Mdha-Ala-X-Masp-Aba + NH4 499 533 572 
Ala-X-Masp-Aba + NH4 416 450 489 
X-Masp-Aba + NH4 345 379 418 
Mdha-Ala-X-Masp-Aba + H 482 516 555 
Ala-X-Masp-Aba + H 399 433 472 
X-Masp-Aba + H 328 362 401 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
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Appendix E.6: Tandem mass spectrometry fragment assignments for the CYN06 -XL microcystin congeners observed by ESI CID. 
Fragment Assignment 
a MC-LL 
X = 113 Da
 
MC-FL 
X = 147 Da 
MC-WL 
X = 186 Da 
M + H 952 986 1025 
M – NH3 + H 935 969 1008 
M – H2O + H 934 968 1007 
M – Glu or Masp + H 823  896 
M – Adda sidechain + H 818 852 891 
M – Adda sidechain – H2O + H 800 834 873 
M – Adda + H 639 673 712 
M – Adda – H2O + H 621 655 694 
Adda-Glu-Mdha-Ala-X – NH3 + H 693 727 766 
Adda-Glu-Mdha-Ala – NH3 + H 580 580 580 
Adda-Glu-Mdha – NH3 + H 509 509 509 
Glu-Mdha-Ala-X + H 397 431 470 
Adda’-Glu-Mdha-Ala-X + H 559 593 632 
Adda’-Glu-Mdha-Ala + H 446 446 446 
Adda’-Glu-Mdha + H 375 375 375 
Mdha-Ala-X-Masp-Leu + NH4  561 600 
Ala-X-Masp-Leu + NH4  478 517 
X-Masp-Leu + NH4  407 446 
Unknown fragment ion 440 474 513 
Unknown fragment ion 535 535 535 
Mdha-Ala-X-Masp-Leu + H 509 544 583 
Ala-X-Masp-Leu + H 426 461 500 
X-Masp-Leu + H 355 390 429 
a X = Position two amino acid; Adda’ = Adda minus NH2 and the sidechain (C9H11O). 
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Appendix F.1: Advanced Marfey’s amino acid analysis of standard amino acids derivatised with 
L-FDLA (A) and DL-FDLA (B). 
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Appendix F.1 continued: Advanced Marfey’s amino acid analysis of standard amino acids 
derivatised with L-FDLA (A) and DL-FDLA (B). 
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Appendix F.2: Advanced Marfey’s amino acid analysis of standard ornithine and arginine derivatised with 
L-FDLA (A), D-FDLA (B) and DL-FDLA (C). 
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Appendix F.3: Advanced Marfey’s amino acid analysis of hydrolysed MC-LR (7) derivatised with 
L-FDLA (A) and DL-FDLA (B). 
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Appendix F.4: Advanced Marfey’s amino acid analysis of hydrolysed MC-FA (163) derivatised with L-FDLA (A) and 
DL-FDLA (B). 
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Appendix F.5: Advanced Marfey’s amino acid analysis of hydrolysed MC-WA (165) derivatised with L-FDLA (A) and 
DL-FDLA (B). 
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Appendix F.6: Advanced Marfey’s amino acid analysis of hydrolysed MC-RA (16) derivatised with L-FDLA (A) 
and DL-FDLA (B). 
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Appendix F.7: Advanced Marfey’s amino acid analysis of hydrolysed MC-RAba (19) derivatised with 
L-FDLA (A) and DL-FDLA (B). 
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Appendix F.8: Advanced Marfey’s amino acid analysis of a hydrolysate of the Antarctic -LR microcystin congeners 
derivatised with L-FDLA (A) and DL-FDLA (B). 
  
 A
p
p
en
d
ix
 F
 
  
2
3
9
 
Appendix F.9: Advanced Marfey’s amino acid analysis of a hydrolysate of the Antarctic -RR microcystin congeners 
derivatised with L-FDLA (A) and DL-FDLA (B). 
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Appendix G.1: Downfield region for the 
1
H NMR spectrum of MC-FA (163) in CD3OD. 
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Appendix G.2: Upfield region for the 
1
H NMR spectrum of MC-FA (163) in CD3OD. 
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Appendix G.3: 
13
C NMR spectrum of MC-FA (163) in CD3OD. 
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Appendix G.4: 
13
C DEPT NMR spectra of MC-FA (163) in CD3OD; 
DEPT-135 (A), DEPT-90 (B) and DEPT-45 (C). 
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Appendix G.5: HSQC NMR spectrum of MC-FA (163) in CD3OD. 
 
 
Appendix G.6: HMBC NMR spectrum of MC-FA (163) in CD3OD. 
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Appendix G.7: COSY NMR spectrum of MC-FA (163) in CD3OD. 
 
 
Appendix G.8: ROESY NMR spectrum of MC-FA (163) in CD3OD. 
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Appendix G.9: Selective TOCSY experiment to assign the aromatic signals 
from the phenylalanine residue of MC-FA (163) in CD3OD. The 7.37 ppm 
proton signal was irradiated using a mixing time of 10 ms (A) and 50 ms (B). 
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Appendix H.1: Downfield region for the 
1
H NMR spectrum of MC-WA (165) in CD3OD. 
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Appendix H.2: Upfield region for the 
1
H NMR spectrum of MC-WA (165) in CD3OD. 
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Appendix H.3: 
13
C NMR spectrum of MC-WA (165) in CD3OD. 
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Appendix H.4: 
13
C DEPT NMR spectra of MC-WA (165) in CD3OD; 
DEPT-135 (A), DEPT-90 (B) and DEPT-45 (C). 
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Appendix H.5: HSQC NMR spectrum of MC-WA (165) in CD3OD. 
 
 
 
Appendix H.6: HMBC NMR spectrum of MC-WA (165) in CD3OD. 
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Appendix H.7: COSY NMR spectrum of MC-WA (165) in CD3OD. 
 
 
 
Appendix H.8: ROESY NMR spectrum of MC-WA (165) in CD3OD, with 
continuous wave suppression of the OH/H2O solvent peak. 
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Appendix I.1: Downfield region for the 
1
H NMR spectrum of MC-NfkA (175) in CD3OH, with electronic sculpturing 
suppression of the OH/H2O solvent peak and continuous wave suppression of the CHD2OH solvent peak. 
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Appendix I.2: Upfield region for the 
1
H NMR spectrum of MC-NfkA (175) in CD3OH, with electronic sculpturing suppression 
of the OH/H2O solvent peak and continuous wave suppression of the CHD2OH solvent peak. 
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Appendix I.3: 
13
C NMR spectrum of MC-NfkA (175) in CD3OD. 
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Appendix I.4: Downfield region for the HSQC NMR spectrum of MC-NfkA (175) 
in CD3OH, with continuous wave suppression of the OH/H2O solvent peak. 
 
 
Appendix I.5: Upfield region for the HSQC NMR spectrum of MC-NfkA (175) 
in CD3OH, with continuous wave suppression of the OH/H2O solvent peak. 
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Appendix I.6: HMBC NMR spectrum of MC-NfkA (175) in CD3OH. 
 
 
Appendix I.7: COSY NMR spectrum of MC-NfkA (175) in CD3OH, with 
continuous wave suppression of the OH/H2O solvent peak. 
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Appendix I.8: ROESY NMR spectrum of MC-NfkA (175) in CD3OH, with 
continuous wave suppression of the OH/H2O solvent peak. 
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Appendix J.1: Tandem mass spectrometry fragment assignments for the -LR Antarctic microcystin congeners observed by ESI CID. 
Fragment Assignment 
a 
MC-LR b 
[Gly1, Asp3, Dhb7] 
MC-LR 
[Gly1, Asp3, Dhb7] 
MC-LHar 
[Gly1, Asp3, ADMAdda5, 
Dhb7] MC-LR 
[Gly1, Asp3, ADMAdda5, 
Dhb7] MC-LHar 
M + H 995.6 967.6 981.6 995.6 1009.6 
M – HOAc + H - - - 935.5 949.3 
(Me)Asp-Arg/Har-(ADM)Adda-Glu-Mdha/Dhb-Gly/Ala + H 882  868.6  896.9 
Arg/Har-(ADM)Adda-Glu-Mdha/Dhb-Gly/Ala + H 753  753.3  781.4 
(Me)Asp-Arg/Har-(ADM)Adda-Glu + H 728  728.4  756.4 
Arg/Har-(ADM)Adda-Glu-Mdha/Dhb + H 682 682.5 696.1 710.3 724.3 
Glu-Mdha/Dhb-Gly/Ala-Leu-(Me)Asp-Arg/Har + H 682  668.0   
Arg/Har-(ADM)Adda-Glu + H 599 599.3 613.2 627.2 641.4 
(Me)Asp-Arg/Har-(ADM)Adda + H 599    627.3 
(ADM)Adda’-Glu-Mdha/Dhb-Gly/Ala-Leu + H 559  545.4   
Mdha/Dhb-Gly/Ala-Leu-(Me)Asp-Arg/Har + H 553 525.2 539.4 525.2 539.3 
Glu-Mdha/Dhb-Gly/Ala-Leu-(Me)Asp + H 526   498.2  
Arg/Har-(ADM)Adda + H 470    512.3 
Gly/Ala-Leu-(Me)Asp-Arg/Har + H 470 442.3 456.2 442.1 456.1 
(ADM)Adda’-Glu-Mdha/Dhb-Gly/Ala + H 446 432.2 432.1   
Leu-(Me)Asp-Arg/Har + H 399 385.1 399.1 385.4  
Glu-Mdha/Dhb-Gly/Ala-Leu + H 397   383.1 383.1 
(ADM)Adda’-Glu-Mdha/Dhb + H 375 375.1 375.2 375.2  
Mdha/Dhb-Gly/Ala-Leu-(Me)Asp + H 397   369.2  
(ADM)Adda’-Glu + H 292 292.1 292.2 292.1 292.1 
Gly/Ala-Leu-(Me)Asp + H 314  286.1 286.3 286.1 
ADMAdda – HOAc + H - - - 282.2 282.2 
ADMAdda – HOAc – NH3 + H - - - 265.1 265.2 
(Me)Asp-Arg/Har + H 286 272.1 286.1 272.1 286.1 
Glu-Mdha/Dhb-Gly/Ala + H 284 270.2 270.2 270.1 270.2 
Mdha/Dhb-Gly/Ala-Leu + H 268 254.3 254.1 254.1 254.1 
Leu-(Me)Asp + H 243  229.2 229.0 229.1 
Glu-Mdha/Dhb + H 213 213.1 213.1 213.1 213.1 
Gly/Ala-Leu + H 185 171.0 171.1 171.0 171.1 
(ADM)Adda’ + H 163 163.1 163.1 163.1 163.0 
Arg/Har + H 157 157.0 171.1 157.1 171.1 
Mdha/Dhb-Gly/Ala + H 155 141.0 141.0 141.1 141.1 
(ADM)Adda sidechain 135 135.1 135.1 163.1 163.0 
Arg/Har immonium 129 129.2 143.1 129.1 143.1 
Arg/Har fragment 112 112.1 112.0/126.1 112.0 111.9/126.1 
a Fragments containing CO losses and NH4
+ adducts were not included; Adda’ = Adda minus NH2 and the sidechain (C9H11O or C10H11O2). 
b m/z values for MC-LR fragments are theorised nominal values.45,75,78 
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Appendix J.2: Tandem mass spectrometry fragment assignments for the -RR Antarctic microcystin congeners observed by ESI CID. 
Fragment Assignment 
a
 MC-RR b 
[Gly1, Asp3, Dhb7] 
MC-RR 
[Gly1, Asp3, Dhb7] 
MC-RHar 
[Gly1, Asp3, ADMAdda5, 
Dhb7] MC-RR 
[Gly1, Asp3, ADMAdda5, 
Dhb7] MC-RHar 
M + H 1024.7 1010.7 1024.7 1038.7 1052.7 
M – CN2H2 + H 982 968.9 982.5 996.5 1010.8 
M – HOAc + H - - - 978.6 992.5 
Arg/Har-(ADM)Adda-Glu-Mdha/Dhb-Gly/Ala-Arg + H 909 895.3 909.6   
(Me)Asp-Arg/Har-(ADM)Adda-Glu-Mdha/Dhb-Gly/Ala + H 882  868.6  896.4 
(Me)Asp-Arg/Har-(ADM)Adda-Glu-Mdha/Dhb + H 811  811.5 825.1 839.8 
Arg/Har-(ADM)Adda-Glu-Mdha/Dhb-Gly/Ala + H 753 739.2 753.4  781.0 
(Me)Asp-Arg/Har-(ADM)Adda-Glu + H 728 714.3 728.3 742.1 756.2 
Arg/Har-(ADM)Adda-Glu-Mdha/Dhb + H 682 682.2  710.2 724.2 
Glu-Mdha/Dhb-Gly/Ala-Arg-(Me)Asp-Arg + H 725 697.5  697.3  
Arg/Har-(ADM)Adda-Glu + H 599  613.5  641.2 
(Me)Asp-Arg/Har-(ADM)Adda + H 599 585.2 599.2 613.4 627.9 
Mdha/Dhb-Gly/Ala-Arg-(Me)Asp-Arg/Har + H 596  582.4 568.7  
Har-ADMAdda – HOAC + H - - -  452.5 
(ADM)Adda’-Glu-Mdha/Dhb-Gly/Ala + H 446 432.2    
Glu-Mdha/Dhb-Gly/Ala-Arg + H 440 426.4  426.2  
Mdha/Dhb-Gly/Ala-Arg-(Me)Asp + H 440 412.1 412.3 412.2 412.3 
(ADM)Adda’-Glu-Mdha/Dhb + H 375 375.1 375.2   
Gly/Ala-Arg-(Me)Asp + H 357 329.1  329.1 329.1 
Mdha/Dhb-Gly/Ala-Arg + H 311 297.1 296.9 297.0 297.0 
(ADM)Adda’-Glu + H 292   292.1  
ADMAdda – HOAc + H - - - 282.3 282.1 
ADMAdda – HOAc – NH3 + H - - - 265.4 265.3 
(Me)Asp-Arg/Har + H 286 272.3 286.2  286.1 
Arg-(Me)Asp + H 286 272.3 272.1 272.2 272.5 
Glu-Mdha/Dhb-Gly/Ala + H 284 270.0  270.1  
Gly/Ala-Arg + H 228 214.1 214.0 214.1 214.2 
Glu-Mdha/Dhb + H 213 213.1 212.9 213.1 213.2 
(ADM)Adda’+ H 163 163.0 162.9 163.0  
Har + H - -  - 171.0 
Arg + H 157 157.0 157.1 156.6 156.9 
Mdha/Dhb-Gly/Ala + H 155 141.5 140.9 141.2 140.7 
(ADM)Adda sidechain 135 135.1 135.1 163.0  
Har immonium - - 143.1 - 143.1 
Arg immonium 129 129.5 129.1 129.1  
Har fragment - - 112.0/126.0 - 111.8/125.8 
Arg fragment 112 112.2 112.0 112.1 111.8 
a
 Fragments containing CO losses and NH4
+
 adducts were not included; Adda’ = Adda minus NH2 and the sidechain (C9H11O or C10H11O2). 
b
 m/z values for MC-RR fragments are theorised nominal values.
78,265
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Appendix J.3: Tandem mass spectrometry fragment assignments for the Antarctic linear peptides observed by MALDI PSD 
and/or ESI CID. 
Fragment Assignment 
a
 
Peptide 800 
X = MePhe 
Peptide 816 
X = MeTyr 
Peptide 830A 
X = MeTyr(OMe) 
Peptide 814 
X = MePhe 
Peptide 830B 
X = MeTyr 
Peptide 844 
X = MeTyr(OMe) 
M + H 801 817 831 815 831 845 
C9H14NO2-Ile-X-MeTyr + H 620 636 650 620 636 650 
C9H14NO2-Ile-X + H 443 459 473 443 459 473 
C9H14NO2-Ile + H 282 282 282 282 282 282 
C9H14NO2 + H 169 169 169 169 169 169 
X-MeTyr-(Me)Hpla + H 520 536 550 534 550 564 
MeTyr-(Me)Hpla + H 359 359 359 373 373 373 
Ile-X + H 275 291 305 275 291 305 
C9H14NO2 – H2O + H 151 151 151 151 151 151 
C9H14NO2 – CO + H 141  141 141   
Fragment of C9H14NO2 113  113 113   
MeTyr/Hpla sidechain 107  107 107   
X sidechain 91  121 91   
Mass of X (Da) 161 177 191 161 177 191 
a X = Position three amino acid; C9H14NO2 is the unidentified 168 Da N-terminus.  
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Appendix K.1: The relative abundance of eleven microcystin congeners during a 
40-day batch culture of Microcystis CYN06. Graphs focussing on the -XR 
and -XA congeners (A) and on the -RR, -RZ and -XL congeners (B). 
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Appendix K.2: Correlation matrices showing the statistical significance of 
the changes in microcystin congener abundance a batch culture of 
Microcystis CYN06. Matrix was constructed using the p-values from a 
one-tailed Student’s t-test; statistically significant changes are indicated by 
grey shading (p≤0.05). No statistically significant differences were observed 
for the -RZ microcystin congeners (p>0.05). 
 
MC-RR Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 
Day 1  0.009 0.134 0.007 0.010 <0.001 
Day 8 0.009  0.635 0.060 0.039 <0.001 
Day 15 0.134 0.635  0.060 0.036 0.002 
Day 22 0.007 0.060 0.060  0.306 0.056 
Day 29 0.010 0.039 0.036 0.306  0.202 
Day 36 <0.001 <0.001 0.002 0.056 0.202  
 
MC-XRs Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 
Day 1  0.043 0.002 0.008 <0.001 <0.001 
Day 8 0.043  0.029 0.139 0.002 <0.001 
Day 15 0.002 0.029  0.856 0.036 0.022 
Day 22 0.008 0.139 0.856  0.007 0.002 
Day 29 <0.001 0.002 0.036 0.007  0.544 
Day 36 <0.001 <0.001 0.022 0.002 0.544  
 
MC-XAs Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 
Day 1  0.012 0.005 0.004 0.004 <0.001 
Day 8 0.012  0.068 0.081 0.020 <0.001 
Day 15 0.005 0.068  0.592 0.083 0.010 
Day 22 0.004 0.081 0.592  0.063 0.005 
Day 29 0.004 0.020 0.083 0.063  0.362 
Day 36 <0.001 <0.001 0.010 0.005 0.362  
 
MC-XLs Day 1 Day 8 Day 15 Day 22 Day 29 Day 36 
Day 1  0.996 0.998 0.998 0.014 <0.001 
Day 8 0.996  0.499 0.707 0.003 <0.001 
Day 15 0.998 0.499  0.725 0.003 <0.001 
Day 22 0.998 0.707 0.725  0.003 <0.001 
Day 29 0.014 0.003 0.003 0.003  0.351 
Day 36 <0.001 <0.001 <0.001 <0.001 0.351  
  
Appendix K 
264 
 
Appendix K.3: Scatter-plots of log10 microcystin content against nitrate 
concentration. 
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Appendix K.4: Scatter-plots of log10 microcystin content against incubation time 
for the time-points with nitrate concentrations less than 0.005 mM. 
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Appendix K.5: Correlation matrix showing the statistical significance of 
the differences between the gradients for the relationship of 
log10 microcystin content against incubation time. Matrix was constructed 
using the p-values from a two-tailed Student’s t-test; statistically significant 
changes are indicated by grey shading (p≤0.05). 
 
 MC-RR MC-XRs MC-RZs MC-XAs MC-XLs 
MC-RR  0.001 <0.001 <0.001 <0.001 
MC-XRs 0.001  0.427 0.117 0.010 
MC-RZs <0.001 0.427  0.332 0.030 
MC-XAs <0.001 0.117 0.332  0.189 
MC-XLs <0.001 0.010 0.030 0.189  
 
 
 
Appendix K.6: Correlation matrix showing the statistical significance of 
the differences between the gradients for the relationship of 
log10 microcystin content against nitrate concentration. Matrix was 
constructed using the p-values from a two-tailed Student’s t-test; statistically 
significant changes are indicated by grey shading (p≤0.05). 
 
 MC-RR MC-XRs MC-RZs MC-XAs MC-XLs 
MC-RR  <0.001 <0.001 <0.001 <0.001 
MC-XRs <0.001  0.490 0.129 0.008 
MC-RZs <0.001 0.490  0.315 0.021 
MC-XAs <0.001 0.129 0.315  0.174 
MC-XLs <0.001 0.008 0.021 0.174  
  
2
6
7
 
Appendix L.1: Purification scheme for the fractionation of the CYN06 microcystins (Chapters 3 and 4). 
Freeze-dried CYN06 
Remaining Cell Material
Extract BExtract A
MC-XAs & MicroviridinsMC-XAs & MC-XRs & MC-RZs
70% EtOH
Extraction
100% MeOH
Extraction
Neutral C18
Acid C18
Neutral C18
Repeated
LH-20
LH-20
Solid-Phase
Cleanup
Mostly MC-XAs
MC-RA MC-RAba MC-NfkA MC-WAMC-FA
MC-XAs
Mostly MC-FA
Mostly MC-XRs
Mostly MC-WA
MC-LA & Ox-Trp -XAs
MC-FA MC-WA
MC-RZs
Mostly MC-RZs
MC-RAbaMC-RA MC-NfkA
Ox-Trp -XAs
Isocratic
HPLC
Isocratic
HPLC
LH-20
Isocratic
HPLC
Solid-Phase
Cleanup
Neutral C18
Isocratic
HPLC
Acid C18
Neutral C18
MC-LR & Ox-Trp -XRs
LH-20
MC-XRs
MC-LR & MC-NfkR
Isocratic
HPLC
Solid-Phase
Cleanup
MC-LR & MC-NfkR
Solid-Phase
Cleanup
 A
p
p
en
d
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Appendix L.2: Purification scheme for the fractionation of the Antarctic 
oligopeptides (Chapter 5). 
 
 
 
 
Extract
70% MeOH
Extraction
Neutral C18
LH-20
-LR Antarctic 
Microcystins
Neutral C18
Neutral C18
Gradient
HPLC
Antarctic Sample
MicrocystinsLinear Peptides
-LR Microcystins
-RR Antarctic 
Microcystins
-RR Microcystins
Gradient
HPLC
Neutral C18
Antarctic Linear 
Peptides
Linear Peptides
Gradient
HPLC
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Appendix M: List of the compounds referred to in this thesis. 
 
1. Aeruginosin 103 A 
2. Anabaenopeptin A 
3. Cyanopeptolin A 
4. Aerucyclamide B 
5. Microginin FR1 
6. Microviridin A 
7. MC-LR 
8. [Asp3] MC-LA 
9. MC-LA 
10. [Asp3, Glu(OMe)6] MC-LAba 
11. MC-LAba 
12. MC-LV 
13. [Asp3] MC-LL 
14. MC-LL 
15. MC-AR 
16. MC-RA 
17. MC-YA 
18. MC-AHar 
19. MC-RAba 
20. [Asp3, Dha7] MC-LR 
21. [Asp3, Dha7] MC-EE(OMe) 
22. MC-LM 
23. [Asp3] MC-LF 
24. MC-VF 
25. [Asp3, Dha7] MC-LY 
26. MC-YAba 
27. MC-VR 
28. MC-RV 
29. MC-RApa 
30. [Asp3] MC-LR 
31. [Asp3, Dhb7] MC-LR 
32. [DMAdda5] MC-LR 
33. [Dha7] MC-LR 
34. MC-AW 
35. [Dha7] MC-EE(OMe) 
36. [Asp3, Dha7] MC-E(OMe)E(OMe) 
37. MC-LF 
38. [Asp3] MC-LY 
39. [Asp3, Dhb7] MC-HilR 
40. [Asp3, Glu(OMe)6] MC-LR 
41. MC-RL 
42. [(6Z)Adda5] MC-LR 
43. [Dha7] MC-E(OMe)E(OMe) 
44. [Ser7] MC-LR 
45. [Asp3] MC-HilY 
46. [Asp3, Ser7] MC-E(OMe)E(OMe) 
47. [Ser7] MC-EE(OMe) 
48. MC-LY 
49. MC-YL 
50. [Asp3, MeSer7] MC-LY 
51. [Asp3, ADMAdda5, Dhb7] MC-LR 
52. [Asp3, ADMAdda5] MC-LR 
53. [Glu(OMe)6] MC-LR 
54. [Mdhb7] MC-LR 
55. MC-HilR 
56. [Asp3, Dha7] MC-RR 
57. [Asp3] MC-LW 
58. [MeSer7] MC-LR 
59. [Asp3] MC-FR 
60. [Dha7] MC-FR 
61. [Asp3] MC-RF 
62. [Ser7] MC-E(OMe)E(OMe) 
63. [Asp3, Dha7] MC-RY 
64. MC-YM 
65. [Asp3, ADMAdda5] MC-LHar 
66. [ADMAdda5] MC-LR 
67. [Asp3] MC-RR 
68. [Asp3, Dhb7] MC-RR 
69. [Dha7] MC-RR 
70. MC-LW 
71. MC-M(O)R 
72. MC-FR 
73. MC-RF 
74. [Dha7] MC-HphR 
75. [Asp3] MC-YR 
76. [Dha7] MC-YR 
77. [Asp3, Dha7] MC-HtyR 
78. [Asp3] MC-RY 
79. [Dha7] MC-RY 
80. MC-LY(OMe) 
81. MC-YM(O) 
82. [Leu1] MC-LR 
83. [ADMAdda5] MC-HilR 
84. [ADMAdda5] MC-LHar 
85. MC-RR 
86. [Asp3] MC-YY 
87. [Asp3, Glu(OMe)6] MC-RR 
88. [(6Z)Adda5] MC-RR 
89. [Ser1, ADMAdda5] MC-LR 
90. [ADMAdda5, MeSer7] MC-LR 
91. [Asp3, MeSer7] MC-RR 
92. [Ser7] MC-RR 
93. [Asp3, Dhb7] MC-HtyR 
94. [Dha7] MC-HtyR 
95. [Asp3] MC-HtyR 
96. MC-YR 
97. MC-RY 
98. [Asp3, MeSer7] MC-RY 
99. [Ser7] MC-YR 
100. MC-(H4)YR 
101. [Asp3, Dhb7] MC-HtyY 
102. [Asp3, ADMAdda5, Dhb7] MC-RR 
103. [Glu(OC3H6OH)
6] MC-LR 
104. [Asp3] MC-WR 
105. MC-HtyR 
106. [Ser7] MC-HtyR 
107. [MeSer7] MC-YR 
108. [MeSer7] MC-RY 
119. MC-HarHar 
110. [Asp3, Dhb7] MC-HtyHty 
111. [ADMAdda5] MC-RR 
112. MC-WR 
113. [Asp3, ADMAdda5] MC-HtyR 
114. [Asp3, ADMAdda5, Dhb7] MC-HtyR 
115. MC-RY(OMe) 
116. [ADMAdda5] MC-(H4)YR 
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117. [MeLan7] MC-LR 
118. Nodularin-R 
119. seco[Asp3] MC-RR 
120. Anabaenopeptin B 
121. Anabaenopeptin B1 
122. Anabaenopeptin C 
123. Anabaenopeptin D 
124. Anabaenopeptin E 
125. Anabaenopeptin F 
126. Anabaenopeptin F1 
127. Anabaenopeptin G 
128. Anabaenopeptin G* 
129. Anabaenopeptin H 
130. Anabaenopeptin I 
131. Anabaenopeptin J 
132. Anabaenopeptin T 
133. Anabaenopeptin HU892 
134. Anabaenopeptin KT864 
135. Anabaenopeptin MM823 
136. Anabaenopeptin MM850 
137. Anabaenopeptin MM913 
138. Anabaenopeptin NZ825 
139. Anabaenopeptin NZ841 
140. Anabaenopeptin NZ857 
141. Anabaenopeptin 820 
142. Anabaenopeptin 908 
143. Anabaenopeptin 915 
144. Ferintoic Acid A 
145. Ferintoic Acid B 
146. Lyngbyaureidamide A 
147. Lyngbyaureidamide B 
148. Nodulapeptin A 
149. Nodulapeptin B 
150. Nodulapeptin 899 
151. Nodulapeptin 901 
152. Nodulapeptin 917 
153. Oscillamide B 
154. Oscillamide C 
155. Oscillamide H 
156. Oscillamide Y 
157. Schizopeptin 791 
158. Mozamide A 
159. Anabaenopeptin 906 
160. [Asp3] MC-RA 
161. [Asp3] MC-RAba 
162. [Asp3] MC-FA 
163. MC-FA 
164. [Asp3] MC-WA 
165. MC-WA 
166. MC-FAba 
167. MC-WAba 
168. MC-FL 
169. MC-WL 
170. MC-KynR 
171. MC-OiaR 
172. MC-NfkR 
173. MC-KynA 
174. MC-OiaA 
175. MC-NfkA 
176. MC-KynAba 
177. MC-OiaAba  
178. MC-NfkAba 
179. [Gly1, Asp3, Dhb7] MC-LR 
180. [Gly1, Asp3, Dhb7] MC-LHar 
181. [Gly1, Asp3, ADMAdda5, Dhb7] MC-LR 
182. [Gly1, Asp3, ADMAdda5, Dhb7] MC-LHar 
183. [Gly1, Asp3, Dhb7] MC-RR 
184. [Gly1, Asp3, Dhb7] MC-RHar 
185. [Gly1, Asp3, ADMAdda5, Dhb7] MC-RR 
186. [Gly1, Asp3, ADMAdda5, Dhb7] MC-RHar 
187. Antarctic peptide 800  
188. Antarctic peptide 816 
189. Antarctic peptide 830A 
190. Antarctic peptide 814 
191. Antarctic peptide 830B 
192. Antarctic peptide 844 
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